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General introduction – Scope of the thesis 
 
 
Bladder cancer is one of the most common malignancies in the Western world. 
The incidence increases with age, and the largest number of new patients is 
found between 60 and 70 years. Some of the etiological factors of bladder 
cancer, cigarette smoking and occupational exposure are  mainly responsible 
for the  2 to 3 times higher incidence in men. Herewith it is the fourth most 
occuring malignant tumour in men. In Europe every year 120,000 patients are 
being diagnosed with bladder cancer and 35,000 patients die from the disease.  
More than 90% of the bladder cancers are urothelial cell carcinomas (UCC). A 
small minority is squamous cell carcinoma or adenocarcinoma. Of the patients 
with urothelial cell carcinoma two third will present with a superficial (non-
muscle invasive) bladder tumour (Ta, T1, carcinoma in situ). One third of the 
patients has a muscle invasive bladder tumour (T2-T4) at first presentation. 
This latter group is a completely different entity, i.e., these patients are treated 
with cystectomy, chemotherapy and /or  radiation according to the extent of 
the tumour (Figure 1) 
 
 
 
 
Figure 1 Ta/CIS – no invasion of the lamina propria (Stage 0) 
 T1 –  invasion of the lamina propria (Stage I)  
 T2 –  invasion of the muscle (Stage II)  
 T3 –  invasion of the perivesical fat (Stage III)  
 T4 – invasion of perivesical organs (Stage IV)  
Chapter 1 
 
14 
The clinical spectrum of superficial bladder tumours covers low risk, 
intermediate risk and high risk tumours. All tumours within this spectrum are 
being treated with a transurethral resection followed by intravesical 
instillations with chemo- or immunotherapy. Currently mainly used are 
Mitomycin-C  and Bacillus Calmette-Guérin instillations, respectively. The low 
risk tumours are characterized by a high recurrence rate, although the 
mortality risk of these tumours is very small. The high risk tumours on the 
other hand show a high recurrence rate (up to 85%) and even more important, 
loss of differentiation implying a high risk of progression (up to 50%) to 
muscle invasive disease. This latter group has a very poor prognosis, with 3-
year disease specific survival being only 37% compared to 67% for patients 
with a de novo initial muscle invasive bladder tumour, and the 5-year disease 
specific survival  of 90% for patients with superficial bladder cancer. So 
frequent surveillance is necessary for all patients within this spectrum. The 
combination of cystoscopy (Figure 2) and cytology is the current gold 
standard in surveillance of superficial bladder tumours. With cystoscopy 
papillary tumours are easily seen, but flat – and per definition high grade - 
carcinoma in situ lesions are easily missed. Furthermore, the procedure is 
costly and invasive, and thus bothersome for the patient. Cytology on the 
other hand, shows a high sensitivity for high grade tumours, but the 
moderately or good differentiated lesions are easily missed. Moreover, the 
results of cytology are not reliable in case of infection or after intravesical 
therapy and the test is interpretor dependent.  The risk of  
 
 
 
 
    Figure 2 Cystoscopy 
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recurrence for individual patients is currently estimated using clinical factors 
like number of tumours, size of the tumour and prior recurrence rate. The risk 
of progression is estimated by stage, grade, presence of CIS, tumour status at 3 
months and depth of lamina propria invasion. Several of these factors are 
combined in the EORTC Risk Tables. Using clinical factors is convenient, since 
all urologists can obtain this information and an estimation of the risk can be 
made. However, there is still a strong need for a prognostic factor that can 
precisely predict the course of the disease in an individual patient.  
 
In this thesis two important aims in improving the surveillance of bladder 
cancer patients are being discussed. First, improvement of the gold standard 
in diagnosis and second, individualizing patients policy. More specific this 
means, lowering the number of cystoscopies (and thus lowering morbidity) by 
the use of urinary markers on one hand and make a better prediction of the 
course of the disease by the use of prognostic markers (and thus lowering 
mortality) on the other hand. 
 
Overview 
 
 
In chapter 2  first an overview is given of the gold standard, non-invasive 
methods and fluorescence cystoscopy for diagnosis and follow-up of 
superficial bladder cancer.   
 
 
Diagnostic markers 
 
 
In chapters 3 to 7 the value of (‘new’) diagnostic urinary markers is discussed. 
In chapter 3 the NMP22® BladderChek® Test is studied in 106 voided urinary 
specimens of patients with suspicion of bladder cancer.  The NMP22 test 
detects a nuclear matrix protein in urine which is supposed to correlate with 
the presence of urothelial cell carcinoma. In chapter 4 an overview is given of 
the use of FISH in bladder cancer.  Chapter 5 describes a 4-target FISH 
analysis, UroVysion® , in 103 voided urinary samples of patients under 
surveillance for superficial bladder cancer. The probe set of UroVysion® 
consists of probes to the chromosomes 3, 7, 17 and the 9p21 band.  
Abnormalities in these (part of) chromosomes are associated with the presence 
of urothelial cell carcinoma.   Chapter 6 shows both the diagnostic and 
Chapter 1 
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prognostic value of UroVysion® after retrospective collection of 1,000 tests 
obtained from more than 500 patients.   The last urinary marker studied is 
quantitative cytology (Quanticyt®), in chapter 7.  Quantitative cytology is an 
automated karyometric analysis, using a personal-computer-based image 
analysis system. For each nucleus, the DNA content and the nuclear shape 
feature PASS are determined. Based on these features, patients are divided in 
risk groups for presence of tumour  and identification of high risk superficial 
bladder cancer patients is possible. A disadvantage of the test is the necessity 
to perform an invasive procedure to obtain the required bladder wash sample. 
This study investigated whether the test can be performed on voided urine 
with reliable results, consistent with the results of the test performed on 
bladder wash. 
 
 
Prognostic factors 
 
 
Chapter 8 is a general overview of prognostic factors and risk stratification in 
bladder cancer. In chapter 9 the prognostic value of the p53  status of bladder 
washes, determined by mutation analysis is studied, in 105 patients with high 
risk superficial bladder cancer and a long term follow-up. p53  is a tumour 
suppressor gene. Loss of function of this gene leads to a diminished cell cycle 
arrest, DNA repair and apoptosis. Mutations in the p53 gene are found in 
about half of all human malignancies. In chapter 10 the prognostic value of 
p53 is studied in an unselected group of 122 bladder cancer patients in a 
community hospital.  Chapter 11 discusses the impact of the presence of 
Human Papilloma Virus (HPV) DNA and p53 status in relation to the clinical 
outcome of bladder cancer.   HPV encodes two oncoproteins, E6 and E7. The 
E6 protein interacts with p53 stimulating degradation of this tumour 
suppressor gene. The presence of HPV DNA was determined in  176 bladder 
washes of patients with (a suspicion of) a bladder tumour by the SPF10-LiPA 
HPV detection / genotyping assay, p53 status by mutation analysis. Results 
were correlated with histopathological features and clinical outcome.   
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The Gold standard, non-invasive methods and fluorescence cystoscopy 
for diagnosis and follow-up of superficial bladder cancer 
 
Abstract 
 
Purpose: to give a practical overview of the current gold standard, non-
invasive methods and fluorescence cystoscopy in diagnosis and follow-up of 
superficial bladder carcinoma. 
 
Conclusions: flexible cystoscopy is still the gold standard in diagnosis and 
follow-up of superficial bladder. Cytology is not the best method for diagnosis 
and follow-up, but it is easy to perform and the specificity is high.  No present 
marker can replace cystoscopy or can be used in screening as a single tool. If a 
marker is used, exclusion of patients with factors like urinary tract infection or 
urinary stones, improves the test results. Best test results are acquired if a 
marker is used in combination with another marker or in combination with 
cytology. The use of photo-sensitizers improves the detection of lesions in 
general and more importantly, of CIS lesions. The recurrence and progression 
rate of tumours can be diminished by applying fluorescence cystoscopy.  
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Introduction 
 
 
Bladder cancer is the second most common genitourinary neoplasm with more 
than 55,000 and 120,000 new cases diagnosed each year in the United States 
and Europe, respectively 1,2.  Superficial transitional cell carcinoma (TCC) of 
the bladder is characterized by a high risk of recurrence (60-85%), with a 
maximal incidence in the first year 3-5. Of all patients with superficial tumours, 
10-15% develop subsequent invasive or metastatic cancer 6. Despite this risk, 
the 5-year survival rate is close to 90% 7. The greatest concern in patients with 
superficial bladder cancer is, therefore, not to reduce mortality but to lower 
and postpone the number of recurrences and prevent progression to invasive 
disease. Consequently, long-term follow-up is required. Urethrocystoscopy 
(UCS) and cytology are routinely used for the diagnosis and follow-up of 
superficial bladder tumours. Cytology, however, has low sensitivity in 
diagnosing low-grade TCC 8,9, and the intraobserver and interobserver 
reproducibility is poor 10. Although UCS can reliably diagnose exophytic 
tumours, flat lesions (like carcinoma in situ) remain an endoscopic dilemma. 
Besides that, cystoscopy is costly and invasive. Identification of primary or 
recurrent TCC of the urinary tract is one goal. Another diagnostic goal may be 
early detection, for example in risk groups. Screening individuals at high risk 
for bladder cancer, such as those exposed to known carcinogens       (cigarettes, 
cyclophosphamide, aromatic amines and pelvic radiation), with an accurate 
marker may be useful for detecting bladder cancer while it is still confined to 
the bladder mucosa. This can be accomplished by screening through the use of 
microscopic examination (urinary tests), instead of waiting for macroscopic 
signs of malignancy (haematuria).   
A test, non-invasive, objective, and easy to perform, with low costs and a rapid 
result, that detects bladder tumours and has a high specificity could improve 
the diagnosis and follow-up of people at risk and patients with superficial 
bladder cancer.   
The aim of this overview is to describe the practical value of 
cystoscopy/cytology, non-invasive tests, and fluorescence cystoscopy for 
diagnosis and follow-up of TCC of the urinary tract.  
 
First, two basic definitions need to be addressed: sensitivity and specificity.  
Sensitivity is the percentage of positive cases detected by the assay (true 
positives), specificity is the percentage of negative cases with a negative test 
Overview diagnostic methods  
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result (true negatives). These definitions are widely used in studies on new 
urinary marker assays. Consequently, if we wish to use the assay to reduce the 
number of negative UCS procedures, a high negative predictive value, and 
thus a high sensitivity is important. High sensitivity is especially important for 
for high-grade lesions, because tumour progression for solitary low-
grade/low-stage lesions is less than 2% 11-13. High grade lesions of any size 
should be detected early in view of the high risk of disease progression and 
the immediate consequences of treatment. Conventional cytology has more 
than 90% sensitivity for grade III and carcinoma in-situ (CIS) lesions 14,15. It is 
evident that all new assays should match this gold standard for the detection 
of high-grade tumours. 
  
 
Gold standard 
 
Cystoscopy 
 
The current gold standard in diagnosis and follow-up of TCC of the urinary 
tract is urethrocystoscopy (UCS). Although considered as the gold standard, 
UCS can miss certain lesions. In particular, small areas of carcinoma in-situ 
(CIS) may be less easily detected. Other limitations of UCS are the fact that it is 
invasive and thus bothersome for the patient. And economically not 
unimportant, it is expensive.  
That cystoscopy is not the ideal gold standard was demonstrated by Brausi et 
al. 16. They found that during resection of Ta and T1 papillary tumours many 
lesions are missed.  The study, in which 2410 patients were included, showed 
that of patients with a single tumour, between 3.5% and 20.6% had a 
recurrence at first follow-up. Of patients presenting with multiple tumours, 
between 7.4% and 45.8% had a recurrence at first follow-up. Of course some of 
these tumours might be new occurrences or true recurrences, but at first 
follow-up at least a substantial number of tumours will have been residual 
lesions after the initial resection. Furthermore, one might assume that with 
current video controlled flexible cystoscopy techniques results are better. Still, 
it should be borne in mind that recurrence at any site in the bladder at the first 
follow-up cystoscopy after TUR is one of the most important prognostic 
factors for time to progression 17-19.    
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In a recently published fluorescence cystoscopy study Schmidbauer et al. 20 
studied the detection of CIS with normal white light and blue light combined 
with an intravesical photosensitizer. The conditions in this study were 
optimal, meaning high risk patients, trained investigators and biopsy proven 
CIS with reference pathologist. The sensitivity for CIS was disappointingly 
low: 64/83 (77%) of the CIS patients and 58% of the CIS lesions were detected 
in standard cystoscopy with white light. However, also the detection rate of 
pTa and pT1 tumours was not optimal: 88% and 87% respectively. With the 
use of a photosensitizer, in this study Hexaminolevulinate (HAL, Hexvix®, 
PhotoCure ASA, Oslo, Norway), the detection rate for CIS patients, CIS 
lesions, pTa and pT1 lesions was significantly better: between 96% and 97%. 
The current route of administration is intravesically, with consequently few to 
no systemic side effects, compared to side effects like prolonged skin 
sensitisation found in the past with systemic administration. 
Hexaminolevulinate is one of the new photosensitisers and  provides better 
selectivity, brighter fluorescence, less photobleeching and permits a shorter 
instillation time of approximately 1 hour, compared to older photosensitisers 
like aminolevulinic acid (ALA) 21,22.   
Another major disadvantage of UCS is the invasive character of the procedure. 
Vriesema et al. 23 examined patients’ opinions about the required validity of 
non-invasive diagnostic tools. In other words, they defined the minimal 
accepted sensitivity (MAS) for a urinary test at which the patient prefers this 
urinary test to UCS. They found that in general the treshold for cystoscopy is 
low. The more UCS procedures a patient had experienced, the less the 
procedure was evaluated as bothersome. This study indicated that 89%  of the 
patients chose  flexible UCS, if the sensitivity of the urinary test was lower 
than 90%. Using this end-point, the current commercially available markers 
are not yet able to replace UCS.  
 
Cytology 
 
Currently cytology combined with cystoscopy are the standard diagnostic 
tools for superficial bladder cancer. Cytology, however, exhibits variable 
sensitivity depending on tumour grade with the lowest sensitivity in low 
grade tumours 8,9 and therefore it has been used only as an additive to 
cystoscopy.  In addition, for the interpretation of a urine specimen 
intraobserver and interobserver reproducibility is poor 10. Lotan et al. 
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summarized 18 studies about cytology in their review to come to an overall 
median sensitivity for cytology of 34% and an overall median specificity of 
99% 24. Recently the differences between local and review urinary cytology in 
diagnosis of bladder cancer were studied by Raitanen et al. 25  in an 
interobserver multicenter analysis. A total of 575 voided samples of 129 
patients with a newly diagnosed bladder cancer and 446 patients under 
follow-up, were first analysed by a local pathologist, and then re-analysed by a 
central reviewer. The sensitivities of local and review cytology in detection of 
primary bladder cancer were 38.8% and 31.0%, respectively. A possible 
explanation for this difference is the fact that review cytology was performed 
blinded tot the result of cystoscopy or any other clinical data, whereas the 
majority of the local pathologists were aware of tumour presence in patients 
with primary bladder cancer since the urine specimens were obtained for 
analysis at least 2 weeks after diagnostic cystoscopy.  In patients under follow-
up, urine samples were obtained prior to routine follow-up cystoscopy.  
Recurrence was detected by both local and review cytology in 17.6%. 
Specificities of local and review cytology were 97.6% and 96.6% respectively, 
although determination of specificity is questionable  since not all recurrences 
are cystoscopically visualised. Then the agreement between the two 
independent interpretations of cytopathological readings was assessed and 
classified. Overall the agreement was better in patients with high grade 
primary tumours, as compared to patients with low grade tumours.  
 
Non-invasive assays 
 
 
As a consequence of the disadvantages and limitations of cystoscopy and 
cytology, a wide spectrum of alternative procedures and markers has been 
introduced and studied for detecting bladder cancer. Such a new technique 
should be a non-invasive technique; objective with a high reproducibility; and 
with a high sensitivity and specificity, and not only for high grade lesions. 
Finally it has to be simple in performance.   
For daily practice, it is important to divide tests into two categories, i.e. ‘on-
bench’ tests and laboratory tests. Laboratory tests take several days to produce 
a result, but on-bench tests can be performed within several minutes and 
enable instant implementation of the result in the outpatient care, which has 
great practical (and emotional) advantages.  
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BTA-TRAK  and  BTA stat 
 
 
The bladder tumour-associated antigen detected in urine by the BTA-TRAK 
and BTA stat assay (Bard Diagnostic Sciences Inc., Washington, USA) has been 
identified as a human complement factor H-related protein (hCFHrp) 26. It has 
been demonstrated hat hCFHrp is produced and secreted by several human 
bladder cancer cell lines, but not by normal epithelial keratinocytes 27,28.  It has 
also been demonstrated by in situ hybridization that bladder tumours produce 
hCFHrp 26. The function of this protein is similar to that of human complement 
factor H, i.e. by down-regulating the alternative complement pathway this 
protein may help bladder cancer cells escape lysis by the host immune system. 
BTA-TRAK is a quantitative test performed in the laboratory, with a cut-off 
value based on the manufacturer’s instructions of 14U/ml. But a variable cut-
off value, based on receiver operator characteristic curves (ROC) is used in 
different studies. BTA stat is a qualitative assay that can be performed within 
several minutes. The literature recently reviewed by Lotan et al. yielded 54 
publications and more than 10,000 patients. They found an overall median 
sensitivity and specificity of 0.71 and 0.73 respectively, for BTA stat (based on 
10 studies) and 0.69 and 0.90 for BTA-TRAK (based on 4 studies) 24.  Glas et al. 
included  42 studies in a recent review and their results showed a sensitivity 
between 63% and 100% for BTA stat (8 references) and a sensitivity between 
62% and 76% for BTA-TRAK (5 references). A specificity between 52% and 
93% and between 51% and 98% was found for BTA stat  and BTA-TRAK, 
respectively 29.   
 
ImmunoCyt 
 
The ImmunoCyt test (Diagnocure, Saint-foy, Quebec, Canada) combines 
cytology with an immunofluorescence assay. ImmunoCyt detects cellular 
markers that are relatively specific for bladder cancer exfoliated cells of the 
urothelium using three fluorescent antibodies 30. Antibody 19A211 labeled 
with Texas red identifies a high molecular weight form of carcinoembryonic 
antigen. Antibodies M344 and LDQ10 labeled with fluorescein are directed 
against mucins. Mucins are high molecular weight glycoproteins that are 
usually expressed on the surface of epithelial cells. In bladder cancer, the 
glycoprotein is not as heavily glycosylated as in the normal urothelium 31. This 
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results in a part of the protein backbone being exposed to the immune system. 
M344 and LDQ10 recognize epitopes in this region 31,32.    
Recent literature show a sensitivity between 38.5% and 100% 32-36 and a 
specificity between 73% and 84.2%  32,33,35,36 for ImmunoCyt.   
 
 
Urinary Bladder Cancer test 
 
 
The Urinary Bladder Cancer  (UBC) test ( IDL Biotech, Sollentuna, Sweden) 
detects the cytokeratins 8/18 pair in urine. The development of urothelial 
tumours causes exophytic growth of tumour into the bladder and urothelial 
cell damage. This can exfoliate lysed and alive malignant cells into the bladder 
and a concomitant discharge of intracellular components into the urine. One 
group of these intracellular components are cytokeratins (CK’s). CK fragments 
are expressed in varying combinations and levels depending on the epithelial 
type, degree of differentiation, and existence of malignancy 37. Malignant cells 
generally retain the intermediate filaments of their progenitor cell type. 
Moreover, CK expression is retained throughout almost all stages of epithelial 
malignancy. For these reasons, CK’s have been used to characterize neoplastic 
cells of epithelial origin 38.  It has also been suggested that CK’s may be a 
specific biomarker for detecting bladder cancer. For this detection the Urinary 
Bladder Cancer test is an example. Because the results of the assay can be 
affected by different urinary creatinine levels, it is recommended that the UBC 
concentration is corrected for urinary creatinine concentration. The cut-off 
value as advised by the manufacturer is 12 µg/l. But different values are used 
in studies, both for the non-corrected and the corrected value of UBC.   
UBC has a sensitivity between 20.7% and 80.7% 39-43 and a specificity between 
72% and 84.7% 39-42. But Lotan et al. shows an overall median sensitivity of 0.66 
and an overall median specificity of 0.91 (2 studies) 24.   
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NMP22 
 
 
The NMP22 assay (Matritech, Newton, Massachusetts), detects a nuclear 
matrix protein specific for urothelial cell carcinoma. More specific it is a 
nuclear mitotic apparatus protein that is an abundant component of the 
nuclear matrix. This 240 kDa. protein is distributed within the nucleus during 
interphase and localizes with the spindle poles during mitosis. In tumour cells 
nuclear mitotic apparatus is elevated and released from cells in detectable 
levels, perhaps after cell death. The NMP22 test is a quantitative microtiter 
sandwich enzyme linked immunoassay that uses 2 monoclonal antibodies, of 
which each recognizes a different epitope on nuclear mitotic apparatus, for 
detecting nuclear mitotic apparatus in urine.  The cut-off value based on the 
manufacturer’s instructions is 10 U/ml., but again based on the ROC other 
values are being used in different studies.  
Lotan et al. found an overall median sensitivity of 0.73 and an overall median 
specificity of 0.80 (15 studies) for the NMP22 assay 24.  Glas et al. gave a 
sensitivity between 44% and 100% and a specificity between 60% and 95% (14 
references) 29.  Recently, an on-bench NMP22 test has been introduced, which 
gives results within 30 minutes with a cut-off value of 12 U/ml. The first 
results are promising, and the application is very practical. Future studies 
must define the role of this test.  
 
 
 
Quanticyt 
 
 
Quanticyt is an automated image analysis system that evaluates nuclear shape 
and DNA content of exfoliated cells in bladder wash specimens. Based on 
these samples, patients can be divided into being at low-, intermediate-, and 
high-risk for the presence of bladder cancer 44. It allows the cytopathologist to 
assign an objective score to cytological features to arrive at a diagnosis. The 
disadvantages of the technique are that it is more elaborate than routine 
cytology and it has proven to be valuable only in bladder wash material. 
However, good reproducibility and the objective scoring enable comparison of 
subsequent samples.  
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Van der Poel et al. performed extensive research into Quanticyt. In their study 
an overall sensitivity of 69% was found, and the specificity of the test was 
72.5%. Important is the fact that this lower specificity was accompanied by a 
better prediction of tumour recurrence after a normal UCS. A limitation is the 
fact that a small percent of the samples may not be analysed by Quanticyt due 
to too few urothelial cells or an abundance of leucocytes and erythrocytes in 
the sample 45.   Wiener et al. found a sensitivity of 59% and a specificity of 
93%, but 30% of their specimens proved insufficient for Quanticyt analysis 15. 
In a later study Van der Poel et al. also found that high-risk Quanticyt scores 
are associated with an elevated risk of high-grade disease and progression to 
invasion 46. 
 
Several reviews and meta-analyses are performed with regards to urinary 
markers. Van Rhijn et al.47  reviewed the literature on 18 markers solely for 
UCC surveillance (Table 1). They found that the clinical evidence to warrant 
the substitution of cystoscopy by any of the urine marker tests is insufficient. 
They suggest however that urine markers can be used on an individual basis 
to help planning a next UCS, but support by clinical evidence for this 
suggestion is not available. Microsatellite analysis, ImmunoCyt, NMP22, 
CYFRA21-1, LewisX and FISH are found to be the most promising markers at 
this time. Microsatellite analysis and FISH both detect genetic alterations, 
ImmunoCyt and LewisX are examples of immunocytology, the NMP22 assay 
measures the quantity of NMP22, a nuclear matrix protein and CYFRA21-1 is 
a cytokeratin based assay. A meta-analysis was performed by Glas et al. 29 on 
urine based markers in the detection of primary bladder cancer (Table 1). 
Cytology had the best specificity and telomerase the best sensitivity. 
Telomerase prevents the decrease of Telomere length with age. Renewed 
expression of telomerase is thought to immortalize cancer cells and is seen in 
most cancers. None of the markers studied had a sensitivity greater than 80% 
and consequently none of the markers could be recommended for daily 
routine. A few years ago Lotan et al. 24 reviewed the literature on more than 
10,000 patients and calculated the overall sensitivity and specificity of the 
urinary markers (Table 1). They concluded that all the evaluated urinary 
markers have a higher sensitivity than cytology, both overall and after 
stratification by stage and grade. Specificity however is overall inferior to 
cytology. 
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Van Rhijn et al. Glas et al. Lotan et al.  
Sensitivity 
(range) 
 
Specificity 
(range) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Sensitivity 
(95% CI) 
Specificity   
(95% CI) 
BTAstat 58 (29-74) 73(56-86) 70(66-74) 75(64-84) 71(57-82) 73(61-82) 
BTAtrak 71(60-83) 66(60-79) 66(62-71) 65(45-81) 69(55-80) 90(38-98) 
NMP22 71(47-100) 73(55-98) 67(60-73) 78(72-83) 73(47-87) 80(58-91) 
FDP 54(47-68) 61(25-80) - - 77(41-93) 87(77-94) 
ImmunoCyt 67(52-100) 75(62-82) - - 86 79 
Cytometry 60(45-85) 82(50-92) - - - - 
Quanticyt 58(45-65) 76(68-87) - - - - 
HB-dipstick 40(37-41) 87(87) - - 52(27-76) 82(62-93) 
LewisX 75(68-79) 85(67-86) - - - - 
FISH 79(70-86) 70(66-93) - - - - 
Telomerase 39(29-66) - 75(71-79) 86(71-94) 77(53-91) 99(46-99) 
Microsatellite 82(75-92) 89(79-100) - - - - 
CYFRA21-1 85(75-88) 82(73-95) - - 94(74-99) 69(57-78) 
UBC 60(21-80) 87(72-95) - - 66(50-79) 91(84-96) 
Cyto 
keratin20 
85(79-87) 76(76) - - 91(83-96) 84(66-93) 
BTA 48(32-58) 92(91-92) 50(30-65) 79(70-86) 49(24-74) 86(66-95) 
TPS 65(50-80) 83(63-95) - - 64 84 
Cytology 35(13-75) 94(85-100) 55(48-62) 94(90-96) 34(20-53) 99(83-99.7) 
BCA - - - - 83(55-95) 84(45-96) 
TPA - - - - 88 55 
BCLA-4 - - - - 96 85 
Chemilumi 
nescent Hgb 
- - - - 67 63 
HA - - - - 89(67-97) 92(83-96) 
HAase - - - - 82 84 
HA-HAase - - - - 92 84 
Beta-HCG - - - - 35 100 
• van Rhijn et al. 47 ; Median values for sensitivity and specificity for patients under surveillance 
based on 64 articles 
• Glas et al. 29 ; Meta-analysis of 42 studies on the diagnosis of primary bladder cancer  
• Lotan et al. 24; Overall median values for sensitivity and specificity based on meta-analysis of 54 
publications and more than 10,000 patients  
 
 
Table 1  Sensitivity and specificity of the evaluated urinary markers per study  
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They conclude that all markers can be used in the follow-up of low-
grade/stage tumours but cystoscopy should not be replaced. 
 
In conclusion, urinary markers in general have a better sensitivity than 
cytology, but at the cost of some specificity. None of the currently available 
urinary markers is a substitution for cystoscopy. So, what is the reason that 
these tests do less than expected. Bad quality and handling of urinary 
specimens could be one reason. Disturbing factors like urinary tract infection, 
urinary stones, or therapies can cause a false test result. Another explanation 
for a false-positive test could be prediction of a subsequent tumour. In other 
words, the test possibly can detect presence of a tumour before it is visible 
with the eye.  However, this question is still not answered in recent literature. 
In all, enough markers are currently under investigation, so that the chance of 
finding a diagnostic – and maybe even a prognostic- marker is conceivable.  
 
 
Fluorescence Cystoscopy 
 
 
Since 40 years photodynamic diagnosis (PDD) is investigated to decrease the 
risk of underdiagnosing bladder tumours 48. After some drawbacks,  the first 
clinical report of 5-aminolaevulinic acid (ALA) as a photosensitizing agent in 
the early 1990s 49, revived the interest in PDD.  ALA is the starting point of the 
haem biosynthesis pathway. Immediately before haem in this pathway is 
protoporphyrin IX (PPIX), which is a fluorescent substance. After exogenous 
(intravesical) administration of ALA, protoporphyrin IX accumulates up to 10 
times more in tumour than in normal cells 50. The precise reason for this  
preference is unknown, but several theories are proposed, such as : higher 
permeability to ALA as a result of inflammation; accumulation in the cells by 
hyperproliferation of the urothelium; differences in the level of cellular 
metabolism; reduced activity of ferrochelatase which metabolizes PPIX; a 
greater concentration of porphobilinogen deaminase in tumour tissue, which 
is a rate-limiting enzyme in the biosynthesis cycle and structural 
characteristics of diseased urothelium 51. The cellular uptake of  highly 
charged molecules like ALA is limited. Solution to this limitation is 
esterification of the molecule. After esterification of 5-ALA, the hexylester 
ALA (HAL) gives twice the fluorescence, in the half of the  time and with a 20-
Chapter 2 
 
30 
times lower concentration 52. Since March 2005, HAL (Hexvix® , PhotoCure 
ASA, Norway) has been approved for the diagnosis of bladder cancer in 26 
EU/EEA countries, through the European Mutual Recognition Procedure. 
HAL is administered intravesically 1 hour before cystoscopy through a 
urethral catheter. The endoscopic equipment has to be adjusted since special 
telescopes and a specific light source is required. The procedure is simple, the 
light can be operated with a foot pedal or a push-button on the camera. 
Several studies have compared the efficacy of PDD using HAL with white 
light cystoscopy (WLC). All reports showed that patients having a resection 
under PDD have significantly less residual tumour 53-55. So this technique may 
improve the quality of the TURBT. But eventually the most important aim is 
the reduction in long-term recurrence. In the first study investigating this, a 
recurrence free survival in the fluorescence diagnosis group after both 12 and 
24 months was 89.6% versus 73.8% and 65.9% respectively in the white light 
group (P = 0.004) 53. The detection of CIS is another important  point of 
attention in which PDD can be meaningful (Figure 1) . In the most recent 
study performed by Schmidbauer et al. the proportion of patients with 
detection of additional CIS lesions by HAL cystoscopy was significantly 
higher compared to standard WLC (55% vs 4%, P < 0.0001). So a significant 
improved detection of CIS with consequences for patients clinical 
management and prognosis was found 56. In 2001  a study  with ALA was 
performed and 57% of the CIS lesions were not detected on a conventional 
WLC 57. In 2004 abstracts of multicenter studies with HAL  were published. 
Results show that PDD is complementary to WLC and that PDD has a relevant 
impact on the patient’s management 58-60. 
Since in the outpatient department flexible cystoscopy is  widely used, 
feasibility of flexible fluorescence cystoscopy (FFC) was evaluated in two 
recent studies. An equivalent or slightly inferior result was found when 
flexible fluorescence cystoscopy was compared to rigid fluorescence 
cystoscopy. Flexible fluorescence cystoscopy showed comparable results to 
rigid white light cystoscopy and both flexible and rigid fluorescence 
cystoscopy were superior to flexible white light cystoscopy 61,62.  
Although detection of tumours is significantly improved, positive fluorescence 
is not limited to tumour lesions only. These false-positive results occur for 
several reasons. Excitation by a  tangential instead of a perpendicular beam 
gives normal mucosa  (especially at the bladder neck, trigone and at 
diverticula) a red fluorescence. So these false positives are caused by 
inexperience with PDD. Inflammation or scarring of the bladder when PDD is  
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used within 6 weeks after previous TURBT may give a minor fluorescence, 
although not as intense compared to tumour lesions 63 . And when PDD is 
used within 6 months after previous instillation a significantly higher rate of 
false-positive biopsies was seen 64.  
Numerous studies have showed that PDD offers increased sensitivity in 
detecting bladder tumours, however use of the technique is still no common 
practice. It is important for a urologist to understand which patient groups 
may benefit from PDD. So in summary, most important is probably the use of 
PDD in the detection of CIS, especially in patients with positive cytology and 
no evidence of tumour at cystoscopy. CIS lesions are easily missed while it 
may appear as normal looking urothelium, but the progression rate of 
untreated CIS to invasive disease is about 50%. As mentioned before the use of 
PDD in the TURBT, gives a significant reduction in residual tumour and 
recurrence rate. And even after intravesical therapy PDD may still be of value,  
despite the higher false-positive rate since additional cases of CIS are still 
found 64. When a reresection is performed PDD has no additional value, as it 
only detects superficial disease and the scarring tissue produces frequent false-
positive results 63. Whether PDD has value in patients presenting with 
haematuria has to be determined. Since in these cases the additional value lies 
in the detection of  solitary tumours otherwise missed on conventional white 
light flexible cystoscopy.  
 
 
 
 
 
 
 
 
 
 
Figure 1 Histological proven carcinoma in situ (CIS) with fluorescence cystoscopy 
(left) and conventional white light cystoscopy (right) 
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Conclusions 
 
 
Urinary markers in general have an improved sensitivity over cytology, but at 
the cost of some specificity. Cytology, on the other hand, may not be the best 
method for diagnosis and follow-up, but it is easy to perform and the 
specificity is high. 
No present marker can replace cystoscopy, no present marker can be used in 
screening and if a marker is used, one has to exclude patients with disturbing 
factors like urinary tract infection or urinary stones. The best results are 
acquired when a marker is used in combination with cytology or in 
combination with another marker. For patients with high grade lesions the 
gold standard, UCS with cytology, is the best approach. In patients with low 
grade lesions a modified follow-up scheme, alternating UCS and a urinary 
marker could be an option. Fluorescence cystoscopy has proven to enhance 
the detection of superficial bladder cancer lesions, both papillary and CIS with 
an apparent influence on recurrence and progression rate. 
 
.  
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Abstract 
 
 
Introduction: To study the diagnostic efficacy of the NMP22® BladderChek® 
test and to compare it to cytology in the detection of bladder cancer.   
 
Methods: We evaluated 106 voided urinary specimens of patients with 
suspicion of bladder cancer. All voided urine samples were evaluated by the 
NMP22 BladderChek test, cytology, sediment and culture.  The diagnostic 
value of the NMP22 BladderChek test was evaluated according to correlation 
with cystoscopic findings and, in case of tumour, histological findings. A 
negative test result in a pTaG1 tumour was not considered false-negative in 
this study.  The results were compared to the diagnostic value of cytology. 
Moreover, the value of the combination of cytology and the NMP22 
BladderChek test was determined. 
 
Results: In total, 29 patients had histologically proven transitional cell 
carcinoma of the bladder.  The NMP22 BladderChek test detected 40% of 15 
pTa tumours and 83.3% of the 6 pT1 tumours. Cytology detected pTa in 33.3% 
and pT1 in 66.6%. The 1 CIS lesion was detected by cytology. In the group of 
patients in follow-up the sensitivity and specificity were 57.1% (CI 28.8-82.3) 
and 89.8% ( CI 79.2-96.2) for the NMP22 BladderChek test and 42.9% (CI 17.7-
71.7) and 93.2% (CI 83.5-98.1) for cytology.  
 
Conclusion: The NMP22 BladderChek test has a slightly higher sensitivity 
compared to cytology, without a relevant loss in specificity. Furthermore it is 
an easy test with instant result. However, no extra tumours were detected by 
adjunction of the NMP22 BladderChek test. 
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Introduction 
 
 
Superficial transitional cell carcinoma of the bladder is characterized by a high 
risk of recurrence (30-85%), with a maximal incidence in the first three years1-3. 
A minority of patients will show progression to muscle-invasive disease, so 
long and frequent follow-up is required. This follow-up consists of 
cystoscopies (UCS) and cytology. Cytology however lacks diagnostic efficacy  
in the diagnosis of tumours of  low grade malignancy 4,5 and the result of 
cytology depends on the expertise of the cytopathologist 6. To overcome these 
limitations, new diagnostic tests are under investigation. Extensive research 
was done on the precursor of the NMP22® BladderChek® Point of  Care (POC) 
assay (Matritech GmbH, Freiburg, Germany) , i.e. the NMP22 Bladder Cancer 
Test. The NMP22 test detects a nuclear matrix protein in urine which 
correlates with the presence of transitional cell carcinoma 7,8. The NMP22 
Bladder Cancer test was investigated in many studies and based on a meta-
analysis of 2,290 patients, the sensitivity was estimated to be  67% (CI: 60% to 
73%) and specificity 78% (CI: 72% to 83%) 9. The Food and Drug 
Administration approved the test as an aid in the diagnosis of patients at risk 
or with symptoms of bladder cancer. But the Bladder Cancer test is an 
instrument which is performed in the laboratory. An assay that gives a direct 
result, that enables immediate implementation in patient management is 
preferred.   So the aim of  this study was to investigate whether the  new 
“Point of care”(POC) version of the NMP22 Bladder Cancer test – the NMP22 
BladderChek test – has value  in the diagnosis of patients with superficial 
bladder cancer and compare it’s value to cytology.  
 
 
Material and Methods  
 
 
Patients  
 
Between June 2004 and March 2005 we prospectively evaluated 106 voided 
urinary specimens in three groups: ⒜ 28 patients presenting with haematuria, 
who were visiting the urologic outpatient department for a cystoscopy. None 
of these patient had a history of superficial bladder cancer. ⒝ 57 patients in 
follow-up for superficial bladder cancer (pTa, pT1, carcinoma in situ) with an 
appointment for a routine cystoscopy. In both groups fresh voided urinary 
NMP22® BladderChek® test in the diagnosis of superficial bladder cancer 
 
43 
specimens were collected before instrumentation, according to the protocol. 
Moreover, ⒞ of 21 patients samples were collected just before the 
transurethral resection of their bladder tumour. This latter group of patients 
with known presence of tumour was included, to increase the number of 
patients with tumour at the time of sample collection. Informed consent was 
acquired of all patients. All voided urinary samples were evaluated by the 
NMP22 BladderChek test, cytology, sediment and culture.  
 
 
NMP22® BladderChek®  Test 
 
The NMP22 BladderChek test for the nuclear matrix protein NMP22 is an 
immunochromatographic assay utilizing monoclonal antibodies in a lateral 
flow strip encased in a plastic box. Two different antibodies are used, one as a 
capture and one as a reporter antibody. A prerequisite for a soluble urine 
marker is the maintenance of urine in the bladder long enough for detachment 
of the cells, the time needed for lysis and the release of the NMP22. For 
prevention of false-negative test results, the advice was given to maintain the 
urine in the bladder for about 2 hours, before performing the NMP22 
BladderChek test. So patients were only included on the condition that they 
had achieved this. No intravesical therapy was given within 4 weeks prior to 
inclusion. In case of BCG instillations, the last instillation was given at least 10 
weeks ago, as was advised by Gutierrez et al. 10. All voided urine samples 
were obtained before any instrumentation. Samples were examined for the 
presence of any benign inflammatory conditions, using the Megutest 7 urine 
test strip. On positive urine samples, the NMP22 BladderChek test was not 
performed, herewith preventing false-positive test results. Other exclusion 
criteria were the presence or history of a foreign body, e.g. stent or a 
nephrostomy tube, renal / bladder calculi, a bowel interposition segment, 
another infiltrating genitourinary cancer and any invasive procedure within 2 
weeks before the analysis 11. All this to prevent false-positive test results. The 
samples of all eligible patients were  evaluated by the NMP22 BladderChek 
test, cytology, sediment and culture. The NMP22 BladderChek test was 
performed immediately on fresh voided urine. The maximum delay was set at  
30 minutes after receiving the sample from the patient, because  proteolytic 
enzymes can destroy the NMP22 protein. Then 4 drops were placed in the 
sample field of the BladderChek test device. After 30 to 50 minutes the result 
was read in the test field. The test is positive when a pink coloured band 
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appears or negative if the band is absent (Figure 1 and 2). Even a very small 
faint band is judged as positive.  
 
                                                                        
Cytopathological analysis was considered positive when malignant cells were 
present. Atypical and reactive cells were considered negative. Flexible 
cystoscopy was performed in men and rigid or flexible cystoscopy in women. 
Cystoscopy was considered positive if it was followed by a resection and 
histological findings confirmed malignancy. Tissue was examined by the local 
pathologist; staging and grading according to the TNM classification 12 and 
WHO/ISUP 1998 13. A negative test in a PTaG1 tumour, was not considered a 
false-negative result. Assessment of the NMP22 BladderChek test result was 
done without knowledge of the urine cytology and bladder wash analyses. 
The effect of presence of erythrocytes and leucocytes in the urine on the 
accuracy of the NMP22 BladderChek Test was determined. Furthermore, 
imaging of the upper urinary tract as required by the EAU guidelines was 
performed and results were noted. 
 
 
Statistical analysis 
 
Sensitivity and specificity of the tests (with 95% exact confidence intervals) 
were determined in 2 groups of patients, the patients presenting with 
haematuria and the patients in follow-up. Of the group of patients with a 
known bladder tumour (group ⓒ), only the superficial tumours were used in 
determination of sensitivity and specificity. In case of malignancy, histology 
was considered the gold standard. In absence of tumour the gold standard 
was the cystoscopy result.  The result of the NMP22 BladderChek test and 
cytology were combined to investigate whether the result of the combination 
improved compared with either of the tests alone. The sample was called 
positive when either of the tests used was positive. For stratification to stage 
and grade all samples were used, including the pT2-pT4 tumours of group ⓒ. 
The statistical Package for Social Sciences, release 12.0 was used for analyses.  
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Results 
 
 
In total  132 fresh voided urinary specimens were collected. Twenty-six 
urinary samples could not be included, 3 because of a urinary tract infection, 
18 samples of patients who had not retained the urine in the bladder for at 
least 2 hours, 3 samples of patients who did not underwent a cystoscopy 
according to judgment of the urologist  and 2 samples of patients with 
urolithiasis. The remaining 106 patients (79 male and 27 female) had a median 
age of 66.4 years (range 26.9 to 86.1). Twenty-nine patients (27.4%) had a 
histologically confirmed malignancy.  In Table 1 the test results per tumour 
are summarized.   
 
In Table 2 the sensitivity and specificity for the group of patients with 
haematuria is summarized. The sensitivity for detection of superficial lesions 
was 100% for both the NMP22 BladderChek test and cytology. The specificity 
was 92.0% and 100%. The 2 false-positive NMP22 BladderChek results were 
real benign, with a negative cytology result.  
 
 
 
Figure 2  
Positive NMP22 BladderChek test 
Figure 1  
Negative NMP22 BladderChek test 
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Histology NMP22 BladderChek 
Test 
Negative      Positive     
Cytology 
 
Negative      Positive  
Ta G1 (7) 5 2 4 3 
Ta G2 (4) 1 3 2 2 
Ta G3 (3) 2 1 3 - 
Ta G3 +CIS (prostatic urethra) 1 - 1 - 
T1 G2 (2)  - 2 1 1 
T1 G3 (2) 1 1 - 2 
T1 G3 + CIS (2) - 2 1 1 
CIS (prosatic urethra) 1 - - 1 
T2 G2  - 1 1 - 
T2 G3 (2) - 2 - 2 
T2G3 + CIS (2) - 2 - 2 
T3 G2 (2) - 2 - 2 
 
Table 1     NMP22 BladderChek Test and cytology results per tumour 
 
 
 
 
 Sensitivity % (CI) Specificity % (CI) 
NMP22 Bladder Chek 100 (29.2-100) 92.0 (74.0-99.0) 
Cytology 100 (29.2-100) 100  (86.3-100) 
Combination* 100 (29.2-100) 92.0 (74.0-99.0) 
* Combination = NMP22 BladderChek plus cytology 
 
Table 2     Sensitivity and specificity for the NMP22® BladderChek® Test and 
      cytology  in the patient group with haematuria (n=28) and malignancy (n=4)                   
 
            
In the follow-up group the sensitivity and specificity for the NMP22 
BladderChek test for detection of superficial lesions was  57.1% and 89.8% 
respectively. Combination of the NMP22 BladderChek test and cytology 
improves sensitivity to almost 80%. Results are summarized in Table 3.  
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 Sensitivity % (CI) 
 
Specificity % (CI) 
NMP22 Bladder Chek 57.1 (28.8-82.3)  89.8 (79.2-96.2) 
 
Cytology 42.9 (17.7-71.7) 93.2 (83.5-98.1) 
 
Combination* 78.6 (49.2-95.3) 84.7 (73.0-92.8) 
 
* Combination = NMP22 BladderChek plus Cytology 
 
Table 3     Sensitivity and specificity for  the NMP22® BladderChek® Test and 
      cytology  in the Follow-up group (n = 73) and malignancy (n = 18)   
 
 
Detection of tumours by the NMP22 BladderChek test tends to be better with 
increasing stage and grade. For stratification of detection by stage and grade 
all samples were included. These results are shown in Table 4 and Table 5.  
 
 
 n NMP22 (%) Cytology (%)  
pTa 15 6 (40) 5 (33.3) 
pT1 6 5 (83.3) 4 (66.7) 
pT2-T4 7 7 (100) 6 (85.7) 
 
Table 4      Detection by the NMP22® BladderChek® Test and cytology per stage 
 
 
 
 n NMP22 (%) Cytology (%) 
Grade 1 7 2 (28.6) 3 (42.9) 
Grade 2 9 8 (88.9) 5 (55.6) 
Grade 3* 13 8 (61.5) 8 (61.5) 
* CIS was considered as Grade 3 
Table 5     Detection by the NMP22® BladderChek®  Test and cytology per grade 
 
 
After stratification by leucocytes and erythrocytes no difference in results was 
found among the subgroups. So presence of haematuria and leucocytes in the 
urine has no major effect on value of the NMP22 BladderChek test. 
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Discussion 
 
 
Due to the limitations of the current gold standard, cystoscopy in combination 
with cytology, the need for a new urinary marker is evident. A urinary test can 
be used for 1) screening in the general population and 2) in patients in follow-
up for superficial bladder cancer. For the use of  a test as a screening tool for 
the general practitioner in patients with haematuria, the specificity and 
positive predictive value should be very high. The advantage in that case is 
that few patients will undergo a cystoscopy unnecessarily. There are also 
arguments for a test with a high negative predictive value. That means that if 
the test is negative, there is no reason to refer the patient to the hospital for a 
cystoscopy. In the follow-up group the sensitivity must be high, to tailor the 
amount of cystoscopies. During the past years, several studies have been 
performed to examine both the diagnostic and prognostic value of the NMP22 
test. In 2001 Lokeshwar et al. reviewed the at that time available bladder 
cancer tests, including the NMP22 laboratory test. Based on fourteen articles 
both sensitivity and specificity in most studies was between 60% and 70% and 
the test appeared to detect all grades of cancer with similar sensitivity 14. Glas 
et al. performed a meta-analysis. Based on 2,290 patients a sensitivity of 67% 
(CI: 60% to 73%) and a specificity of 78% (CI: 72% to 83%) for the NMP22 
Bladder Cancer Test was found 9. More recently van Rhijn et al. reviewed 
urinary markers solely for UCC surveillance 15. Based on 838 and 1203 patients 
a median sensitivity of 71% (range 47-100) and  a median specificity of 73% 
(range 55-98) for the NMP22 Bladder Cancer test was found. Considering the 
sensitivity of the test, it was concluded that the test cannot reduce the number 
of follow-up cystoscopies. However, the FDA panel has approved the test as 
an aid in the diagnosis of bladder cancer. Reason enough to develop a point of 
care test of the NMP22 concept. Few studies with this NMP22 BladderChek 
test have been completed at this moment. Tomera 16 states that the use of the 
test in combination with cystoscopy improves the performance of cystoscopy 
and that the NMP22 BladderChek test provides a higher sensitivity at every 
stage of disease compared to cytology. This is in accordance with our findings. 
Moreover a role in the primary care setting is foreseen by Tomera, for testing 
high-risk patients characterized by smoking history, occupational exposure or 
age. Grossman et al. 17 performed the NMP22 BladderChek test on urinary 
samples of 1331 patients at risk for bladder cancer. Patients with a history of 
smoking, or symptoms of  haematuria or dysuria were included. In total 79 
patients were diagnosed with bladder cancer. Herewith they found a 
NMP22® BladderChek® test in the diagnosis of superficial bladder cancer 
 
49 
sensitivity and specificity of 55.7% and 85.7% respectively. Moreover, four 
cancers not visualized by endoscopy were detected. The NMP22 BladderChek 
test was considered as a useful adjunctive tool in the evaluation of patients at 
risk for bladder cancer.  Akkad et al. and Hautmann et al. presented  their 
results of the NMP22 BladderChek test at the EAU 2005. Akkad et al. 18  used a 
group of 90 patients in screening or in follow-up for bladder cancer. Another 
30 patients were included as a control group. They found a sensitivity and 
specificity comparable to that of Grossman et al. and  detection was enhanced 
with increasing tumour grade (16% G1, 51% G2, 75% G3). Hautmann et al. 19 
presented results of 52 patients with a bladder tumour and 23 control patients. 
A higher sensitivity (85%) and a comparable specificity (91%) was found. 
However, comparison of studies remains difficult, while differences in patient 
group, collection and specimen processing may result in varying results. In 
our study only 4 patients who presented with haematuria had a malignancy, 
so extension of this group is required to have reliable results.  In the follow-up 
group the sensitivity of the NMP22 BladderChek test is better compared to 
cytology, but still not more than 57.1%. When the two tests are combined the 
sensitivity improves to 78.6%, while specificity shows a minor decrease to 
84.7%. It must be noted that a relative large number of grade 3 tumours are 
missed by both the NMP22 BladderChek test and cytology. In 2 of these cases 
detachment of cells for lysis and release of the NMP22 was not sufficient as a 
consequence of situation of the tumour in the prostatic part of the urethra. The 
NMP22 Bladder Cancer test, ImmunoCyt and FISH are seen as some of the 
most promising markers for surveillance at this time by van Rhijn et al. 15. 
When these results are compared to the NMP22 BladderChek test results in 
our study, sensitivity of this test is lower and the specificity is higher.  
In this study 100% of the T2-T4 tumours were detected by the NMP22 
BladderChek test. However, an overrepresentation of patients with a 
superficial bladder tumour was used, because in the follow-up situation we 
are especially interested in the detection of these tumours. While we consider 
avoidance of cystoscopies in patients with a negative tumour marker the most 
important possible use of a tumour marker, it is most relevant to accurately 
assess the negative predictive value of the test. This negative predictive value 
is largely dependant on the test’s sensitivity. The estimated positive predictive 
value (PPV) and negative predictive value (NPV) for the NMP22 BladderChek 
test were respectively 40.5% and 94.7%. In comparison for cytology these 
estimated values were 43.0% and 93.1% respectively.  
The patients in follow-up have to undergo frequent cystoscopies. In this study 
a negative test result in a TaG1 tumour was not considered a false-negative 
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result. The test avoids an invasive and bothersome cystoscopy for patients in 
follow-up at a moment that there is no need for surgical treatment. The 
necessary follow-up is performed and the tumour is found on a moment that 
intervention is required, while there is still a risk of recurrence and even 
progression. By comparison, sensitivity and specificity for the patients in 
follow-up would be 50% and 92.5% when a negative test result would be 
considered false-negative, versus 57.1% and 89.8% when it is considered true-
negative. 
 Atsu et al. studied the correlation between the presence of haematuria and 
pyuria and a false-positive test result in an experimental model and in human 
subjects. They found a significant effect of pyuria and haematuria on the 
NMP22 laboratory test, in the group without malignancy and in the 
experimental model. Nevertheless, in the group with known bladder cancer 
these disturbing factors had a negligible effect 20. We found that presence of 
leucocytes in the urine or haematuria induced no difference in results of the 
NMP22 BladderChek test. 
The NMP22 BladderChek test is very easy to perform. A potential 
disadvantage is that it is necessary to ask the patients to retain the urine in the 
bladder for two hours, for prevention of false-negative results. This time is 
needed for detachment of the cells, lysis and the release of the NMP22 protein. 
However, this did not lead to problems in this study.  
 
Conclusion 
 
 
The NMP22 BladderChek test is easy to perform, is user independent and 
gives an in office result. Compared to the precursor of the test, the NMP22 
Bladder Cancer test, the sensitivity for the NMP22 BladderChek test is lower 
and the specificity is higher for patients in follow-up. A slight improvement is 
sensitivity compared to cytology is seen, with a minor loss in specificity. 
Tumour detection however was not enhanced by adjunction of the NMP22 
BladderChek test. In summary, for patients in follow-up the test is convenient 
but gives no additional improvement to earlier urine tests. Whether the test 
has  value in the non-urological setting for detection of bladder tumours in 
patients with haematuria must be further evaluated.  
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Summary 
 
 
Non-muscle invasive bladder cancer is characterized by a high risk of 
recurrence for the low risk tumours and a high risk of recurrence and 
progression for the high risk subgroup of tumours. Therefore, frequent 
surveillance of all bladder cancer patients is a necessity. Several markers have 
been developed and studied as an alternative or as an addition to the 
combination of cystoscopy and cytology. Bladder cancer is a disease with 
chromosomal abnormalities. UroVysion® detects these abnormalities in 
chromosomes 3, 7, 17 and the 9p21 locus by fluorescence in situ hybridisation 
(FISH). Studies indicate the test as one of the most promising markers for 
bladder cancer. However, since large meta-analyses or reviews are absent, the 
patient selection remains indefinite. Furthermore, the test is labor-intensive 
and costly,  resulting in a low practical implementation.   
 
 
Introduction 
 
 
Non-muscle invasive bladder cancer covers a broad spectrum of tumours. At 
the one end the relatively innocent pTaG1 tumours are seen, with a high risk 
of recurrence whereas the risk of progression is low. On the other end the 
possibly life-threatening pT1G3 + CIS is found, characterized by both a high 
risk of recurrence and a high risk of progression. Consequently, frequent 
surveillance is necessary in all patients with non-muscle invasive bladder 
tumours. Traditionally the surveillance regimen consists of the combination of 
cystoscopy (UCS) and cytology. Both methods have pros and cons. With 
cystoscopy even the low grade papillary tumours are found. On the other 
hand the procedure is invasive and thus a burden for the patient. Moreover 
the high grade carcinoma in situ lesions can be completely imperceptible, even 
for highly experienced cystoscopists as is also demonstrated by the use of 
intravesical 5-aminolevulinic acid (fluorescence cystoscopy) 1. Cytology has 
more chance to detect these flat lesions, although recent series found a 
detection rate of only 60% of grade 3 lesions by cytology. Also the accuracy of 
cytology appears to be influenced by the investigator, the result is unreliable 
in case of infection or after intravesical therapy and the sensitivity in low 
grade lesions is very low (11% for grade 1 and 31% for grade 2 lesions) 2.  
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Thus, although used as a gold standard in the follow-up of patients with non-
muscle invasive bladder cancer, this combination is far from perfect.  
Fluorescence in situ hybridization (FISH) is known for several years in the 
diagnosis of bladder tumours. The test was FDA approved in 2001 for use in 
monitoring urothelial carcinoma for tumour recurrence. In bladder cancer 
chromosomal abnormalities are seen, just like in most other malignancies. The 
cells that are examined are derived from urine or a bladder wash of the 
patient. The multitarget FISH analysis shows the enumeration of copies of 
(parts of) chromosomes in interphase (figure 1). The test is composed of a 
combination of probes, which combination yields the highest sensitivity and 
specificity for bladder cancer recurrence: the Centromeric Enumeration Probes 
(CEPs) for chromosomes 3 (red), 7 (green), 17 (aqua) and the Locus-Specific 
Identifier (LSI) probe for 9p21 (gold). Deletions within the short arm of 
chromosome 3 (3p) have been found in high grade, muscle-invasive bladder 
cancer and numerical abnormalities of chromosome 7 are the most sensitive 
marker for urothelial cancer detection 3. The p53 tumour suppressor gene 
(TSG) was identified on chromosome 17 and a mutation in this TSG is 
associated with higher malignancy grade and stage.  Homozygous deletions of 
the p16 gene at 9p21 are one of the most common alterations in urothelial cell 
carcinoma (UCC) and occur early in the development of bladder cancer 4. The 
FISH slide is scanned for morphologically abnormal cells, the same as 
considered in cytology. A minimum of 25 of these cells are viewed and the test 
is considered positive if ≥ 4 of those cells exhibit gains of ≥ 2 chromosomes or 
when in ≥ 12 cells a total loss of 9p21 signals is seen. So with FISH the 
molecular DNA changes are added to the conventional morphological 
changes. 
 
 
Overview 
 
 
For several years the FISH analysis has been studied. Most recently the results 
of 9 studies performed between 2000 and 2004  evaluating the role of FISH in 
bladder cancer surveillance was reviewed by Jones 5.  
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Overall sensitivity of FISH was 74%. The sensitivity of FISH for grade 1, 2 and 
3 tumours was 58%, 77% and 96% respectively.  Similar findings occurred by 
stage, where the sensitivity for Ta, T1 and muscle-invasive carcinoma was 
64%, 83% and 94% respectively. FISH outperformed conventional cytology 
across all stages and grades. Cytology detected only 67% of  CIS versus 100% 
detection by FISH. The specificity of FISH was comparable to that of cytology. 
In 2005 van Rhijn et al. 6 reviewed four studies performed between 2000 en 
2003 with patients under surveillance. They found a median sensitivity of 79% 
(range 70-86) and a median specificity of 70% (range 66-93) for the FISH 
analysis. They considered the test as one of the most promising markers for 
surveillance at this time. The specificity of the FISH analysis appears to be 
comparable to that of cytology, in other words it is not 100%. That means that 
there are patients with FISH positivity in absence of concurrent detectable 
malignancy. However, a vast majority of these patients develop clinical 
evidence of tumour within several months. The term anticipatory positive 
(AP) results has therefore been introduced by Sarosdy et al. 7 to replace the 
term false positivity. That means that FISH is positive in anticipation of 
development of morphologic findings in a large majority of cases.  
Figure 1 
  
A) FISH positive nucleus     
 
B) Chromosome 3; Red       
 
C) Chromosome 7; Green     
 
D) Chromosome 17; Aqua     
 
E)  Locus 9p21; Gold 
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Besides the use of the test in the surveillance of patients, several other 
applications have been considered. Especially since the FISH result, unlike 
other urinary markers and conventional cytology, is not affected by 
haematuria, infection, instrumentation or intravesical therapy. One of the 
other applications is the assessment of the response to intravesical therapy by 
FISH. Although studied in a small number of patients (37), Kipp et al. 8 found 
FISH useful in prediction of recurrence and even progression based on a 
positive post-therapy FISH result. Another approach is the use of the test in 
case of an atypical or negative cytology result. Skacel et al. 9 retrospectively 
tested 120 urine samples of patients with known malignancy. They found that 
FISH detected 85% of the cancers that had been missed by conventional 
cytology. Bollmann et al. 10 classified the FISH results of their pilot study in 3 
groups: negative, low risk and high risk, depending on the amount of 
chromosomal abnormalities in the sample. Their results indicate that FISH 
may help to individualize the patient’s follow-up, meaning identifying those 
patients at risk for progression while lowering the number of cystoscopies in 
patients with low-grade disease.  Although the results presented are very 
promising, clinical implementation remains low and a clear cut selection of the 
patient group that benefits most of this assay remains necessary.  This can be 
caused by the absence of large meta-analyses or reviews. Small differences in 
the processing and / or scoring of the samples and moreover, differences in 
the selected patient groups make it difficult to compare different studies. 
Furthermore, a consensus for the criteria used for the evaluation of abnormal 
cells is lacking. And lastly, the test has a high work-load and costs. So, 
although FISH appears to be one of the most sensitive and promising marker 
for bladder cancer at this moment, the use in everyday practice of the urologist 
is limited.  
 
 
Conclusion 
 
 
Although FISH appears to be one of the most sensitive and promising markers 
for bladder cancer at this moment, the precise indication remains unclear and 
the clinical utility of the test remains low.  
 
 
 
 
Using FISH in detecting bladder cancer 
59 
   
 Five-year forecast 
 
 
A consensus in the definition for the criteria used for the evaluation of 
morphologically abnormal cells must be attained. 
 
Since recent unpublished data do not all confirm the initial positive results, further 
large, prospective studies will be performed to determine the value of the FISH 
test in patients with non-muscle invasive bladder cancer.  
 
The patient group which benefits most of application of the test will be defined.  
Probably patients treated with intravesical therapy, with equivocal cytology 
results or  after cystectomy. 
 
Possibly the patients policy can be individualized by stratifying them according to 
their chromosomal abnormalities. That means that patients at risk for progression 
are detected at an early stage, whereas the number of unnecessary cystoscopies is 
lowered in patients with low grade disease. 
 
Automated dot counters and other instruments will increase the ease and reduce 
the costs of the test. 
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Abstract 
 
Introduction: The multitarget fluorescence in situ hybridization (FISH) probe 
set Vysis® UroVysion consisting of probes for chromosomes 3, 7, 17 and for the 
9p21 band, was studied to evaluate its value in the follow-up of  patients with 
bladder cancer.  The results were compared to conventional cytology and 
quantitative cytology (Quanticyt®). Aim of this study is to evaluate whether 
UroVysion® is a better adjunct to urethrocystoscopy as compared to cytology 
and quantitative cytology. 
 
Methods: UroVysion®, cytology and quantitative cytology was performed on 
113 voided urinary samples of 105 patients under surveillance for non-muscle 
invasive bladder cancer. Prior to the urethrocystoscopy or TURB, a voided 
urinary sample was obtained. The results of all tests were compared to 
evaluate the value of UroVysion®. 
 
Results: Sixty-four patients had biopsy proven UCC. Sensitivity and specificity 
were respectively 39.1% and 89.7% for UroVysion®,  40.6% and 89.7% for 
cytology and 42.1% and 67.9% for quantitative cytology. When the 
UroVysion®  test and cytology were combined, the sensitivity increased to 
53.1% but the specificity decreased to 79.5%. Sensitivity in Ta tumours was 
equal for cytology and UroVysion® (26.7%), in T1 and T2-T4 samples by 
UroVysion® was 60% and 50% respectively. Sensitivity in grade 1, 2 and 3 
tumours by UroVysion® was 21.4%, 36.8% and 66.7% respectively and in 4 
cases the UroVysion® test was positive, but no abnormalities were seen at 
cystoscopy.  
 
Conclusion: Our data suggest that the use of UroVysion® gives no 
improvement in the diagnosis of recurrent non-muscle invasive bladder 
tumours as compared to cytology or quantitative cytology.  
Chapter 5 
64 
Introduction 
 
 
The spectrum of non-muscle invasive bladder tumours covers low risk, 
intermediate risk and high risk tumours. The risk of recurrence or progression 
for individual patients within this spectrum can be estimated by use of the 
EORTC Risk Tables 1. In short, at one end of the spectrum, low risk tumours 
are found. Although the mortality risk of these tumours is very small, the 
recurrence rate is relatively high. At the other end of the spectrum the high 
risk tumours are found, also with a high recurrence rate but more important, 
with loss of  differentiation implying a high risk of progression to muscle-
invasive disease. Therefore, surveillance is required for all non-muscle 
invasive bladder tumours, with a minimum of 5 years follow-up for the 
patients with a low-risk tumour, up to lifelong follow-up for the patients with 
a high-risk tumour. The combination of cystoscopy with cytology is currently 
used for the surveillance of tumours in all different risk groups. During 
cystoscopy papillary tumours are clearly seen, but the high grade carcinoma in 
situ (CIS) lesions are readily missed. On the other hand cytology shows a high 
sensitivity for high grade tumours, while tumours with a moderate or good 
differentiation are easily missed. Moreover, the results of cytology are not 
reliable in case of an infection or after intravesical therapy and the test results 
are operator dependent. Two important aims in improving the surveillance of 
bladder cancer patients are first adding to the value of cystoscopy and 
cytology and second individualizing treatment policy. Herewith, for example, 
the number of unnecessary cystoscopies in low risk patients can be 
diminished. For several years urinary markers have been developed and 
studied for this purpose. In general their sensitivity is higher compared to 
cytology, but at the cost of a decreased specificity caused by higher false-
positive rates.   
The multitarget fluorescence in situ hybridization (FISH) assay shows the 
enumeration of copies of (parts of) chromosomes in interphase. The multicolor 
FISH probes allow simultaneously targeting of chromosome 3, 7, 17, and the 
9p21 region  in a single cell. Deletions within the short arm of chromosome 3 
(3p) have been found in high grade, muscle-invasive bladder cancer and 
numerical abnormalities of chromosome 7 are the most sensitive marker for 
urothelial cancer detection 2. Mutations in the p53 tumour suppressor gene 
(TSG) on chromosome 17 is associated with higher malignancy grade and 
stage.  Homozygous deletions of the p16 gene at 9p21 are one of the most 
common alterations in urothelial cell carcinoma (UCC) and occur early in the 
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development of bladder cancer 3. The initial results of the FISH assay in the 
detection of bladder tumours were promising and the test was FDA approved 
in 2001 for use in monitoring urothelial carcinoma for tumour recurrence.  
However, clinical implementation remained low and a clear cut selection of 
the patient group that benefits most of this assay remains indefinite.   
Quantitative cytology is a method of cellular analysis which was proven to be 
superior to urine cytology for the identification of patients at risk for tumour 
recurrence and progression 4,5. In short, quantitative cytology is an automated 
karyometric analysis, using a personal-computer-based image analysis system. 
For each analyzed nucleus, the DNA content and the nuclear shape feature 
PASS are determined. Based on these features, patients are divided in risk 
groups for presence of tumour. 
The aim of this study was to determine the value of the UroVysion assay for 
the patient group under surveillance for bladder cancer, and to compare it to 
conventional urine cytology and quantitative cytology.  
 
  
Methods  
 
 
Between March 2005 and April 2006 113 voided urinary samples and bladder 
wash samples were obtained of 105 patients who provided informed consent. 
All patients had (a suspicion of) a bladder tumour. An overrepresentation of 
tumours was used to increase the number of positive samples at the time of 
collection. Urinary samples were used for routine cytological examination, 
sediment, culture and FISH analysis. Quantitative cytology was performed on 
bladder wash samples 4. The persons who performed the different tests, were 
blinded to each other’s result, and to the pathology report. Clinical 
information was recorded and matched with the results of the tests. All 
resected tissue was examined by one uropathologist; staging and grading was 
done according to the TNM classification 6 and World Health Organization 
1973 7. Imaging of the upper urinary tract was performed according to  the 
EAU guidelines. The influence of red blood cells and white blood cells in the 
sample was studied. Statistical analysis was performed using the Statistical 
Package for Social Sciences (SPSS), release 12.0.  
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UroVysion® 
 
Fluorescence in situ hybridization (FISH) was performed using the Vysis® 
UroVysion Bladder Cancer recurrence kit (Abbott laboratories Inc, Hoofddorp, 
The Netherlands). In brief, urine samples were spun down (10 min 1000 rpm) 
within 24 hours from collection. The sample was washed in PBS and 
subsequently fixed in a mixture of methanol/acetic acid (3:1). Microscopic 
preparations were made by dropping 10-15 µl of fixed and resuspended cells 
onto a microscopic slide. After a pepsine pre-treatment and post-fixation in a 
1% formaldehyde solution, probe hybridization was performed onto the 
slides. In total a 3 µl UroVysion® probe mixture and 8 µl hybridization 
solution were administered under a coverslip of 18 x 18 mm and denatured 
simultaneously on a Hybaid Omnislide (Thermo Electron). The probe set 
consists of repetitive sequences specifically recognizing the centromeric 
regions of chromosomes 3, 7 and 17, and a unique locus sequence that 
recognizes the 9p21 region. These DNA sequences were directly labeled with 
the fluorophores SpectrumRed, SpectrumGreen, SpectrumAqua and 
SpectrumGold, respectively (figure 1, page 57). Post-hybridization was 
performed as described in the protocol of the used kit. A Zeiss Axiophot-2 
microscope equipped with appropriate fluorescence filters was used for 
analyzing the fluorescence signals. Images were captured by a Leica DC350FX 
camera using a Leica CW 4000 software package.  The specimen was scanned 
for morphologically abnormal cells, i.e. cells with a large nuclear size, irregular 
nuclear shape, “patchy” DAPI staining or cell clusters The test was considered 
positive if ≥ 4 of the 25 morphologically abnormal cells showed gains for 2 or 
more chromosomes (3, 7, or 17) in the same cell, or ≥ 12 of the 25 cells had zero 
9p21 signals. From each sample the signals were counted in a minimum of 25 
morphologically abnormal cells 8. In case of doubt about the test result, the 
number of counted cells was increased.  
 
Results 
 
 
A total of 113 voided urinary samples were obtained of patients under 
surveillance for bladder cancer. In 5 cases the sample was excluded because 
the FISH analysis could not be performed due to haematuria (2) or too few 
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cells (3) in the sample. In all these cases the cytology result was available. 
Another five samples were excluded due to an incomplete histology  or 
cytology result. The 103 analyzable samples were derived of 73 men and 22 
women, with a median age of 69.9 years (range 43.7-93.2 years). In 64 cases a 
histologically confirmed bladder tumour was found. A mean of 29 (range 0-51) 
morphologically abnormal cells were counted. Sensitivity and specificity for 
all tests are shown in table 1. Sensitivity and specificity of the different tests 
according to stage and grade are shown in table 2 and tumour stage and grade 
in relation to abnormalities in chromosomes 3, 7 ,17 and locus 9p21 are shown 
in table 3.  In four cases a positive FISH result was found without presence of a 
malignancy on cystoscopy. The presence of microscopic haematuria and white 
blood cells in the sample did not diminish the value of the FISH analysis.   
 
 
 
 
 Sensitivity (%) Specificity (%) 
UroVysion 39.1 89.7 
Cytology 40.6 89.7 
Combination (Uv+Cyt) 53.1 79.5 
Quantitative Cytology 42.1 67.9 
 
Table 1 Overall sensitivity and specificity   
 
 
 
 
 
 Ta (44) T1 (10) T2- 4 (4) G1 (27) G2 (19) G3* (18) 
UroVysion 26.7 60 50 22.2 36.8 66.7 
Cytology 26.7 70 75 22.2 26.3 83.3 
Combination 
(Uv & Cyt) 
40 80 75 29.6 52.6 88.9 
Quantitative 
Cytology 
35.7 57.1 NR** 40 35.7 55.6 
*   CIS (6) is grade 3 
** quantitative cytology results were not applicable 
 
Table 2 Sensitivity (%) per stage and grade 
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Chrom 3 Chrom  7 Chrom 17 Locus 9p21 Total  
n (%) n (%) n (%) n (%)  
Benign 26 (66.7) 20 (51.3) 15 (38.5) 1 (2.6) 39        
Ta 25 (55.6) 22 (48.9) 21 (46.7) 11 (24.4) 44 
T1 10 (100) 8 (80) 8 (80) 3 (30) 10 
T2-T4 4 (100) 4 (100) 3 (75) 1 (25) 4 
G1 14 (51.9) 13 (48.1) 11 (40.7) 6 (22.2) 27 
G2 14 (73.7) 10 (52.6) 11 (57.9) 5 (26.3) 19 
G3 17 (94.4) 16 (88.9) 14 (77.8) 7 (38.9) 18 
 
 
Table 3 Chromosomal abnormalities according to stage and grade 
 
 
 
Discussion 
 
 
The use of a urinary marker in the follow-up of patients with a non-muscle 
invasive bladder tumour can be of great value. The UroVysion®   test is such a 
urinary marker. Several applications of the test have been proposed and 
studied. For instance, the use of the test in patients with haematuria or dysuria 
suspected for bladder cancer , the use of the test as an additive if cytology is 
inconclusive and the use of the test in patients under surveillance. However, 
most studies combine the results of several patient groups and determine an 
overall sensitivity and specificity. Moreover, urinary samples and bladder 
wash samples are simultaneously used, which makes it difficult to compare 
the results of our study with the literature. Van Rhijn et al. 9 reviewed 4 
studies determining the value of FISH for patients under surveillance and 
found a median sensitivity of 79% (range 70-86) and a median specificity of 
70% (range 66-93). Sarosdy et al. reported a sensitivity of 71% and a specificity 
of 65.8% based on 176 patients with a tumour in the previous 9 months 10. 
Unfortunately no information was given about the technique of the FISH 
analysis or the number of cells that were scored. Laudadio et al. 11 found a 
sensitivity of 71% (56-86) and a specificity of 71% (58-86) based on 141 patients 
with a history of TCC. The processing of the samples and scoring after 
hybridization applied by this group was comparable to the technique used in 
our study. These results all show a higher sensitivity than was found in our 
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study, whereas our specificity result is among the best. The low sensitivity in 
our study might have been influenced by 22 pTa G1 tumours that were not 
detected. When these pTa G1 tumours are excluded, the sensitivity increases 
to 51.4%. The number of patients with a tumour (64/113) is relatively high. We 
aimed at this overrepresentation of tumour samples, because in the follow-up 
situation we consider avoidance of cystoscopies the most important possible 
use of a tumour marker. This can be achieved if the test has a high negative 
predictive value, which is largely dependent on the sensitivity of the test. To 
accomplish a reliable sensitivity, the number of patients with a tumour has to 
be relatively high. The estimated negative predictive value (NPV) and positive 
predictive value (PPV) for the UroVysion test were 92.4% and 31.3% 
respectively. By comparison, for cytology these estimated values were 92.6% 
and 32.4% respectively.  Taking into consideration that the cytology result 
strongly depends on the cytopathologist, in other words is subjective, this 
result of the FISH assay is an improvement since this test is more objective, 
provided that is is performed by an experienced FISH analyst. The overall 
sensitivity in Ta G1 lesions  is 21.4% for UroVysion® compared to 25% in 
cytology. By comparison, Sarosdy et al. found a sensitivity in Ta G1 lesions of 
55% for UroVysion® and 20% for cytology.  On the contrary, the sensitivity in  
CIS lesions is high for both tests (5/6) in our study. Sarosdy et al. found a 
detection of CIS lesions in 100% of the cases by UroVysion® and in only 33% of 
the cases by cytology. The sensitivity in grade 1 to grade 3 tumours increases 
in our study from 21.4% to 66.7%. This is overall lower compared to data 
found by Halling et al. 8, who detected 36%, 76% and 97% of grade 1, 2 and 3 
lesions respectively. So, in all, our sensitivity results appear lower as reported 
in literature thus far. However, a higher number of abnormalities is seen with 
higher grade for all chromosomes evaluated (table 3). Moreover, the 
percentage of abnormalities in T1 to T4 tumours is much higher in 
chromosomes 3, 7 and 17 as compared to abnormalities found at locus 9p21. 
This is expected since alterations at 9p21 occur early during the development 
of bladder cancer (table 3).  
 
The variety in results between studies may be caused by the fact that the FISH 
analyses are not carried out uniformly. Small differences can occur in the 
processing and /or scoring of the sample. Moreover, a consensus for the 
criteria used for the evaluation of abnormal cells is lacking. Unfortunately, 
some authors do not report this information in their paper, which complicates 
the comparison between different studies. In summary, in our study a 
relatively large number of tumours are missed, varying from Ta G1 tumours 
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to CIS and even muscle-invasive tumours, lowering the sensitivity. However, 
our specificity is high and comparable to the specificity of cytology. 
Studies on FISH have been extensive and are still going on. Several studies 
determined the value of the test in groups combining patients with 
haematuria and in follow-up 12-14 and an important role for FISH was seen in 
cytologically equivocal or negative urine samples 15. Several attempts have 
been undertaken to adapt treatment policy to the outcome of the FISH analysis 
16,17 and an improvement could be made in the follow-up of patients after BCG 
instillations, using FISH analysis 18.  Moreover,  FISH was combined with 
melanoma antigen genes (MAGE) and correctly identified urothelial cancer in 
97.7% of the patients 19.  
Most recently, several groups presented their results at the EAU congress 
2006. The group of Hakenberg et al. found equal results for the FISH analysis 
and cytology, comparable to our results 20. Since our results, just as the most 
recent results presented at the EAU congress 2006, do not confirm the initial 
potential value of UroVysion® as a marker for recurrent tumour, the value of 
the test in this field must be questioned. Whether the test has value as a 
prognostic marker, as a tool after BCG instillations, or as a screenings tool 
remains to be investigated.  
 
 
Conclusion 
 
 
The multi-target FISH analysis detecting chromosomal abnormalities in 
chromosomes 3, 7, 17 and locus 9p21 (UroVysion®) equally detects recurrent 
non-muscle invasive bladder tumours compared to conventional cytology and 
quantitative cytology. However, this test is more objective compared to 
cytology, and its specificity is high, comparable to the specificity of cytology. 
 
 
Acknowledgments 
 
 
The authors would like to thank the urology department of the Canisius 
Wilhelmina Hospital Nijmegen for their efforts to complete this study. 
 
 
UroVysion® in the surveillance of non-muscle invasive bladder cancer 
71 
References 
 
1. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, 
Denis L et al. Predicting recurrence and progression in individual patients 
with stage Ta T1 bladder cancer using EORTC risk tables: a combined 
analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49: 466-5 
2. Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA 
et al. The development of a multitarget, multicolor fluorescence in situ 
hybridization assay for the detection of urothelial carcinoma in urine. J 
Mol Diagn 2000;2: 116-123 
3. Williams SG, Stein JP. Molecular pathways in bladder cancer. Urol Res 
2004;32: 373-385 
4. van der Poel HG, Witjes JA, van Stratum P, Boon ME, Debruyne FM, 
Schalken JA. Quanticyt: karyometric analysis of bladder washing for 
patients with superficial bladder cancer. Urology 1996;48: 357-364 
5. van der Poel HG, Boon ME, van Stratum P, Ooms EC, Wiener H, 
Debruyne FM et al. Conventional bladder wash cytology performed by 
four experts versus quantitative image analysis. Mod Pathol 1997;10: 976-
982 
6. Greene FL, Balch CM, Fleming ID, Fritz A, Haller DG, and Morrow M et 
al. AJCC Cancer Staging Handbook TNM Classification of Malignant 
Tumours, 6th edition. Union Internationale Contre le Cancer and the 
American Joint Committee on Cancer. Heidelberg: Springer-Verlag , 335-
40 [Part IX]. 2002  
 
 7. World Health Organization (1973) Histological typing of urinary bladder 
tumours. International histological classification of tumours. no 10. 
Geneva.  1973  
 
8. Halling KC. Vysis UroVysion for the detection of urothelial carcinoma. 
Expert Rev Mol Diagn 2003;3: 507-519 
9. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for 
bladder cancer surveillance: a systematic review. Eur Urol 2005;47: 736-748 
Chapter 5 
72 
10. Sarosdy MF, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L et al. 
Clinical evaluation of a multi-target fluorescent in situ hybridization assay 
for detection of bladder cancer. J Urol 2002;168: 1950-1954 
11. Laudadio J, Keane TE, Reeves HM, Savage SJ, Hoda RS, Lage JM, 
Fluorescence in situ hybridization for detecting transitional cell carcinoma: 
implications for clinical practice. BJU Int 2005;96: 1280-1285 
12. Friedrich MG, Toma MI, Hellstern A, Pantel K, Weisenberger DJ, Noldus J 
et al. Comparison of multitarget fluorescence in situ hybridization in urine 
with other noninvasive tests for detecting bladder cancer. BJU Int 2003;92: 
911-914 
13. Halling KC, King W, Sokolova IA, Karnes RJ, Meyer RG, Powell EL et al. 
A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis 
UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 
2002;167: 2001-2006 
14. Halling KC, King W, Sokolova IA, Meyer RG, Burkhardt HM, Halling AC, 
Cheville JC et al. A comparison of cytology and fluorescence in situ 
hybridization for the detection of urothelial carcinoma. J Urol 2000;164: 
1768-1775 
15. Skacel M, Fahmy M, Brainard JA, Pettay JD, Biscotti CV, Liou LS et al. 
Multitarget fluorescence in situ hybridization assay detects transitional 
cell carcinoma in the majority of patients with bladder cancer and atypical 
or negative urine cytology. J Urol 2003;169: 2101-2105 
16. Pycha A, Lodde M, Comploj E, Lusuardi L, Palermo S, Mian M et al. 
Multicolour-FISH for the risk stratification of superficial bladder cancer. 
Eur Urol Suppl 5[2], Abstract 925. 2006  
 
17. Bollmann M, Heller H, Bankfalvi A, Griefingholt H, Bollmann R. 
Quantitative molecular urinary cytology by fluorescence in situ 
hybridization: a tool for tailoring surveillance of patients with superficial 
bladder cancer? BJU Int 2005;95: 1219-1225 
UroVysion® in the surveillance of non-muscle invasive bladder cancer 
73 
18. Kipp BR, Karnes RJ, Brankley SM, Harwood AR, Pankratz VS, Sebo TJ et 
al. Monitoring intravesical therapy for superficial bladder cancer using 
fluorescence in situ hybridization. J Urol 2005;173: 401-404 
19. Kang JU, Koo SH, Jeong TE, Kwon KC, Park JW, Jeon CH. Multitarget 
fluorescence in situ hybridization and melanoma antigen genes analysis in 
primary bladder carcinoma. Cancer Genet Cytogenet 2006;164: 32-38 
20. Hakenberg O, Schmidt U, Berdjis N, Meye A, Wawroschek F, Baldauf A et 
al. Comparison of urinary cytology and fluorescence-in-situ hybridisation 
assay (FISH) for the detection of urothelial bladder carcinoma. Eur Urol 
Suppl. 5[2], Abstract 462. 2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  
Chapter 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PMJ Moonen, MFC Vermeulen, LALM Kiemeney, SC Henzen-
Logmans, R Beekman, AS Bierkens, JA Witjes. Submitted Urology 
The diagnostic and prognostic value of 
UroVysion® in  bladder cancer 
 

Diagnostic and prognostic value of UroVysion® 
  
   77 
Abstract 
 
Introduction: UroVysion® is a FISH assay for bladder cancer. In this large 
retrospective study, the data of a community hospital were used to determine 
the diagnostic and prognostic value of the test. Data were compared to 
cytology and to the results of FISH in an earlier study performed in an 
academic centre.  
 
Methods: Sensitivity and specificity were determined based on 680 urine tests. 
Patients with a true-negative result were compared to those with a false-
positive result (total 258 patients) with respect to clinical outcome. 
Furthermore, patients were divided in a low risk group and a high risk group, 
based on their chromosomal abnormalities and again compared regarding 
their clinical outcome.  
 
Results: Sensitivity and specificity were 78.2% and 76.1% for FISH, 
respectively, and 85.7% and 70.7% for cytology, respectively. In 19% of the 
cases the FISH test gave no result and 49% of all Ta tumours were missed by 
FISH. False-positive FISH results or high risk chromosomal abnormalities did 
not have an impact on clinical outcome. The performance of FISH is better 
compared to the earlier data in a selected group of patients in an academic 
centre. 
 
Conclusion: The sensitivity of FISH  is high (78%) in this study, however low 
stage and low grade lesions are readily missed. There is no significant 
difference in clinical outcome based on false-positive FISH results and high 
risk (7 and 17) chromosomal abnormalities. The value of FISH in this large 
retrospective study is better compared to the data of an earlier study in our 
academic centre (sensitivity 39%). No evidence for the need of replacement of 
cytology in favor of FISH is found.  
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Introduction 
 
 
Bladder cancer is a disease with high impact for the European community, 
with 120,000 new cases per year  and 35,000 deaths in 2004 1.  Approximately 
70% of patients present with a non-muscle invasive bladder tumour, defined 
as a malignant lesion confined to the mucosa or the submucosal layers of the 
bladder (stages Ta, T1, or carcinoma in situ ). These patients are all treated 
with a transurethral resection of the tumour, with one or more subsequent 
intravesical instillations with chemotherapy or immunotherapy.  These 
tumours however cannot be considered a homogeneous group, surveillance is 
therefore required for all patients. Currently cystoscopy in combination with 
cytology is used for this surveillance. Although papillary tumours are easily 
seen with cystoscopy, the flat but highly aggressive carcinoma in situ (CIS) is 
readily missed. Moreover, cystoscopy is an invasive procedure and thus 
bothersome for the patient. Cytology is highly sensitive for high grade lesions, 
but low grade lesions stay frequently undetected. Furthermore, the results of 
cytology are not reliable in case of infection and the results appear to depend 
on the cytologist. In all, a new urinary marker has to be found that may reduce 
the number of cystoscopies, adds to the value of cytology, and individualizes 
patient’s policy.  
The use of multitarget fluorescence in situ hybridization (FISH) in bladder 
cancer is based on the knowledge that urothelial cell carcinoma shows 
frequent genetic alterations in specific genomic regions. These genetic 
alterations can be evaluated by, e.g., karyotyping, microsatellite analysis for 
allelic imbalance, or  fluorescence in situ hybridization.  UroVysion® is such a 
FISH assay. It shows enumeration of copies of (parts of ) chromosomes in 
interphase. The multicolour, multitarget  FISH probes allow simultaneously 
targeting of the centromeric regions of chromosomes 3, 7, 17 and the 9p21 
region (p16) in a single cell. The combination of these chromosomal 
abnormalities was determined as an optimal set for UCC detection 2. The test 
was approved in 2001 for monitoring recurrence in patients with  urothelial 
cell cancer. Although the initial results were promising, the clinical 
implementation stayed behind and a distinct selection of patients who may 
benefit of this assay remained indefinite.  
The aims of this retrospective study were (1) to determine the diagnostic value 
and the prognostic value of the UroVysion® assay in a large patient population 
in a community hospital and compare it to cytology and (2) to compare these 
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data to the data earlier found in our academic centre (Moonen et al. Eur. Urol. 
in press). 
  
 
 
Material and Methods 
 
 
In the Medical Centre Rijnmond Zuid (MCRZ) in Rotterdam, The Netherlands, 
FISH is being used on urine samples since the beginning of  2003,  in all 
patients with symptoms suggesting the presence of a bladder tumour. To 
determine the diagnostic and the prognostic value of this assay (UroVysion®), 
the results of 1,000 FISH assays and corresponding cytology tests, performed 
between February 2003 and December 2005 were analysed and matched with 
the clinicopathological data. All resected tissue was examined by one 
pathologist; staging and grading was done according to the TNM classification 
3 and World Health Organization 1973 4. Imaging of the upper urinary tract 
was done with a minimal frequency as advised in the EAU guidelines. In case 
of a positive FISH result without presence of tumour in the bladder, extra 
imaging of the upper urinary tract was done to rule out malignancy in the 
upper urinary tract. Since FISH is being used in daily practise in this centre, 
the cytology result underwent revision in cases of conflicting results. The final 
cytology result was used in the analysis. Data were compared to the earlier 
data of the Nijmegen study. 
 
For the determination of the prognostic value of the FISH assay, patients with 
a true-negative result, i.e. FISH negative and negative cystoscopy, were 
compared to patients with a false-positive result, i.e. FISH positive and 
negative cystoscopy (total 258 patients) with regards to recurrence-free 
survival, progression-free survival and bladder cancer specific survival. Also 
the risk stratification of Pycha et al 5 was adopted and patients were divided in 
low risk and high risk, according tot their chromosomal abnormalities. Follow-
up and treatment in the case of histological proven tumour was done 
according to the EAU guidelines. Again clinical outcome was compared in 
these two groups.  For the statistical analysis the Statistical Package for Social 
Sciences (SPSS), release 12.0 was used.  
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UroVysion 
 
 
Fluorescence in situ hybridization (FISH) was performed according to the 
manufacturing guidelines using the Vysis® UroVysion Bladder Cancer 
Recurrence kit (Abbott laboratories Inc, Hoofddorp, The Netherlands). The 
probe set consists of repetitive sequences specifically recognizing the 
centromeric regions of chromosomes 3, 7, 17, and a unique locus sequence that 
recognizes the 9p21 region. These DNA sequences are labelled with the 
fluorophores SpectrumRed, SpectrumGreen, SpectrumAqua and 
SpectrumGold, respectively  (figure 1, page 57). The specimen was scanned for 
morphologically abnormal cells, i.e., cells with a large nuclear size, irregular 
nuclear shape, “patchy” DAPI staining or cell clusters. The test was considered 
positive if ≥ 4 of the 25 morphologically abnormal cells showed gains for 2 or 
more chromosomes (3, 7, or 17) in the same cell, or if  ≥ 12 of the 25 cells had 
zero 9p21 signals 6. 
 
 
 
Results 
 
 
Diagnostic value 
 
In total 1,000 urine samples were collected, 320 samples were excluded 
because of insufficient cells in the specimen (111), bad morphology of the cells 
(71), bacterial growth (11), no optimal method (23), incomplete clinical data 
(68), and unknown reasons (36) respectively. As a result of these missing FISH 
values  29 cases were missed: pTa G1 (4), pTa G2 (10), pTa G3 (1),), CIS (3), 
pT1 G2 (2), pT1 G3 (3), pT2 G3 (3), pT4 G3 (1), G3 UCC of the pyelum (1) and 
one tumour in the ureter were missed.  In 14 of these 29 cases cytology was 
positive for tumour, the remaining 15 cases were also missed by cytology. 
After this  exclusion, 680 samples obtained from 358 patients with a median 
age of 74 years (range 23-97) were included. FISH was positive in 227 of the 
680 samples and in 119 samples a malignancy was found. Cytology was 
positive in 266 of the samples, but failed to give a result in 2 samples. Cytology 
underwent revision in 31 cases where the result of FISH was conflicting with 
the cytology result, with an increase in the diagnostic value of cytology as a 
consequence.  For the FISH assays, a median of 25 morphological abnormal  
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  Sensitivity 
(%)   
Specificity 
 (%) 
PPV  
(%) 
NPV  
(%) 
FISH 78.2         
(93/119) 
76.1 
(427/561) 
41.0 
(93/227) 
94.3 
(427/453)        
Cytology 85.7 
(102/119) 
70.7 
(395/559)* 
38.3 
(102/266) 
95.5 
(395/412) 
Combination 87.4 
(104/119) 
64.9 
(363/559)* 
34.8 
(104/299) 
96.0 
(363/378) 
*  in 2 cases cytology gave no result 
 
 
Table 1       Sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV) for FISH, cytology and both tests combined. 
Based on 119 samples with tumour and 561 samples without tumour 
 
                                                                            
 
cells were counted. In 2 cases no morphologically abnormal cells were seen in 
the specimen, in accordance herewith, both cytology and cystoscopy showed 
no signs of malignancy. Values for sensitivity, specificity, positive predictive 
value and negative predictive value for FISH, cytology and both tests 
combined are seen in table 1. The overall sensitivity for FISH and cytology is 
improved, when missing a Ta G1 tumour is not considered a failure. 
Sensitivity for both tests would then be as high as 84.3% and 91.2%, 
 
0
0,2
0,4
0,6
0,8
1
Ta (35) T1 (24) T2-T4 (40)
FISH
Cytology
Combi
 
   
0
0,2
0,4
0,6
0,8
1
G1 (17) G2 (21) G3 (73)
FISH
Cytology
Combi
 
 
Table 2A  
FISH sensitivity according 
to stage 
Table 2B  
FISH sensitivity according 
to grade 
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respectively.  Sensitivities stratified for stage and grade are seen in Figure 2A 
and 2B. Not separately mentioned in the figure are the samples with CIS only. 
FISH detected all 10 cases with CIS (sensitivity 100%), cytology missed 1 of the 
cases (sensitivity 90%).  
 
 
Prognostic value 
 
To examine the prognostic value of FISH we compared the recurrence-free 
survival, progression-free survival and bladder cancer specific survival in 351 
patients with a true negative test result or a false positive test result. After 
analysis of the medical records, 93 patients had to be excluded because the 
clinical data were not complete (49) or because they already had had a muscle-
invasive tumour in their history (44). As a result, 258 patients (59 primary, 199  
in follow-up) were included in the prognostic study with a median age of 73 
(range 24-94) and a mean follow-up time of 12 months (range 0-38 months). Of 
the 258 patients 170 started with a true-negative FISH and 88 with a false-
positive FISH result. A recurrence occurred in 10/170 patients with a true-
negative FISH result and in 11/88 patients with a false-positive FISH result. 
The Kaplan- Meier curve for recurrence-free survival is seen in Figure 3. The 2-
years recurrence-free survival shown is 89% and 77% for the true-negative and 
the false-positive patient group, respectively. The total number of cases with 
progression was 2, one in the false-negative group and one in the false-
positive group.  In total 14 patients died during follow-up, but only 1 patients 
died from bladder cancer. This patient had a true-negative FISH result in his 
history. Since the number of these events is small, no Kaplan-Meier curves are 
presented. We also applied the risk stratification according to Pycha et al. 5 on 
our data. The patients were divided in a low risk group (without 
chromosomal abnormalities, or abnormalities in chromosome 3 or 9), and a 
high risk group (with abnormalities in chromosomes 7 or 17). The recurrence-
free survival for these groups is shown in figure 4 and the difference is not 
significant. 
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Figure 4 
Recurrence-free survival  
according to the risk stratification 
of Pycha et al. 5  , i.e., low risk  
(no abnormalities / abnormalities 
in chrom. 3 and 9) , high risk 
(abnormalities in chrom 7 and 17) 
 
 
 
Figure 3  
Recurrence-free survival compared  
between patients with a true-
negative  and a false-positive FISH 
result. 
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Discussion 
 
 
The need for a new urinary marker, with a better performance in diagnosis 
compared to cystoscopy and cytology is evident. In general, this marker 
should be easy to perform, objective, non-invasive and not expensive. 
Furthermore, this marker should ideally predict the tumour’s biological 
behavior. In this way, treatment policy can be individualized, herewith 
decreasing the number of unnecessary cystoscopies in low risk patients and 
identifying patients at risk for progression in an early stage. Taken together, 
this would diminish the morbidity and mortality for non-muscle invasive 
bladder cancer patients and at best portends a potential in economic savings. 
UroVysion®, a multicolour, multitarget FISH analysis is suggested to be such a 
potential marker. Several groups have studied this marker. Although the 
results were predominantly positive, no consensus has been reached about its 
value and the implementation in daily practice stays behind.  Jones et al. 7 
reviewed the role of FISH in bladder cancer surveillance, based on 9 studies 
published between 2000 and 2004. They found an overall sensitivity of 74% 
and 48% for FISH and cytology respectively. The specificity results were 
comparable and varied between 86% and 97% for FISH. The greatest 
advantage for FISH however was seen in the detection of high grade lesions, 
including carcinoma in situ. They found that FISH outperformed cytology 
across all stages and grades. Moreover, it predicted malignancy before the 
lesions were visible by cystoscopy. This sensitivity of 74% for FISH is in 
agreement with the results of our study (78%). The specificity in our study was 
lower compared to the data of studies earlier performed (76%). A remark 
should be that the number of detected invasive tumours in this group of 
patients is very high. This increases the sensitivity of the test since aggressive 
tumours present more chromosomal abnormalities. If the 40 muscle-invasive 
tumours are excluded from the analysis, sensitivity decreases slightly to 73.4%. 
However, it must be mentioned that in 19% of cases no FISH result was found 
due to limitations of the test (insufficient cells in the specimen, bad 
morphology of the cells or bacterial growth). This means a high number of 
cases in which the test is not applicable.  
Noteworthy is the higher sensitivity of cytology in our study  (86%), and as a 
consequence the lower specificity (70.7%), compared to the majority of earlier 
studies. This is most likely the result of the revision that was performed in the 
case of conflicting cytology result, compared to the concurrent FISH result. 
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This suggests that FISH may improve the value of cytology in case of an 
indefinite result. A comparable result was seen by Skacel et al. 8 where FISH 
detected 31/35 tumours in samples where cytology was atypical (equivocal) 
and 12/20 tumours in patients with a negative cytology. Moreover, FISH is 
more objective compared to cytology, provided that it is performed by an 
experienced lab technician. The negative predictive value of FISH in this study 
is 94%.  This is important, since a high negative predictive value is necessary if 
a tumour marker is being used as a method to decrease the number of 
unnecessary cystoscopies. The FISH results were stratified according to stage 
and grade (Table 2). Detection of Ta, T1 and T2-T4 tumours was 51.4%, 95.8%, 
and 87.5% respectively. By comparison, Krause et al.9 found a detection rate of 
59%, 89%, 99%, and 100% for Ta, T1, T2, and T3-T4 respectively. In our study 
grade 1, grade 2, and grade 3 tumours were detected in 41.2%, 66.7%, and 
91.8%, respectively. Krause et al. found a detection rate of 45%, 80%, and 99%, 
respectively. This seems to confirm the accuracy of our results, however this 
also implies that almost 50% of all Ta tumours and almost 60% of all grade 1 
tumours are missed by FISH. And these tumours are probably the most 
interesting when the test is used in the follow-up of non-muscle invasive 
bladder tumours.  
Many studies have been performed evaluating the prognostic value of FISH. 
The term “anticipatory positive” result has herein replaced the term “false-
positive” result, meaning that FISH may detect malignancy before it is visible 
on cystoscopy 10. Sarosdy et al. 10 found a recurrence rate of 41.1% in the 
“anticipatory positive” group, and a recurrence rate of 19.1% in the true-
negative group. This is a more pronounced difference compared to our data, 
with a 2-years recurrence rate of 23% and 11%, respectively, for the false-
positive group of patients and the true-negative group (Figure 3, log-rank test, 
p = 0.15). Zellweger et al. 11 recently studied the value of FISH for predicting 
recurrence after transurethral resection. In total 138 patients were 
prospectively followed for a median time of 19.2 months. FISH positivity 
according to the manufacturer’s criteria, at the time of a negative cystoscopy, 
was not significantly associated with the risk of recurrence (p = 0.12). Mian et 
al. 12 used the division between low risk patients and high risk patients 5 for a 
prospective study of 75 patients under follow-up. It must be noted that Pycha 
et al. 5 used a cut off level of greater than four aneusomic cells for a positive 
test. However, this does not affect the comparison of clinical outcome when 
patients are divided regarding the chromosomal abnormalities. Mian et al.12 
found a significant longer disease-free survival time in patients with 
abnormalities in chromosomes 3 en 9, compared to patients in whom 
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chromosomes 7 and 17 were affected. We also adopted this risk stratification 
to our data (Figure 4), however our results were not in accordance with those 
found by Mian et al 12.  
Although the value of FISH seems promising, the implementation in daily 
practice is still low. The current study was performed to evaluate the value of 
this assay in a community hospital where FISH is being applied since several 
years. After comparison of the results of this study performed in a large 
unselected group, with the results found earlier in a patient group under 
surveillance for bladder cancer in an academic centre (Moonen et al. Eur. Urol 
in press), we see a difference in the value of this FISH assay. The sensitivity in 
the first study and the current study was 39.1% and 78.2% respectively. The 
specificity was 89.7% and 76.1% respectively. This difference may have been 
caused by various reasons. First, the number of aggressive muscle-invasive 
tumours is much higher in the current study (34%), compared to the earlier 
study (6.3%), increasing the detection rate. This difference is the result of 
patient selection, i.e. patients under surveillance in the Nijmegen study and an 
unselected group of patients in the Rotterdam study. Second, the complexity 
of the test could be a possible explanation. In the current study the data of the 
first 4 months were not included in the analysis, since this period was needed 
to improve the method of the assay. This again confirms the necessity for a 
specialized lab technician, when a hospital decides to implement this test.  
Summarizing, although the test has some limitations that make the 
implementation at this moment more difficult, i.e. the rather expensive DNA 
probes, the presence of specialized laboratory equipment, such as a 
fluorescence microscope and filters, the necessity for specialized analysts and 
the time for this labour-intensive method, the assay can be promising. The test 
has not been studied before in this number of samples, obtained in daily 
practice, but this study shows that under these circumstances the test performs 
well and much better than for example in a group of patients under 
surveillance. The great advantage of FISH, however is not likely to be found in 
the diagnostic value since almost 50% of all Ta tumours are being missed. On 
the other hand, when the test performs comparable to cytology, the fact that 
FISH is a more objective test, may already be an improvement. Moreover, the 
use of the test can improve the diagnostic value of cytology. Some prognostic 
value can possibly be found, although one must bear in mind that if a test 
cannot validly detect the presence of a confirmed tumour, the chance of 
predicting one in the future is questionable. Only 51% of the Ta tumours are 
detected in this study. But, 96% of all T1 tumours and 100% of CIS were found 
by FISH, indicating the potential prognostic value for these high risk tumours.   
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Conclusion 
 
 
In this large retrospective study in a community hospital, FISH performed on 
urine samples has a sensitivity of almost 80%. This is an improvement 
compared to the earlier data of patients under surveillance in an academic 
centre. However, the low stage and low grade lesions are still frequently 
missed. Although FISH seems to improve the value of cytology and is more 
objective, provided that it is performed by an experienced lab technician, there 
is no evidence for implementation of FISH as a diagnostic test in daily 
practice. The risk of recurrence is higher in the patient group with a false-
positive FISH result, and in the patient group with a high risk FISH, although 
not significantly. So further study must be performed focusing on a risk 
stratification based on chromosomal abnormalities.  
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Abstract 
 
Introduction: Quantitative cytology (Quanticyt®) is a valuable marker for the 
identification of high risk superficial bladder cancer (SBC) patients and can be 
used to individualize surveillance of patients. A disadvantage is the necessity 
to perform an invasive procedure to obtain the required bladder wash sample. 
The aim of this study is to investigate whether quantitative cytology can be 
performed on voided urine with reliable results, consistent with the 
quantitative cytology performed on bladder wash samples.  
 
Methods: Between June 2003 and May 2005 a total of 288 voided urine samples 
in combination with bladder wash samples were obtained from SBC patients 
who visited our urological outpatient department. Quantitative cytology was 
performed on all samples. Corresponding clinic pathological features and 
washed cytopathology results were collected. Linear regression analyses were 
performed for comparison of results from both types of samples. 
 
Results: Ninety-one percent of the samples fell into the low- or intermediate 
region on bladder wash. A clear deviation in the nuclear shape (MPASS) was 
seen in the voided urine samples, which led to more low risk results.  The 
clinical characteristics show that this shift is not the result of under staging. 
The nuclear content (2cDI) did not change by performing the analysis on 
urine.  
 
Conclusion: When urine is correctly processed after voiding, quantitative 
cytology can be done on these samples. Voided urine based quantitative 
cytology can be implemented in daily practice.  
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Introduction 
 
 
The combination of urethrocystoscopy and cytology is currently used for 
surveillance of patients with superficial bladder cancer. The limitations of both 
are well known. Cystoscopy is an invasive procedure and carcinoma in situ 
lesions may easily be missed. To compensate, cytology is used which has a 
high sensitivity for these high grade lesions and a high overall specificity. 
Unfortunately it lacks sensitivity for low grade lesions. Moreover it has a low 
interobserver and intraobserver reproducibility 1. One of the goals in 
improvement of surveillance in patients with superficial bladder cancer is 
prevention of unnecessary cystoscopies.  To achieve this, urinary markers are 
being developed with a higher sensitivity than cytology and specificity 
comparable to cystoscopy. Quantitative cytology is a method of cellular 
analysis which has already proven to be superior to urine cytology for the 
identification of patients at risk for tumour recurrence and progression 2,3. 
Sensitivity and specificity are 95.2% and 65% respectively, on the condition 
that presence of tumour is assumed when the result is in the intermediate or 
high risk region. The subsequent risk of a recurrence within one year for the 
low, intermediate and high risk regions is 5.5%, 12.5% and 20.5%. The risk of 
progression at one year is 0.54%, 1.25% and 6.34% respectively 2 (Figure 1).  In 
addition it appeared that a 2cDI cut-off of 2.00c can be used to further stratify 
high-risk quantitative bladder wash cytologic findings. With a median time to 
progression of 20 months, patients with a 2cDI ≥ 2.00c  showed a risk of 
progression of 43% versus 13% for the patients with a 2cDI < 2.00c 4.  
Moreover, addition of consecutive quantitative cytology to urine 
cytopathology evaluations, improves the detection of high-grade lesions and 
provides a more accurate prediction of tumour stage 5. A disadvantage of 
quantitative cytology is the need for an invasive procedure to obtain the 
required bladder wash sample. Earlier attempts to perform the procedure on 
voided urine samples did not succeed because of the vulnerability of the urine 
cells. Therefore adaptations have been made in the method of the analysis i.e. 
the time factor, the method to increase the number of cells in the sample and 
in the fixative used. Aim of this study is the comparison of conventional 
quantitative cytology on bladder wash, with the new technique performed on 
voided urine samples.   
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Figure 1       Report form of quantitative cytology (bladder wash) risk groups  
                      with recurrence (rec.) and progression (prog.) after 1 year of    
                      follow-up  2 
 
 
 
 
Material and Methods 
 
 
Patients 
 
Between June 2003 and May 2005 a total of  288 samples were obtained from 
patients who visited our outpatient department. Patients who underwent 
cystoscopy for surveillance of superficial bladder cancer or for the evaluation 
of symptoms suspicious for bladder cancer were eligible for the study. If 
intravesical instillations were given, the last treatment was at least 6 weeks 
ago. Both a voided urine sample and a bladder wash sample were obtained 
just before and during cystoscopy, respectively. Quantitative cytology was 
performed on all samples.  
 
 
 
LOW RISK
HIGH RISK
Rec.  5.5% 
Prog.0.54% 
 Rec. 20.5% 
 Prog.6.34% 
INT. RISK
Rec. 12.5% 
Prog 1.25% 
2.00c 
2cDI 
(0.00-6.00) 
MPASS (10.00 -20.00) 
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Quantitative cytology 
  
Quantitative cytology is an automated karyometric analysis, using a personal-
computer-based image analysis system. On each slide, 50 randomly selected 
images containing at least 100 nuclei were analyzed. For each nucleus present 
in the images, the DNA content (i.e. the 2c deviation index (2cDI) according to 
Böcking et al. 6) and the nuclear shape feature PASS (based on the smoothed 
Freeman difference chain code) were determined (Figure 2). Based on these 
features patients are divided in risk groups. This division is based on 
correlation with histology data.  Normal samples were mainly found in the 
right lower quadrant of the report form, the low grade malignancies in the left 
lower quadrant and the grade increased with the 2cDI 7,8. On the report form 
these groups are called respectively, low, intermediate and high risk.   
 
a)                 b)            c) 
 
Figure 2          a) low risk cells: round nuclei with normal DNA   b) intermediate  
risk cells: ellipsoid shaped nuclei with normal DNA   c) high risk cells: 
round nuclei with an abnormal amount  of DNA                                    
   
 
Voided urine sample 
 
 
The voided urine samples were obtained at the outpatient department prior to 
cystoscopy. The samples arrived at the laboratory within 30 minutes, where 
they were centrifuged (771 g for 10 minutes) and the pellet was fixed with 
Boonfix® (commercially available at Leiden Cytology and Pathology 
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Laboratory, Leiden, The Netherlands). Further staining and karyometric 
analysis was performed as described by van der Poel et al. 2. 
                                                           
Bladder wash sample 
 
 
The bladder-wash material was obtained by rinsing the bladder at least two 
times with 25 cc saline solution through the cystoscope. Obtaining the bladder 
wash sample is done before inspection of the bladder or other intravesical 
manipulations. The 25 cc of obtained material is instantly fixed in 25 cc of 
Boonfix® and stored at 5°C. At the laboratory, the material was centrifuged 
(771 g for 10 minutes) and the pellet was resuspended in Boonfix®. From that 
point on the procedure was exactly the same as with the fixed urine sample. 
 
 
Clinical information and the washed cytopathology results were matched with 
quantitative cytology. Resected tissue was examined by the local pathologist; 
staging and grading was done according to the TNM classification 9 and WHO 
1973 10, respectively.  Statistical analysis was performed using the Statistical 
Package for Social Sciences (SPSS), release 12.0. Scatterplots were made to 
evaluate the correspondence between quantitative cytology of bladder wash 
and voided urine. The regression coefficients and Pearson correlation 
coefficients were calculated to determine the systematic and  non-systematic 
deviations in the coordinates.  Before the regression coefficient of the 2cDI 
could be computed, a logarithmic transformation (Ln) of the data had to be 
performed because the data did not show a normal distribution.  
  
Results 
 
 
At the time of analysis patients were between 36 and 87 years old (mean ± SD 
63.6 ± 11.2). In total 123 and 21 samples were obtained of patients under 
surveillance and suspicious for bladder cancer respectively. Nine samples 
were analyzed but not included since the analysis was performed on urine 
only, as adaptations in urine fixation had to be made in the beginning of the 
study. The majority of patients had a low- or intermediate risk score based on 
their bladder wash quantitative cytology (Table 1).  
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Scatterplot of X-Y coordinates 
 
 
A scatter plot based on the X-Y coordinates of all coupled samples showed a 
pronounced deviation in the MPASS (Regression coefficient = 0.1). The 
correlation in the 2cDI (ln) is much better (Regression coefficient = 0.64) 
(Figure 3 ).  
 
The mean MPASS in the bladder wash samples and urine samples was 14.7 
(SD 1.37) and 16.0 (SD 1.16) respectively. This accordance is not significant (P 
= 0.11). In 80.4% the MPASS of the urine sample was higher compared to the 
bladder wash samples. The mean 2cDI was 0.80 (SD 0.63) and 0.89 (SD 0.69) in 
the bladder wash – and urine samples respectively. This accordance is 
significant (P<0.001). In 54.2% the 2cDI of the urine samples was higher 
compared to the bladder wash samples.  
 
 
 
 
 QC (voided urine)    
QC (bladder wash) Low  
risk 
Intermed 
risk 
High  
risk 
NA Total 
Low risk 51 1 4 14 70 
Intermediate risk 33 6 3 8 50 
High risk 0 0 10 5 15 
NA 5 0 0 4 9 
Totaal 89 7 17 31 144 
 
Table 1             Quantitative cytology (QC) risk score bladder wash versus  urine QC           
                          (voided urine) 
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Figure 3         Scatterplots of all MPASS-coordinates  (concordance in  
                        nuclear shape) and all 2cDI-coordinates (Ln)  (DNA content)                 
 
 
 
     
    
 
Deviation in risk groups 
 
Low risk 
 
Of 70 patients with a low risk score based on their washed quantitative 
cytology, 51 (72.9%) remained low risk when the analysis was performed on 
urine. One patient showed a minor shift to the left on the diagram, with an 
intermediate risk as result. From the 4 results that showed a shift from the low 
risk to the high risk part of the diagram, 3 were on the boundary of high risk 
(Figure 4) and only one result had a 2cDI of greater than 2.00c  (Figure 4). No 
tumour was found on cystoscopy or in the upper urinary tract. No tumours 
developed during the follow-up of at least 6 months and all 4 samples had a 
washed cytopathology result conform the low risk result. In this low risk 
group, 11 urine samples were not analyzable due to an insufficient cell count 
(100 nuclei are needed to give a reliable result) and in another 3 samples there 
were too many leucocytes that obscured the urothelial cells as a result of an 
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Linear regression analysis 
Intercept = 14.5               (Se = 1.2) 
Regression coeff = 0.1    (Se = 0.08) 
Rpearson = 0.12 
Linear regression analysis 
Intercept = - 0.06            (Se = 0.057) 
Regression coeff = 0.64  (Se= 0.090) 
Rpearson = 0.57 
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infection. On the other hand, in 5 cases the urine sample was analyzable while 
it was the bladder wash sample that showed an insufficient cell count or 
infection.  
 
 
Intermediate risk 
 
In the intermediate risk group on washed quantitative cytology, only a 
minority (6/50) showed no shift when the analysis was performed on voided 
urine. In 66% a shift to the low risk group was seen. In 29 of these 33 samples 
the washed cytopathology confirms the result of the low risk voided 
quantitative cytology and the cystoscopy shows no abnormalities (Table 2). 
Only 2 lesions are missed by the urinary analysis, one pTa G1 also missed by 
cytology and one pTa G2 that was scored by washed cytopathology as being 
low grade malignancy. The 3 samples with deviation to the high risk group 
showed a similar pattern as shown in figure 4, with a 2cDI not greater than 
2.00c. In none of these cases tumour was found on cystoscopy or in the upper 
urinary tract and no tumours developed in the 6 months thereafter. In one case 
washed cytopathology showed a grade 1 malignancy. Eight urine samples 
were not analyzable. Four due to infection and four due to an insufficient cell 
count.  
 
 
High risk 
 
The 10 samples in the high risk group remained high risk. In eight samples 
presence of tumour was found. In 2 cases the high risk result was a false-
positive result, but a tumour (Ta G2) was found after 9 and 17 months of 
follow-up. In five urine samples there was no result, 2 due to insufficient cell 
count and 3 due to infection.  
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Figure 4       Shift from low and intermediate bladderwash (O) to high risk urine (∆) 
 
 
 
Washed  
quantitative cytology 
Voided  
quantitative cytology 
Washed  
cytopathology 
Histology 
Neg Pos NA Neg Pos NA Neg Pos NA 
Benign  (123) 68 47 8 85 14 24 112 5 6 
Ta G1    (1) 0 1 0 1 0 0 1 0 0 
Ta G2    (7) 1 6 0 2 3 2 2 4 1 
Ta G3    (1) 0 1 0 0 1 0 1 0 0 
T1 G2    (1) 0 1 0 0 1 0 0 0 1 
T1 G3    (2) 0 2 0 0 1 1 0 1 1 
CIS        (2) 0 2 0 0 1 1 0 0 2 
≥ T2 G3 (7) 1 5 1 1 3 3 2 2 3 
 
Table 2       Results of quantitative cytology washed and voided and washed  
                    cytopathology versus histology  
 
 
 
 
 
 
 
 
 
 
 
 
 
LOW 
INT   
 
HIGH  
                
2.00c 
2cDI 
(0.00-6.00) 
MPASS   (10.00-20.00) 
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Discussion  
 
 
In the diagnosis and surveillance of superficial bladder cancer urine cytology 
is an important addition to urethrocystoscopy, especially for high grade flat 
carcinoma in situ lesions. While urine cytology has demonstrated a low 
reproducibility, quantitative cytology was developed for an objective 
representation of cytologic features in the bladder wash material. Two nuclear 
features demonstrated correlation with histological grade: DNA content (2cDI) 
and the mean of the nuclear shape feature (MPASS) 7. The test has proven its 
value in the diagnosis of bladder cancer and identification of high risk patients 
with prognostic value for the individual patient. Recently van Rhijn et al. 11 
reviewed urinary markers for the follow-up of bladder cancer. For 
quantitative cytology a median sensitivity and specificity of 59 (45-69) and 79 
(70-93) was found respectively. The disadvantage of the test is the necessity to 
perform an invasive procedure (catheterization or cystoscopy) to  obtain the 
bladder wash sample. Adjustments have been made in the procedure, with the 
aim of using voided urine instead of bladder wash for quantitative cytology. 
These adjustments were the fixation within 30 minutes, enrichment of the 
sample as a result of less dilution, and the use of a new fixative (Boonfix®). In 
this study a lack of correlation is found in the MPASS coordinates, although 
this may be related to the narrow range of MPASS results. This causes a clear 
shift to the right on the report form of voided urine results compared to the 
bladder wash results, meaning a shift from the intermediate to the low risk 
region. The exact reason for this shift is not clear but the nuclei of voided urine 
cells can show swelling and thus loss of the ellipsoid shape 12-14,  characteristic 
for cells in the intermediate region (Figure 2) . So the shift may be attributed to 
the better preservation of bladder wash cells. To examine whether this shift is 
of clinical importance, first the change in risk groups distribution was 
examined and second the possibility of understaging was evaluated. For the 
latter the results of all deviating samples were compared with washed 
cytopathology, cystoscopy and, in case of malignancy, histology result. The 
results suggest that the shift is not the result of understaging. As to the first 
mentioned, the majority of samples stratify the patients in the low- and 
intermediate risk group, with a 2cDI of less than 2.00c. It was already 
demonstrated that there is no significant difference in risk of progression in 
the low- and intermediate risk group 2. Moreover van Rhijn et al. found that 
2.00c is the cut-off value that identifies different risk groups for concomitant 
CIS, invasive TCC and progression 4. Overall 4/21 tumours were missed by 
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quantitative cytology performed on voided samples, because of a low risk 
result, versus 2/21 when the test was performed on bladder wash. 
Furthermore in 7 patients the urine sample was not reliable. But in the group 
of urinary samples the number of results suspicious for tumour (i.e. 
intermediate and high risk) in absence of malignancy, was much lower 
compared to the number of false-positive results in the bladder wash group 
(11.4% versus 38.2%). Most important is the fact that high risk results, which 
identify the patients at risk for progression, remain high risk when the test is 
performed on voided urine.  In five high risk patients a result could not be 
given, so in these patients still a cystoscopy would have been necessary. 
Moreover, when only the group of patients under surveillance for bladder 
cancer is taken into consideration, indeed a lower sensitivity is seen. One Ta 
G1 tumour and 2 Ta G2 tumours are missed by the test on urine versus 1 Ta 
G2 tumour with bladder wash (57.1% urine versus 88.9% bladder wash). On 
the other hand an increase in specificity for the urine test is found (98.4% urine 
versus 59.4% bladder wash). So that means a reduction in unnecessary 
cystoscopies. Indeed in 22 cases the test result is not applicable with urine and 
a bladder wash will have to be taken after all. 
 
 
Conclusion 
 
 
From our study it can be concluded that voided urine samples can be used to 
perform the quantitative cytology analysis. This implies a possible reduction 
in cystoscopies and other invasive procedures for patients under surveillance 
for superficial bladder cancer. 
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Prognostic markers and Risk stratification of Ta, Tis, T1 cancer 
 
 
Introduction 
 
 
The term “superficial bladder carcinoma” encompasses a spectrum of disease 
that ranges from the innocuous Ta grade I tumour, limited to the mucosa, to 
the life-threatening T1 grade III tumour, invading into the submucosa or 
lamina propria. Within the spectrum lie grade II tumours and carcinoma in 
situ, the latter one being high grade, flat, and confined to the epithelium. 
Superficial transitional cell carcinoma of the bladder is characterized by a high 
risk of recurrence (30-85%), with a maximal incidence in the first years 1-3. Of 
patients with superficial tumours, 10-15% develop subsequent invasive or 
metastatic cancer 4.  Currently, the standard clinical management consists of 
routine periodic control cystoscopies to resect recurrent tumours as early as 
possible, to decrease the risk of progression to muscle-invasive disease. 
However, the benefits of maintaining a fixed schedule of routine cystoscopy 
for all patients, irrespective of their individual risk, are questionable 5. There is 
a low-risk group of patients that is clinically cured after a few transurethral 
resections, who then could be spared the intravesical therapy and radical 
operations. On contrary, despite the advent of improved intravesical 
therapies, there remains a group of patients that is at risk of disease 
progression, metastases, and death from their disease. The ideal situation 
would be if the prognosis of the individual patient could be predicted early in 
the course of the disease so that patients with potentially progressive cancer 
could be treated more aggressively earlier. Risk stratification of patients based 
on clinical parameters provides new opportunities for adapting monitoring 
strategies as well as providing a rationale for the use of intravesical 
chemotherapy and immunotherapy, or a radical operation. In summary, 
collection and classification of prognostic factors in superficial bladder cancer 
enables us to make a risk stratification in this heterogeneous patient group. 
This brings us a step forward in minimizing the burden of unnecessary 
investigations and treatments while safely identifying those patients with 
high-risk disease that deserve aggressive treatment.  
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Prognostic markers 
 
 
A great deal has been published about prognostic factors in superficial 
bladder cancer 6-9.  These factors can be divided into two groups, a) 
clinicopathological parameters and b) molecular markers. Currently, the 
clinical and pathological parameters are used to provide necessary prognostic 
information. Millán-Rodríguez et al. 7 studied a large number of these factors 
in 1,529 patients with primary superficial bladder cancer. They found that 
multiple tumours, a tumour larger than 3  cm and instillations with BCG were 
risk factors for recurrence and progression. Presence of CIS was a predictor for 
recurrence, progression and disease-specific mortality and most important, 
grade 3 tumour was proven to be the main predictor for progression and 
mortality. Most recently, the clinicopathological parameters were studied in 
2,596 patients with superficial bladder cancer, and based on these results the 
EORTC risk tables were developed 10. With these tables the risk of recurrence 
and progression can be estimated for an individual patient. Factors that have 
proven to be significantly associated with the risk of recurrence are the 
number of tumours, the size of the tumour and prior recurrence rate. Factors 
determining the chance of progression are tumour stage, tumour grade and 
presence of CIS. Although a step forward, it must be realised that this chance 
is still an estimation, and thus not conclusive. Therefore new candidate 
prognostic markers are tested, to determine if they have a predictive capacity 
beyond the clinical and pathological factors. These new markers should 
ideally, predict recurrence, progression, development of metastases, response 
to therapy, and patient survival.  A large number of markers have been 
reviewed by the International Consensus Panel on Bladder Tumour Markers 9. 
They classified the prognostic markers into six groups:  (1) Microsatellite-
asociated markers (e.g. chromosomal abnormalities in 3p, 7, 9, 10q, 13q, 17p, 
18q). (2) Proto-oncogenes/oncogenes (EGFR, HER-2 or FGFR). (3) Tumour 
suppressor genes (p53, Rb). (4) Cell cycle regulators (p21, p27, Ki-67, cyclin 
D1/E). (5) Angiogenesis-related factors (VEGF, TSP-1, COX-2),  and (6) 
extracellular matrix adhesion molecules (E-cadherin, MMP-2 and TMP-2, 
uPA). They concluded that several proliferation, metastasis, and apoptosis-
related molecules may be promising in predicting recurrence as well as 
progression of bladder cancer. However, the results are contradictory, most 
likely a result of the lack of standardization in assessing the accuracy of a 
marker, the lack of definitive criteria for test positivity, lack of a clearly 
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defined patient population, and lack of clearly defined endpoints. Therefore, 
the tests are not adopted in standard practice yet and should not influence 
decisions for the individual patients.   
 
 
Risk stratification 
 
 
Some authors used the well known clinical and pathological factors to  
propose a risk group classification3,11-15.  In 1987 Takashi et al. 11 clarified the 
relative importance of factors affecting the survival of patients with bladder 
cancer. Unfortunately, in this study both superficial and invasive bladder 
cancer patients were included. A multivariate analysis by Cox’s proportional 
hazards model was performed on 264 patients. Clinicopathological data 
included in the analysis were sex, age, irritative bladder symptoms, interval 
from onset of symptoms to first consultation, smoking history and tumour 
characteristics (location, size, number, shape, histological stage and grade). A 
selection was made of factors according to the amount of contribution to 
survival. The selected factors were stage (T2-T4 versus Ta-T1), size, symptoms, 
age and grade, in order of statistical significance, with the last, grade, having 
the limiting level of significance (p=0.05). According to the presence of these 5 
factors, the patients were categorized into 6 groups and their survival was 
further evaluated (see Table 1.1). The six groups clearly demonstrated 
different survival probabilities; indicating that these five characteristics are 
definite determinants of survival in bladder cancer patients. Regrettably, no 
follow-up advices were given for these six risk groups by the authors. In 1989 
Parmar et al. 12 used data from 2 large randomized British Medical Research 
Council studies to identify several factors influencing the recurrence of newly 
diagnosed stage Ta or T1 tumours. The factors evaluated were the result of the 
3-month cystoscopy study, the number of tumours (multiple or single) at 
initial diagnosis, the maximum diameter of the largest tumour, the pathology 
grade, posterior wall involvement and tumour category (pTa or pT1). 
Multivariate analysis identified the result of the 3-month cystoscopy study as 
the single most important prognostic factor. Nearly as important, and the next 
factor to be chosen, was the number of tumours (multiple or single) at initial 
diagnosis. The analysis also suggested that the factors grade, category and 
maximum diameter are strongly associated with the result of the 3-month 
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cystoscopy study and number of tumours at presentation. Based on the two 
selected factors, three prognostic groups with regard to the risk of recurrence 
were formed (see Table 1.2). Evidently group 1 defined a set of patients who 
had a particularly good prognosis and, therefore, the follow-up schedule 
could be less stringent (follow-up at 3 months and then yearly). The patients in 
group 2 had an intermediate prognosis and should undergo an intermediate 
follow-up schedule (every 3 months for one year, every 6 months for one year 
and then yearly). The patients in group 3 had the worst prognosis and are 
likely to have recurrence within one year after the 3-month cystoscopy study. 
Thus, they should be followed intensively (every 3 months for 2 years and 
then yearly). According to this group, adoption of their proposed system 
could reduce the number of cystoscopies for the large proportion of patients 
who have a low risk of recurrence. This should lead to considerable savings in 
cystoscopy studies, which benefits both clinician and patient. Modifications of 
the policy are possible once a tumour has recurred, so a patient could start in 
group 1 and after recurrence may be reclassified in group 2 or 3. Such 
modification could provide a more personalized approach to patient 
management. 
 
 
 
Group Number of characteristics* Number of 
patients (%) 
1 None of the characteristics 97 (36.7) 
2 Any one of the characteristics 53 (20.1) 
3 Any two of the characteristics 41 (15.5) 
4 Any three of the characteristics 39 (14.8) 
5 Any four of the characteristics 24 (9.1) 
6 All of the characteristics 10 (3.9) 
* Characteristics: High-stage tumour; tumour > 3cm; irritative symptoms; age>70 years; high-
grade tumour 
 
 
Table 1.1 Risk groups (percentage of a total of 264 patients) according to Takashi et 
al. 9 
 
 
In 1993 Kiemeney et al. 3 not only wanted to discriminate between low-risk 
and high-risk patient groups, but also tried to optimize prediction of disease 
outcome in individual patients. Patient and tumor characteristics of 2,705 cases 
of primary pTa or pT1 bladder cancer were used to identify prognostic factors 
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Group Prognostic factors for recurrence Recurrence-free rate 
after 2 years (%) 
1 UCS negative at 3 months and 
 single tumour at presentation 
74 
2 UCS positive at 3 months or  
multiple tumours at presentation 
44 
3 UCS positive at 3 months and  
multiple tumours at presentation 
21 
 
Table 1.2 Risk groups according to Parmar et al. 12 
 
 
for recurrence and progression. After analysis tumour stage, extent (the 
number of bladder areas in which tumour tissue was found) and 
multicentricity (multiple tumours versus 1 solitary tumour) appeared to have 
predictive ability for the risk of first recurrence. For the risk of progression the 
most important prognostic factors were tumour stage, grade, multicentricity 
and dysplasia or carcinoma in situ in random biopsy specimens. By summing 
the regression coefficients (β values) of the multivariate Cox models on 
recurrence and progression, a prognostic index was constructed. A high score 
indicated that a patient had a poor prognostic profile (See Table 1.3A). Then 3 
risk groups were defined, based on the distribution of the prognostic index 
scores, so that the low and high-risk groups each represented at least 20% of 
all patients (See Table 1.3B).  Subsequently they evaluated the reliability of the 
prognostic index by comparing the observed and predicted actuarial risks of 
tumour recurrence and progression. The reliability seemed to be good, but 
then, they commentated, even if a prognostic factor does have such ability to 
differentiate in subgroups, this is no guarantee that prediction of disease 
outcome for individual patients will be accurate.  Two years later Kurth et al. 
13 followed and analysed 576 patients with Ta or T1 tumours to examine the 
relative importance of prognostic factors in superficial bladder tumours and 
suggested grouping of patients in three different prognostic groups. The 
following factors contributing to recurrence, invasion and survival were 
investigated: age, sex, size of largest tumour, number of tumours, T-category, 
grade, time from diagnosis (years), prior recurrence rate/year and site of 
involvement. After performing a multivariate analysis based on Cox’s 
proportional hazards regression model, three main factors determined 
patient’s prognosis: tumour size, grade and prior recurrence rate/year. Based 
on these three factors and their association with invasion and death due to 
malignant disease, an index was computed reflecting the risk of both early 
invasion and death due to malignant disease. Risk groups suggested were 
based on the index (see Table 1.4). In the analysed patient group the observed 
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Prognostic factor Recurrence β 
value 
Progression β 
value 
Tumour stage   
pTa 0 0 
pT1 0.40 0.56 
Tumour grade   
1 - 0 
2 - 0.53 
3 - 0.98 
Multicentricity   
Solitary 0 0 
Multiple 0.27 0.95 
No. of areas involved   
1 0 - 
2 0.17 - 
3 or more 0.52 - 
Therapy   
Transurethral resection alone 0 - 
Instillations - 0.43 - 
Result of random biopsies   
Normal - 0 
Not performed - 0.37 
Dysplasia/carcinoma in situ - 0.64 
 
 Table 1.3a Prognostic factors according to Kiemeney et al. 3 
 
 
 
 
 
Risk Group Prognostic index Range * 
 Recurrent disease Progressive disease 
Low 0 0 - 0.53 
Intermediate 0.17-0.57 0.56-1.73 
High 0.67-1.19 1.85-3.13 
* Based on total β scores 
 
 Table 1.3b Risk groups according to Kiemeney et al. 3 
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rate of tumour progression and death due to malignant disease was 7.1% and 
4.3% respectively in group 1 versus 41.6% and 36.1% respectively in group 3. 
According to Kurth et al. it is easy to assign a given patient to one of the three 
risk groups, because the used prognostic factors are available in daily practice. 
Obviously, more aggressive treatment (e.g. cystectomy and urinary diversion) 
should be considered only for those patients who failed conservative therapy 
and those who are assigned to risk group 3 (see Table 1.4). Patients possessing 
the criteria for the best profile might be spared adjuvant chemo- or 
immunotherapy until a worsening of one of these prognostic factors occurs. In 
1998 Allard et al. 14 proposed a simple prognostic index for anticipating more 
precisely the early clinical course of primary Ta and T1 bladder cancer, based 
on patient and tumour characteristics of 333 patients. Patients with pure 
carcinoma in situ (Tis) were systematically excluded. Prognostic factors 
analysed were: age, sex, smoking status, number of tumours (single or 
multiple), largest tumour diameter, stage, grade, mucosal biopsy and tumour 
site. Four factors were significant predictors of earlier recurrence in a 
multivariate Cox regression model. These predictors were 1) primary tumour 
multiplicity, 2) diameter > 3cm, 3) stage T1 and 4) grade 2 or 3. Thus, a four-
category prognostic index was created in which each category was solely 
defined by the number of adverse tumour characteristics (ATCs) at initial 
resection (see Table 1.5). According to analysis of the clinical course of the 
patients (recurrence-free probability at 12 and 24 months, recurrence and 
tumour rates and progression) in these risk groups, a prognostic index based 
on the number of adverse tumour characteristics (ATCs) initially present 
seemed a strong indicator of the clinical course within 3 years of the first 
endoscopic resection. In the group free of ATCs the recurrence-free probability 
at 12 and 24 months was 86% and 69%, respectively, and none experienced 
progression. 
 
 
Grade 
RR<1 
< 1.5  
RR<1 
1.5 - 3  
RR<1 
> 3  
RR 1-3 
< 1.5  
RR1-3 
1.5 - 3  
RR 1-3 
> 3  
RR>3  
< 1.5  
RR>3  
1.5 - 3  
RR>3 
> 3 
G1 1 1 1 1 2 2 2 2 3 
G2 1 2 2 2 2 3 3 3 3 
G3 2 2 2 2 3 3 3 3 3 
 
Based on three main factors that determine the patient’s prognosis: 
1. Tumour size: < 1.5 cm, 1.5-3 cm., and >3 cm 
2. Prior recurrence rate (RR) per year: RR < 1, RR 1-3, and RR > 3 
3. Grade: grade 1 (G1), grade 2 (G2), and grade 3 (G3) 
Risk groups (1, 2, or 3) are made, reflecting the risk of early invasion and death due to malignant 
disease. 
 
Table 1.4 Risk groups according to Kurth et al. 13 
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Group 1 No adverse tumour characteristics 
Group 2 One adverse tumour characteristic 
Group 3 Two adverse tumour characteristics 
Group 4 Three or four adverse tumour characteristics 
 * Primary tumour multiplicity; diameter > 3 cm;  stage T1;  grade 2 or 3 
 
Table 1.5 Risk groups according to Allard et al. 14 
 
 
Versus 30% and 19%, respectively and 7% with progression within 35 months 
of follow-up in the patient group with 3 or 4 ATCs. This four-category 
prognostic index presented by Allard et al. seems easy to apply in urological 
practice, as the information needed is routinely available. Although this 
simple prognostic index could greatly help to identify indicators for adjuvant 
intravesical therapy and to determine the optimal periodicity of control 
cystoscopy regimens, it is their own opinion that it is premature to 
recommend the use in routine urological practice and that further validation 
in future studies is needed. Most recent Millán-Rodríguez et al. 15 identified 
risk groups according to progression, mortality and recurrence rate by a 
multivariate analysis in a cohort of 1,529 patients with primary superficial 
bladder cancer. Possible prognostic factors, like stage, grade, multiplicity, 
tumour size > 3cm, carcinoma in situ association, and treatment with bacillus 
Calmette-Guerin (BCG) instillation were studied. Based on the analysis of 
these factors, a risk group classification was made (see Table 1.6). The rates of 
recurrence, progression and mortality were 37%, 0% and 0% in the low, 45%, 
1.8% and 0.73% in the intermediate and 54%, 15% and 9.5% in the high risk 
group, respectively. According to Millán-Rodríguez et al. this classification 
achieves good differentiation of recurrence, and particularly good 
differentiation of progression and mortality. Moreover, these are the main 
variables that determine the prognosis and management of superficial bladder 
cancer, so the classification may be useful for designing treatment and follow-
up strategies. 
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1. Low risk 
• Grade 1,  stage Ta 
• Grade 1,  stage T1,  single tumour 
2. Intermediate risk 
• Grade 1,  stage T1, multiple tumours 
• Grade 2,  stage Ta 
• Grade 2,  stage T1,  single tumour 
3. High risk 
• Grade 2,  stage T1,  multiple tumours 
• Grade 3,  stage Ta 
• Grade 3,  stage T1 
• Carcinoma in situ association 
 
Table 1.6 Risk groups according to Millán-Rodríguez et al. 15 
 
 
Discussion and conclusion 
 
Some factors appear to be significant in the majority of the aforementioned 
risk stratification schemes, although none of these studies has included all 
categories of superficial bladder cancer patients. The factors stage, grade and 
multiplicity are mentioned in the majority of the studies, whereas size of the 
tumour, recurrence rate, carcinoma in situ association, symptoms and age are 
mentioned only in the minority of studies. Additional potential clinical 
prognostic factors not used in these schemes, are prostatic urethral 
involvement and response to intravesical instillations. Additional 
histopathological factors are the level of infiltration into the sub epithelial 
connective tissue, growth pattern (solid versus papillary) and urothelial 
abnormalities in normal appearing mucosa. Extensive research is done with 
regards to molecular markers. However, the results are still conflicting, or 
preliminary. At this moment, no marker is ready to be implemented in daily 
practise, to influence treatment policies of patients. In the future most 
probably a panel of markers will be needed rather than one specific marker 
for, for example, recurrence or progression of superficial tumours. More 
research in this area is ongoing, and technical developments like micro array 
techniques will speed up the application. However, at this moment many, if 
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not almost all of these factors, have not found their way from the research 
laboratory to the clinical setting. Finally, there are some general limitations in 
the use of prognostic factors and stratification schemes. First, it is difficult to 
compare the different stratification schemes because of different definitions of 
begin- and end points. Most literature deals with Ta and T1 tumours, whereas 
carcinoma in situ is systematically excluded from the study or CIS association 
is a bad prognostic factor, as is also the case in some of the aforementioned 
schemes. Recurrence-free survival, recurrence rate per year, invasion and 
mortality are commonly used end points. Second, like Kiemeney et al. 3 
commentated on their own study, even if a prognostic factor seems to have the 
ability to differentiate in subgroups, this is no guarantee that prediction of 
disease outcome for individual patients (the ultimate goal of prognostic 
models) will be accurate. Third, these stratification schemes are hardly ever 
used in daily practice. Nevertheless, an important application has been 
implementation of these factors in guidelines, such as the AUA 18 – and EAU 
guidelines. In the EAU guideline, for example, patients are differentiated in 
low-risk: single Ta, G1, ≤ 3 cm diameter; high- risk: T1, G3, multifocal or 
highly recurrent, CIS and intermediate risk: all other tumours, Ta-1, G1-2, 
multifocal, > 3 cm diameter 19.  Apparently it is impossible to make risk 
stratification for every tumour and predict it’s possible evolution. So, further 
validation of the known risk stratification classifications, and development of 
molecular markers is needed to design treatment and follow-up strategies. 
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Abstract 
 
 
Introduction: The risk of developing muscle-invasive disease for a high risk 
superficial bladder cancer patient is up to 50%. Identification of those patients 
at risk for progression remains an unsolved problem. A suggested 
prognosticator is presence of mutations in the p53 tumour suppressor gene. In 
this study the value of a p53 mutation, demonstrated by mutation analysis is 
determined in a clinically selected group of high risk superficial bladder 
cancer patients.  
 
Methods: P53 mutation analysis was performed by automated sequencing of 
bladder wash samples of 105 patients with high risk superficial bladder 
cancer. The mutation and the wild type group were subsequently compared 
with regard to mortality, progression, disease worsening and recurrence-free 
period.  
 
Results: Twenty-nine patients had a mutation and 76 were wild type. The 
patients had a median follow-up of 58.3 (range 3-161) months. In total 13 
patients died of bladder cancer, 6/29 with a mutation and 7/76 patients in the 
wild type group. P53 mutation had no significant prognostic value for 
decreased survival, progression or disease worsening. The recurrence–free 
survival was significantly lower in the wild type group.  
 
Conclusion: We observed a trend towards a worse clinical outcome for high 
risk patients with a p53 mutation in the bladder wash. However, no significant 
differences were seen in clinical outcome parameters. Based on these data we 
conclude that the prognostic value of a p53 mutation is insufficient for 
individual patient policy making.  
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Introduction 
 
 
Superficial bladder cancer varies from a relatively innocent TaG1 tumour to 
the very aggressive and possibly life-threatening T1G3 tumour plus carcinoma 
in situ (CIS) . All these   lesions are treated with a transurethral resection and 
one or more instillations of intravesical chemotherapy or a course of 
intravesical immunotherapy. Despite adequate treatment, the disease will 
recur in up to 80% of the patients 1,2. The progression rate differs between low 
risk and high risk tumours. The risk of progression for the high grade  T1 G3 
tumours 3 and CIS 4  is reported to be as high as 50%. Moreover, Schrier et al. 5 
found that the 3-year bladder cancer specific survival for patients who 
progressed to muscle invasive cancer was significantly worse compared to 
patients with a primary muscle-invasive disease. Consequently, it is extremely 
important to identify those patients at high risk for progression and intervene 
prior to developing muscle invasive disease.  Although used in daily practice, 
tumour stage, grade, size and multifocality are not sufficient to predict clinical 
outcome. Identification of additional prognosticators is therefore essential. 
Such markers should predict the tumour biological potential and determine 
which patients should be treated more aggressively to prevent progression 
from non-musle “invasive” cancer. Although the literature is not conclusive,  
one of the most promising markers is the tumour suppressor gene p53 located 
on chromosome 17p. Normally, when DNA is damaged the p53 mediated 
pathways repair the injury through cell cycle arrest, DNA repair and if 
necessary, apoptosis.  However, in about half of all human malignancies 
mutations in the p53 gene are found 6. Also in urothelial cancer, the p53 gene 
is frequently inactivated.  Inactivation of the p53 gene by mutation or other 
mechanisms can result in the production of a dysfunctional protein with a 
prolonged half-life compared to the wild-type protein. A mutation in the p53 
gene can be found by mutation analysis or by immunohistochemistry. P53 
immunostaining is often used as a surrogate for p53 mutation, as the 
accumulation of p53 protein correlates with the amount of mutated p53 gene 7.   
Mutation analysis consists of SSCP screening for presence of mutations in 
exons 5 to 8 and in case of a shift direct sequencing of the gene. Mostly exons 5 
to 8 are analysed since 80% of all mutations are found in this central region of 
the gene 8. 
In this study we looked at the prognostic value of a p53 mutation found by 
mutation analysis for a worse clinical outcome, i.e., mortality, progression, 
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disease worsening and recurrence-free survival  in high risk superficial 
bladder cancer patients.  
 
 
Materials and Methods 
 
Patient Selection and Follow-up 
 
P53 mutation analysis was performed by automated sequencing of DNA 
isolated from bladder wash samples of 105 patients with high risk superficial 
bladder cancer from the Radboud University Nijmegen Medical Centre, the 
Netherlands. Clinical data were retrospectively abstracted from the records. 
These patients were then divided in a group with a mutation in the p53 gene 
and a p53 wild type group. Retrospectively the records of all these patients 
were analyzed. The first mutation analysis was taken as the starting point for 
follow-up. If a positive mutation analysis was preceded by negative analyses, 
follow-up was started with the positive test.  Progression was defined as 
development of ≥ T2 tumour, distant metastases or death due to bladder 
cancer. Disease worsening as a clinical indication to change the conservative 
policy, i.e.,  a recurrent papillary tumour within 1 year despite optimal 
treatment with ≥ 6 x BCG; T1 G3 recurrence; multiple recurrences; a 
recurrence of CIS between month 6 and 12, despite optimal treatment with      
≥ (6+3) x BCG.  A recurrence was defined as a tumour after at least one normal 
cystoscopy, a tumour at the first 3-month cystoscopy was not considered a 
recurrence. Disease history preceding the first analysis was taken into account. 
More specifically as possible additional prognosticators high recurrence rate  
(≥ 2 recurrences in 24 months), multiplicity (≥ 2 lesions), presence of (high 
grade) disease history and treatment of the primary tumour. Finally the 
association between the result of the mutation analysis and the presence of 
(high grade) malignancy, stage and grade was analyzed using samples of all, 
i.e. low, intermediate and high risk patients.  Resected tissue was examined by 
one uro-pathologist; staging and grading was done according to the TNM 
classification 9 and WHO 10, respectively.  
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P53 mutation analysis 
 
DNA extraction 
 
For DNA extraction 200 µl of bladder washing material was centrifuged for 5 
minutes at 13,000 rpm. After decanting the supernatant, the pellet was washed 
twice with a mixture of acetone/methanol (1:1). Subsequently, the cells were 
lysed in 100 µl lysis buffer (10 mM Tris/HCl pH 8.0, 100 mM NaCl, 25 mM 
EDTA, 0.45% SDS) with 1.0 µg/µl proteinase K, for 2 hours at 55oC. Proteinase 
K was inactivated by 40 µl 6 M NaCl. Next, the sample was centrifuged for 5 
minutes at 13,000 rpm, after which the supernatant was pipetted to a fresh 
tube. After a second centrifugation step DNA was precipitated adding an 
equal amount of 100% isopropanol to the supernatant and incubating on ice 
for 10 minutes. After centrifugating the sample for 20 minutes at 4oC, 13,000 
rpm, the pellet was washed twice with 80% ethanol. Finally, the pellet was 
dissolved in 40 µl milliQ and incubated at 60oC for 30 minutes. 
 
 
Amplification of DNA for sequence analysis 
 
Five µl of extracted DNA was added to a mixture of 45 µl containing: 250 µM 
deoxynucleotide triphosphates (Roche Diagnostics GmbH, Mannheim, 
Germany),  20 pmol of each primer (Invitrogen Life Technologies, Breda, The 
Netherlands), PCR Buffer (HT Biotechnologies Ltd., Cambridge, United 
Kingdom) and 1.5 units of SuperTaq polymerase (HT Biotechnologies Ltd., 
Cambridge, United Kingdom). Primers used for amplification are described in 
Table 1. Thermocycling was performed on an Eppendorf Master Cycler 
Gradient as follows: after denaturation at 94oC for 2 min, PCR consisted of 35 
cycles of 40 s at 94oC, 40 s at 60oC, 57oC, 67oC, 53oC for exon 5, 6, 7, and 8 
respectively, 40 s at 72oC; followed by 72oC for 10 minutes and cooling at 10oC. 
PCR products were purified using the Wizard PCR Preps DNA Purification 
System (Promega, Madison, USA) and dissolved in 35 µl milliQ. 
One µl was finally sequenced using an automated sequencer and 10 pmol of 
the forward and reverse PCR primers. 
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Statistical analysis was performed using the Statistical Package for Social Sciences 
(SPSS), release 12.0. Survival statistics and significance testing were calculated using 
the Kaplan-Meier methods and the log-rank test. Correlation between presence of 
(high grade) malignancy and p53 mutation was determined by the Fisher’s Exact Test. 
Correlation between stage, grade and p53 mutation by the Pearson χ2 –test.  
 
 
Results 
 
The studied group of high risk patients contained 93 men (88.6%) and 12 
woman (11.4%) with a mean age of 64 years at the time of analysis. Twenty-
nine patients had a p53 mutation and 76 were p53 wild type patients. The 
median follow-up was 58.3 months (range 2.9–161.1 months). In total 13 
patients died from bladder cancer,  6/29 patients with a mutation and 7/76 
patients in the wild type group (Figure 1A). Progression was seen in 9/29 
(31%) and 16/76 (21%) patients in the mutation and the wild type group 
respectively (Figure 1B).  Disease worsening was observed in 8/29 (28%)  and 
17/76 (22%) patients in the mutation and wild type group respectively (Figure 
1C). The recurrence–free survival was significant worse in the wild type 
group, compared to the mutation group (Figure 1D). Combining the results of 
all risk groups, the correlation between the presence of a tumour and a  
 Name Sequence (5’→3’) 
Exon 5 5s 
5as 
GCC GTG TTC CAG TTG CTT TAT C 
GAG GAA TCA GAG GCC TGG 
Exon 6 6s 
6as 
GAG ACG ACA GGG CTG GTT 
GAG ACC CCA GTT GCA AAC 
Exon 7 7s 
7as 
GGC CTC ATC TTG GGC CTG TG 
CAG TGT GCA GGG TGG CAA GT 
Exon 8 8s 
8as 
CCT TAC TGC CTC TTG CTT 
CAT AAC TGC ACC CTT GGT CT 
 
  Table 1  Primers for preparation of PCR products for  
           sequence analysis 
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Figure 1A Disease-specific survival; P53 mutation group compared to wild type 
group (Log-rank Test P = 0.16) 
 
Figure 1B Progression-free survival; P53 mutation group compared to wild type 
group (Log-rank test P = 0.37) 
 
Figure 1C Disease worsening-free survival;P53 mutation group compared to wild 
type group (Log-rank Test  P =  0.41) 
 
Figure 1D Recurrence-free survival; P53 mutation group compared to wild type 
group (Log-rank Test P = 0.02) 
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p53 mutation is evidently present (mutation frequency in samples with and 
without tumour is 28.6% and 10.2% respectively, Fisher Exact Test p<0.01). 
The same holds for the correlation with  a  G3 / CIS or highly recurrent 
tumour (mutation frequency in G3/CIS samples versus samples without 
G3/CIS,  38.9% and 9.0% respectively, Fisher Exact Test p<0.01).  In all Ta, T1 
and T2-T4 tumours, the percentage of p53 mutations is 6.0%, 32.8% and 45.2% 
respectively (χ2-Test, p < 0.01). In grade 1, 2 and 3 tumours the percentage of 
p53 mutations is 0%, 9.5% and 39.8%  respectively (χ2-Test, p < 0.01). 
   
 
Discussion 
 
 
Anomalies in the p53 tumour suppressor gene have been associated with 
different malignancies. In urothelial cancer p53 mutations have been found in 
invasive tumours but also in carcinoma in situ and dysplasia 11,12. Systematic 
reviews and meta-analyses determined the value of the p53 gene as a 
prognosticator for recurrence, progression and mortality. An association was 
found between p53 changes and higher grade and stage, recurrence, 
progression and mortality 13-16. However, whether a p53 mutation is an 
independent predictor of prognosis remains unclarified. In our study a specific 
patient population was used, i.e. the patients with high risk superficial bladder 
cancer. These patients have a high risk of developing a muscle-invasive 
disease. Furthermore, in an earlier study we found that the 3-year bladder 
cancer specific survival for a progressive patient with muscle invasive cancer 
is 37% versus 67% for a primary muscle-invasive patient 5. So finding a reliable 
prognosticator that can determine which patients have to be treated more or 
less conservative is an important goal.  However, no clear difference was seen 
for the clinical outcome parameters. On the other hand, after combining the 
results of all risk groups in a cross-sectional analysis the correlation between 
presence of (high grade) malignancy, stage, grade and p53 mutation was 
evidently found. When we compare our data to the literature, we see several 
differences that makes it difficult to determine the concordance.  More specific, 
different patient populations were included, immunohistochemical staining 
instead of mutation analysis was used, just as different specimen material and 
there are differences in the definition of the outcome parameters. It is the high 
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risk patient group where a prognosticator is the most needed and a mutation 
analysis is more reliable than immunohistochemical analysis since 
discrepancies can be found between the immunohistochemical and genetic 
analysis 7,17,18.  Therefore we tried to study a clinically relevant patient group 
with the most reliable technique to detect mutations in the p53 gene. In the 
overall analysis, also including the intermediate and low risk group patients, a 
clear association with higher stage, grade and overall presence of (high grade) 
malignancy was found.  
 
However, no significant correlation was seen for mortality, progression and 
disease worsening. When we look at the curves for progression we see a more 
pronounced difference between the groups at a follow-up of 60 months. After 
that point we see the 2 groups approaching each other. Earlier studies often 
did not have the chance to achieve a follow-up as long as the one in our study. 
This may have caused the more positive associations between the analysis and 
clinical outcome. It could be a possibility that the group of patients that show 
progression after this point of 60 months follow-up, is a group with a different 
biological potential, i.e. a group that needs more hits to mutate and eventually 
show progression. However, after restriction of the follow-up to a maximum 
of 60 months, the difference between the 2 groups was still not significant. 
Another reason for the lack of difference between the groups may have been 
the use of the p53-analysis result for clinical decision making, based on the 
early expectations that p53 status predicts disease outcome. 19,20.   This may 
have caused a more aggressive approach in patients with a p53 mutation and 
may have diminished the difference in outcome parameters between the wild 
type and the mutation group. However, when we adjusted the data for clinical 
decisions i.e. cystectomy performed before progression had occurred, the 
results did not change.  In summary, there is a trend that patients with a p53 
mutation have a worse clinical outcome, but no significant difference between 
the groups is found. Therefore we conclude that p53 analysis of bladder 
washes has no additional value over the known prognostic factors and there is 
no justification for adaptation of the policy of an individual patient.  
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Conclusion 
 
In this group of high risk bladder cancer with a long follow-up a trend is seen 
that patients with a p53 mutation have a worse clinical outcome, compared to 
patients with a wild type p53 gene. However, this difference is not significant. 
P53 mutation analysis has no additional value over the known prognostic 
factors and adjustment of the individual policy based on this analysis is 
therefore not justified. 
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Abstract 
 
 
Introduction: The p53 tumour suppressor gene has been suggested to be a 
promising prognostic marker in bladder cancer. This study identifies the 
prognostic value of p53 status in an unselected group of non-muscle invasive 
bladder cancer patients in a community hospital. A comparison with earlier 
results in a selected group of high risk patients in an academic hospital is 
made.  
 
Methods:  Mutation analyses were performed on DNA isolated from bladder 
wash samples by single strand conformation polymorphism and subsequent 
automated sequencing. Results of the analyses were combined with the 
corresponding clinical data. The association between p53 status, stage and 
grade was determined. In addition, differences in clinical outcome were 
evaluated between groups with and without a p53 mutation. 
 
Results:  An association between p53 mutation and higher stage (χ2–Test, p = 
0.008) and grade (χ2–Test, p < 0.01) is found in 275 samples. By contrast, no 
significant difference is seen with respect to progression-free survival (log-
rank, p=0.08), recurrence-free survival (log-rank, p=0.61) or bladder cancer 
specific survival (log-rank, p=0.96) between the group with or without a p53 
mutation. Results are based on 122 patients, median age of 71 years and 
median follow-up of 39 months.  
 
Conclusion:  Although an association is seen between p53 status, higher stage 
and grade, no significant difference regarding progression-free survival, 
recurrence-free survival and bladder cancer specific survival is seen between 
patients with or without a p53 mutation. There is no proof for using p53 status 
in bladder washing specimen as prognostic marker in non-muscle invasive 
bladder cancer patients or adapting patients policy based on the p53 status.   
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Introduction 
 
 
 
Bladder cancer is a collective noun for different entities within a broad 
spectrum of bladder tumours. First, there is a difference in patients presenting 
with a muscle-invasive (30%) or a non-muscle invasive tumour (70%). 
Moreover, there is a difference in patients within the group of non-muscle 
invasive tumours, a disease by definition confined to the mucosa or the 
submucosal layers of the bladder (Ta, T1, or carcinoma in situ).  Within this 
latter group, tumours can be divided in low risk and high risk. Low risk 
tumours have a high risk of recurrence, but a low risk of progression, and high 
risk tumours have a high risk for both. The risk of progression for high grade 
T1 G3 tumours 1 and carcinoma in situ (CIS) 2 can be as high as 50%. 
Furthermore, Schrier et al. 3 found a 3-year bladder cancer specific survival of 
only 37% for patients who had shown progression to muscle-invasive disease. 
Therefore, identification of patients at risk for progression is one of the main 
goals in non-muscle invasive bladder cancer. At this moment clinical markers 
(tumour stage, grade and presence of CIS) are being used to predict risk of 
progression. The EORTC risk tables 4 are based on these clinical markers and 
provide risk calculation in individual patients. Although an improvement, the 
calculated risk is still an estimation and not conclusive.  Finding a prognostic 
marker that predicts the biological behaviour of the tumour and accurately 
identifies patients at risk for progression, is therefore still essential.  
The p53 tumour suppressor gene has been suggested to be a prognostic 
marker with high potential. Tumour suppressor genes have a function in DNA 
repair through cell cycle arrest, repair, and if necessary apoptosis. Mutations 
can result in the production of a dysfunctional protein. Such a protein has a 
prolonged half-life and can be visualised by immunostaining. Since there is a 
correlation between accumulation of p53 protein and the amount of mutated 
p53 gene 5, immunostaining is used as a surrogate for mutation analyses.  
Mutation analysis consists of single strand conformation polymorphism 
(SSCP) screening for presence of mutations in exons 5 to 8, and in case of a 
shift, direct sequencing of the gene. Mostly exons 5 to 8 are being analysed 
since 80% of all mutations are found in this central region of the gene 6.  
The aim of this study was to determine the prognostic value of p53 status, 
investigated by mutation analysis in an unselected group of non-muscle 
invasive bladder cancer patients in a community hospital and compare it to 
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the results, earlier found in a selected group of high risk patients in an 
academic hospital (Moonen et al. J.Urol. January 2007).  
 
 
 
Methods 
 
 
Patients 
 
Between September 1998 and September 2005, p53 mutation analyses were 
performed in the  Canisius Wilhelmina Hospital in Nijmegen, the 
Netherlands, on DNA isolated from bladder wash samples, by using SSCP 
followed by automated sequencing. These samples were obtained from 
patients in the operating room, before resection of a suspected tumour. 
Follow-up and treatment was performed according to EAU guidelines. The 
p53 mutational results of these samples were combined with the 
corresponding clinical data, by retrospectively studying the medical files. The 
correspondence between p53 status and presence of malignancy, tumour 
stage, tumour grade and presence of CIS were analysed.  Based on the test 
result, patients were divided in a wild type group and a mutation group. The 
first mutation analysis performed was taken as the starting point for follow-
up. However, if a positive mutation analysis was preceded by negative 
analyses, follow-up was started from the time point with positive test results. 
Progression was defined as development of a ≥ T2 tumour, distant metastasis, 
or death due to bladder cancer. Disease worsening as a clinical indication to 
change the conservative policy, i.e. a recurrent papillary tumour within 1 year 
despite optimal treatment with ≥ 6 times BCG; T1 G3 recurrence; multiple 
recurrences; a recurrence of CIS between month 6 and 12, despite optimal 
treatment with ≥ (6+3) times BCG. A recurrence was defined as a tumour after 
at least one normal cystoscopy. Thus a tumour at the first 3 month cystoscopy 
was not considered a recurrence. Analyses were stratified by treatment of the 
primary tumour.  
 
 
 
 
 
 
Chapter 10 
140 
P53 mutation analysis 
 
DNA extraction 
 
Bladder washings were obtained as described before (Vet et al., 1996). For 
DNA isolation, 25 ml bladder washing was centrifuged (5 min;2000 g).The cell 
pellet was washed twice with 750 µl acetone-methanol (1:1). Subsequently, the 
cells were incubated (1 hour, 55°C) in 300 µl lysisbuffer (10mM Tris-HCL, pH 
8.0; 100 mM NaCL; 25 mM Na2EDTA;0.5% SDS; 0.5 µg/µl proteinase K). After 
inactivation (5 min, 95°C) DNA was purified using a puregene genomic DNA 
isolation kit (Gentra). 
 
 
PCR-SSCP 
 
In separate PCR reactions exons 5 through 8 were amplified. Genomic DNA 
(40ng) was subjected to 40 cycles of PCR (95, 55 (exons 5+8) or 60 (exons 6+7) 
and 72°C for 60, 30 and 60 sec, respectively). Amplification was performed in 
25 µl containing: 8 pmol of each primer; 0.25 mM dNTP’s; 1.5 mM MgCl2 
(exons 5A, 6, 8A and 8B) or 1.0 mM MgCl2 (exons 5B, 6B, 7A and 7C) and 
ExpandTM High Fidelity PCR System (Roche Diagnostics). Three µl PCR 
product was mixed with 3 µl denaturing buffer (0.04% bromophenol blue in 
99% formamide), denatured at 95°C for 5 minutes, and snap cooled on ice. 
Four to 6 µl sample was loaded onto a 12.5% polyacrylamide gel (GeneGel 
Excel 12.5/24 kit, GE Healthcare) and electrophoresis was carried out at 5°C 
and 18°C on the GenePhor System (GE Healthcare) for 1.5 hours followed by 
silverstaining (Plus One DNA Silver Staining, GE Healthcare).  
 
 
Sequence analysis 
 
Direct sequencing of the PCR products was performed. However,  when the 
intensity of the mutant band was less than 50% compared to the wild type 
band, the mutant fragment was excised from the polyacrylamide gel, DNA 
was eluted (80°C for 15 minutes in 100 µl TE (20 mM Tris, pH 8.0; 1 mM 
EDTA) followed by an overnight incubation at 4°C) and subjected to PCR 
reamplification.  
Before sequencing, the PCR products were purified using the High Pure PCR 
Product Purification Kit (Roche Diagnostics). Sequence reactions were 
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performed with the DYEnamicTM ET Dye Terminator Kit (MegaBaceTM) using 
the same primers as in the initial PCR reaction. Subsequent products were 
analyzed on a MegaBace 500 DNA analysis platform (GE Healthcare). 
 
 
Study endpoints and statistical analysis 
 
For the statistical analysis the Statistical Package for Social Sciences (SPSS) was 
used, release 12.0. The Kaplan- Meier procedure and the log rank-test were 
used for the construction of curves (survival, progression, disease worsening, 
recurrence-free survival) and significance testing, respectively. Staging and 
grading was done according to the TNM classification 7 and WHO 8 
respectively. Correlation between p53 status and presence of malignancy or 
presence of CIS was determined by using the Fisher’s Exact Test. Correlation 
between p53 status and tumour stage and tumour grade was determined by 
using the Pearson’s χ2-test.  
 
The value of the presence of a mutation in the p53 gene in this unselected 
group of patients in a community hospital, was compared with the results of 
the study earlier performed in the Radboud University Nijmegen Medical 
Centre, the Netherlands, regarding the prognostic value of the p53 gene in a 
selected population with high risk bladder cancer (Moonen et al. J.Urol. 
January 2007).  
 
 
 
Results 
 
 
The p53 mutation analysis was performed on 390 bladder washes, obtained in 
the operating room before transurethral resection of a suspected bladder 
tumour. In total 115 samples had to be excluded because insufficient DNA was 
isolated for analysis (89) or the presence of a shift (26) that was not confirmed 
as mutation or wild type. The 275 remaining samples were obtained from 179 
patients with an age between 31 and 95 years old. In 215 samples presence of 
histological confirmed malignancy was seen. The other 60 samples turned out 
to be benign. In 248 samples a wild type p53 gene was present and a mutated 
gene in 27 samples. The mutation frequency in samples with and without 
tumour was 11.6% (n = 25) and 3.3% (n = 2)  respectively (Fisher Exact Test, p 
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= 0.082). Mutations in Ta, T1, and T2-T4 tumours were found in 4.3%, 12.9% 
and 19.6%, respectively (χ2 - Test, p = 0.008). The number of samples with a 
mutation in grade 1, grade 2 and grade 3 tumours was 1.5%, 2.3%, and 21.6%, 
respectively (χ2 – Test, p < 0.01). In samples with CIS, 28.2% showed a p53 
mutation. In samples without CIS mutation frequency is 8.0% (Fisher Exact 
Test, p = 0.001).  
For analysis of the prognostic value of the p53 status, 253 patients were 
studied. In total 131 patients were not eligible due to an incomplete p53 
analysis (28), a shift in their p53 result that was not confirmed as mutation or 
wild type (16), incomplete clinical information (19), invasive disease before or 
at the moment of the first analysis (47), and no presence of a histological 
confirmed malignancy with a wild type result (21).  Out of 122 patients that 
were included in the prognostic analysis, 108 were male and 14 female, with a 
median age of 71 years (range 31 to 93). A wild type p53, and a mutated p53 
was found in 109 and 13 patients, respectively. The median follow-up was 39 
months (range 0 to 86 months). In total 7 patients died of bladder cancer, 1/13 
and 6/109 in the mutation group and in the wild type group, respectively. The 
3-years bladder cancer specific survival based on the Kaplan-Meier curves 
were 91% and 98%, respectively (figure 1A). Progression was seen in 3/13 and 
7/109 of the patients with and without a mutation, respectively. The 3-years 
progression-free survival based on the Kaplan-Meier curves were 77% and 
93%, respectively (Figure 1B). Disease worsening was found in 3/13 and 1/109 
of the patients with and without a mutation. The 3-years disease worsening-
free survival based on the Kaplan-Meier curves were 77% and 99%, 
respectively (Figure 1C). Recurrence was seen in 6/13 and 35/109 of the 
patients with and without a mutation in the p53 gene, respectively. The 3-
years recurrence-free survival based on the Kaplan-Meier curves were 53% 
and 64%, respectively (Figure 1D). The results were also stratified according to 
the treatment of the tumour at the starting point: intravesical treatment in 
general and specifically BCG. After adjustment, the result for p53 status did 
not change (results not shown). Comparison with the results of an earlier 
study in a selected group of patients with high risk bladder cancer (Moonen et 
al. J. Urol. in press) shows comparable results with regards to the association 
of p53 mutation with stage and grade, and survival curves for mortality, 
progression and disease worsening.  
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Figure 1A Disease-specific survival; p53 mutation group versus p53 wild 
type group (Log-rank Test) 
 
Figure 1B Progression-free survival; p53 mutation group versus p53 wild 
type group (Log-rank Test) 
 
Figure 1C Disease worsening-free survival; p53 mutation group versus p53 
wild type group (Log-rank Test) 
 
Figure 1D Recurrence-free survival; p53 mutation group versus p53 wild 
type group (Log-rank Test) 
 
A B 
C D 
Chapter 10 
144 
Discussion 
 
 
 
The p53 tumour suppressor gene located on chromosome 17p has extensively 
been studied as a possible prognosticator in bladder cancer. In these studies 
two different methods have been used, i.e. immunohistochemistry (IHC) and 
mutation analysis. As a consequence of the complicated process of molecular 
analysis, most studies prefer to use IHC. Although IHC and mutational results 
show a high degree of agreement for negative p53 expression (no mutation) or 
strongly p53-positive samples (p53 mutation present), a high level of 
variability between laboratories and observers exists in the gray zone of low 
p53 positivity between 1% and 20% 9. Thus, caution is warranted when 
interpreting the large amount of research on the association between p53 
expression by IHC and clinical outcome 10. Nevertheless, systematic reviews 
and meta-analyses determined the value of the status of the p53 gene, either 
by IHC or mutational analysis, as a prognostic marker for recurrence, 
progression and survival, although the general consensus was that different 
studies are difficult to compare because of the inclusion of different patient 
populations, the use of IHC versus mutation analysis, the use of different 
specimens and a different definition of outcome parameters. Smith et al. 11 
reviewed 25 studies on the prognostic value of IHC in all stages of bladder 
cancer. They found a correlation between p53 accumulation and higher stage 
and grade, progression and decreased survival. Schmitz-Dräger et al. 12 wrote 
a review, comprising data from 43 trials and almost 4,000 patients, on the 
association of IHC p53 accumulation and prognosis of patients with bladder 
cancer. They found a correlation between IHC p53 accumulation and higher 
stage and grade in the majority of studies. However, it remains nevertheless 
unclarified if p53 has additional value to the classical parameters. Schmitz-
Dräger and co-workers plead for standardization of the assay procedure, the 
assessment of specimens and initiation of prospective multicentre trials. 
Malats et al. 13 reviewed 117 publications with more than 10,000 patients to 
find evidence of changes in p53 status to predict bladder cancer recurrence, 
progression and mortality. In the great majority (96%) of the included studies 
IHC was used as an approach for the assessment of p53 status. No clear 
association of p53 accumulation with recurrence, progression, or mortality in 
either univariate or multivariate analyses was seen. In another study, 
pathologists prospectively studied the value of p53 IHC in a large multicentre 
trial, comprising 502 patients with a median follow-up of 10 years. Their 
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results indicated that p53 IHC was not sufficiently sensitive or specific to 
select patients for radical therapy 14. In addition, the international Consensus 
Panel 10 evaluated markers with the ability to predict tumour recurrence, 
progression, development of metastases, response to therapy or patient 
survival. They concluded that in several studies p53 has been suggested to be 
a potential marker in providing prognostic information related to metastasis, 
recurrence, overall survival and cancer-specific survival. However, the results 
of many studies are contradictory, and there is no accurate marker as yet, they 
state. In this present study, our results are consistent with the conclusions of 
the aforementioned reviews and meta-analyses. In our study, a clear 
association is seen between p53 status and higher stage and grade. However, 
no evidence is found for p53 status as prognostic marker for clinical outcome 
of patients, nor an indication to adapt patients individual policy based on the 
p53 status of the patient.  
In our first study, performed in a selected group of patients with high risk 
bladder cancer (Moonen et al. J. Urol. January 2007), we found an association 
between higher stage and grade and p53 status. In this earlier study we found 
no significant differences in clinical outcome regarding bladder cancer specific 
survival, progression-free survival or time until disease worsening. However, 
we did find a significant lower recurrence-free survival in the group with a 
wild type p53 status. This could have been caused by an adaptation of the 
treatment policy due to the early expectations that p53 status predicted 
outcome, herewith using a less aggressive approach in the group of patients 
with a wild type p53 status.  In the current study we see no significant 
difference regarding bladder cancer specific survival or progression-free 
survival between the groups with or without a p53 mutation. We do see a 
difference between the two groups regarding disease worsening. However the 
number of patients with disease worsening is limited (1 in the wild type group 
and 3  in the mutation group). Noteworthy is the fact that in the present study 
we do not find a significant difference between the two groups regarding 
recurrence-free survival. Since the result of the p53 analyses was not used in 
daily practise in this hospital, in other words had no impact on treatment 
policy,  this supports the conclusion of our earlier study.  
 
 
 
 
 
 
Chapter 10 
146 
Conclusion 
 
 
 
After studying the association of p53 status, examined by the most reliable 
technique to determine mutations, i.e. mutation analysis,  with clinical 
outcome both in an unselected group of bladder cancer patients in a 
community hospital and a selected group of high risk patients in an academic 
hospital (Moonen et al. J. Urol. January 2007), we conclude that there is no 
reason for using p53 status as a prognostic marker in non-muscle invasive 
bladder cancer patients, or adapting patients policy based on the p53 status.  
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Abstract 
 
 
Introduction: High risk HPV types stimulate degradation and deactivation of 
the p53 tumour suppressor gene-associated protein via the ubiquitin-
dependant pathway. For long time changes of the p53 tumour suppressor 
gene have been correlated with poor clinical outcome in patients with 
superficial bladder cancer. We aimed to study the association between 
presence of (high risk) HPV DNA, p53 status and clinical outcome in bladder 
cancer patients. This study must be seen as a preliminary study to investigate 
this potentially important problem.  
 
Methods: From 107 patients 166 bladder wash samples were obtained. p53 
Status was determined by mutation analysis, HPV detection and genotyping 
by the SPF10-LiPA assay. Clinical data were abstracted from the medical files. 
 
Results: The prevalence of all-type and high risk HPV infection in 
malignancies of the bladder was 15.2% and 8.1% respectively. In high grade 
tumours this prevalence was 18.2% and 10.6% respectively. In grade 1, 2 and 3 
tumours the infection rate of high risk HPV types is respectively 0%, 3.3% and 
10.6% (trend test p=0.221). In Ta, T1 and T2-T4 tumours  the high risk HPV 
infection rate is 0%, 12.5% and 18.2% respectively (trend test p=0.045). In the 
p53 wild type patients who showed progression, 1/9 patients had a high risk 
type HPV infection. In the group of wild type patients who showed no 
progression, 4/37 patients had a high risk type HPV infection (odds ratio 1.03; 
95% CI 0.1-10.5).  
 
Conclusion: The data of this pilot study show the suggestion of a positive 
trend in the correlation between tumour grade / stage and high risk type HPV 
infection. However, no additional risk for progression is found for p53 wild 
type patients with a high risk HPV infection.  
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Introduction 
 
 
Bladder cancer is characterized by a large variability in prognosis.  The 
majority of bladder tumours will only recur, but a group of patients will show 
progression to muscle-invasive disease. The latter subgroup of patients shows 
a significantly reduced survival compared to patients with recurrent 
superficial bladder tumours, but also compared to patients with a primary 
muscle-invasive tumour. Many studies into the identification of possible 
prognosticators that can predict the biological behavior of the tumour have 
been performed. Systematic reviews and meta-analyses have determined the 
value of the p53 tumour suppressor gene as a prognosticator for poor clinical 
outcome in bladder cancer patients 1-3. Although a correlation was found 
between p53 mutations and higher grade and stage, recurrence, progression 
and mortality, the independent value of p53 changes remains unclarified.  In 
fact, a considerable number of patients with a poor clinical outcome appear to 
have a wild type p53 gene.  
There is clear evidence that the human papilloma virus (HPV) causes cervical 
cancer. Thirteen different HPV genotypes, among others HPV 16 and 18, are 
associated with malignancy and are referred to as high risk HPVs 4-6 . In 
contrast HPV 6 and 11 are associated with non-malignant genital disease and 
are called low risk anogenital-specific HPV’s. Less intensively investigated, 
despite the fact that condylomata acuminata may involve the bladder 7, is the 
association between HPV infection and presence of malignancy of the urinary 
tract. However, HPV DNA has been detected in both transitional cell and 
squamous cell carcinoma of the bladder 8-11 and an increased high-risk HPV 
prevalence has been found in bladder tumours compared to normal urinary 
bladder specimens 9,10. HPV encodes two oncoproteins, E6 and E7. The E6 
protein interacts with p53 stimulating the degradation of p53-associated 
proteins via the ubiquitin-dependant pathway 12. An inverse correlation 
between p53 mutation and high risk HPV infection has been suggested, but 
not uniformly confirmed in earlier studies. 
In the present study, the p53 status and presence of HPV-DNA were 
determined in bladder washes of patients with symptoms indicating the 
presence of a bladder tumour.  Results were correlated with histopathological 
features and clinical outcome.  
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Material and Methods  
 
 
A total number of 176 frozen bladder wash samples were obtained from 107 
patients of our hospital, who were suspected for a bladder tumour, or were 
under surveillance for bladder cancer. Single strand conformation 
polymorphism (SSCP) was used as a pre- screening technique for the presence 
of mutations in exons 5 to 8 of the p53 gene. In case of a mobility shift direct 
sequencing was performed to confirm the presence of a mutation. In short, 
after DNA extraction of the bladder washing material, PCR amplification was 
performed. The PCR products were purified and sequenced as described by 
van Bokhoven et al. 13. The samples were tested for the presence of HPV DNA 
by the SPF10-LiPA HPV detection / genotyping assay as previously described 
14. Whether the sample could be analyzed was checked by the presence of the 
human β-globin gene as intern control (IC). Clinical data were retrospectively 
abstracted from the medical files. In this study, the correlation between 
presence and typing of HPV infection and clinicopathological features was 
studied using all analyzable samples. The association was studied using a 
trend test. Moreover, p53 status and disease outcome of the patients was 
studied. Progression was defined as development of T2-T4, N+ and/or M+. 
The influence of a high risk  HPV infection on the clinical outcome in patients 
with the wild type p53 gene, was determined by calculating an odds ratio with 
corresponding 95% confidence interval. The Statistical Package for Social 
Sciences, release 12.0, was used for analyses.  
 
 
 
Results 
 
 
In 10 of 176 samples presence of the human β-globin gene (IC) could not be 
detected. In these samples no amplifiable DNA was detected and these 
samples were therefore excluded from the analysis. In 99 samples (72 patients) 
a malignancy was found at the time of the analyses. In 15 (15.2%) of these 
cases a HPV infection was found. High risk HPV was detected in 8 (8.1%) of 
these cases. When only high grade tumours (N=66) are considered, a HPV 
infection was found in 12 (18.2%) of the cases. High risk HPV was detected in 
7 (10.6%) of the high grade cases. Correlation between HPV genotype and 
histology result is shown in table 1. When the tumours are stratified by grade,  
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 *  High risk HPV type     * High risk HPV type 
** CIS is grade 3 
 
 
Table 1a      Table 1b 
HPV typing according to grade   HPV typing according to stage 
 
  
 
prevalence of high risk HPV types was 0%, 3.3% and 10.6% for grade 1, grade 
2 and grade 3 tumours respectively ( trend test, p = 0.221). Distribution 
according to stage shows a prevalence of high risk HPV types in 0% , 12.5% 
and 18.2% for stage Ta, T1 and T2-T4 tumours, respectively (trend test, p = 
0.045).  In table 2 the correlation between HPV genotype and p53 mutation is 
shown. Three (21.4%) of 14 bladder washes with a high risk type HPV 
infection had a p53 mutation while 31 (20.3%) of 153 bladder washes with a 
negative or low-risk type HPV infection had a p53 mutation: OR = 1.07 (95% 
CI: 0.28-4.08). Evaluation, with a median follow-up of 63 months (5 - 163 
months),  of the follow-up data showed that 1 of the 9 patients who showed 
tumour progression while they had a p53 wild type gene, had a high risk HPV 
Grade N HPV Type        N 
 
G1        3 No infection   
         
 
3 
G2        30 No infection    
6 
11 
16* + 18* 
 
 
27 
1 
1 
1 
G3**     66 No infection    
11 
16* 
18*                     
31* 
33* 
39* 
40 
52* 
X                      
54 
1 
1 
2 
1 
1 
1 
1 
1 
3 
Stage    
 
N HPV Type      N 
Ta 30 No infection   
6                       
11                     
28 
1 
1 
T1 32 No infection   
18 *                  
31* 
40 
52* 
X 
26 
2 
1 
1 
1 
1 
T2-T4 11 No infection   
16* 
16 +18* 
 
 
 
 
 
 
 
9 
1 
1 
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type infection. This frequency did not differ from the frequency of high risk 
HPV infection in  the same group of patients with a wild type p53 gene that 
did not progress, being 4 out of 37 (OR = 1.03; 95% CI: 0.10-10.53).  
 
 
 
HPV 
infection 
p53 mutation  
Wild type 122 
Exon 5  Codon 139 AAG Æ AAC Lys Æ Asn** 1 
Exon 5  Codon 180 GAG Æ AAG Glu Æ Lys 1 
Exon 6 Codon 194 CTT Æ CGT Leu Æ Arg 1 
Exon 6  Codon 196 CGA Æ AGA Arg Æ Arg* 1 
Exon 6  Codon 205 TAT Æ TGT Tyr Æ Cys 3 
Exon 6  Codon 213 CGA Æ CGG Arg Æ Arg*/**    5 
Exon 6  Codon 215 AGT Æ GGT Ser Æ Gly 1 
Exon 6  Codon 220 TAT Æ TGT Tyr Æ Cys 1 
Exon 6  Codon 223 CCG Æ CAG Pro Æ Gln 1 
Exon 7  Codon 238 TGT Æ TAT Cys Æ Tyr 4 
Exon 7  Codon 241 TCC Æ TTC Ser Æ Phe 1 
Exon 7  Codon 246 ATG Æ ATA Met Æ Ile 1 
Exon 8  Codon 273 CGT Æ CAT Arg Æ His 1 
Exon 8  Codon 280 AGA Æ ATA Arg Æ Ile 2 
Exon 8  Codon 280 AGA Æ AAA Arg Æ Lys 1 
Exon 8  Codon 280 AGA Æ ACA Arg Æ Thr 2 
Exon 8  Codon 281 GAG Æ GAC Glu Æ Asp 1 
Negative  
 
or 
 
Low risk  
 
Infection 
Exon 8 Codon 285 GAG Æ AAG Glu Æ Lys 3 
 
Wild type 11 
Exon 5  Codon 180 GAG Æ AAG Glu Æ Lys 1 
Exon 6 Codon 194 CTT Æ CGT Leu Æ Arg 1 
High risk  
 
Infection 
Exon 8 Codon 273 CGT Æ CTT Arg Æ Leu 1 
          
 *     polymorphism 
**  two  p53 changes in 1 specimen 
 
 
Table 2         P53 mutations in relation to HPV infection :  
OR = 1.07 (95% CI : 0.28-4.08)   
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Discussion 
 
 
The value of the p53 tumour suppressor gene as a prognosticator marker has 
been evaluated in several reviews and meta-analyses. Although a correlation 
was found between a p53 mutation and clinical characteristics associated with 
worse clinical outcome, i.e., higher grade and stage, the independence of the 
predictor remains unclarified.  Proteins encoded by the oncogenic human 
papilloma virus types bind p53 which results in the degradation of p53. This 
may lead to a loss of function of the p53 tumour suppressor gene product 12. 
Studies determining the association between the human papilloma virus and 
bladder cancer have previously been reviewed 15. The presence of high-risk 
HPV in a significant proportion of bladder tumours and the association of 
HPV with higher grade and stage tumours and with multicentricity suggests 
an etiological role for these viruses in bladder cancer. However, the 
significance of the association remains controversial. For instance a highly 
variable incidence of high–risk HPV DNA was found, ranging from 2.5% to 
81%, with HPV 16 occurring more frequently.  In some studies, however, a 
total lack of HPV DNA in transitional cell carcinoma was found. In our study 
an overall HPV infection rate of 15.2% was found. In 8.1% of the cases this was 
a high risk HPV type infection. In high grade tumours we found a higher 
infection rate of 18.2% overall and 10.6% for high risk HPV types. The increase 
in infection rate in high grade tumours suggests a relation between tumour 
grade and high risk HPV infection. Indeed, a trend (non-significant) in 
correlation was found between high risk HPV infection and increasing stage 
and grade. 
Scheffner et al. showed that high risk HPVs encode two oncoproteins, E6 and 
E7. The E6 protein interacts with wild type p53 and stimulates degradation of  
p53 12. Tenti et al. and Kamel et al. studied the association between p53 status 
and HPV infection in transitional cell carcinoma of the bladder. P53 status was 
in both studies determined by immunohistochemistry and HPV detection by 
PCR and nucleic acid in situ hybridization (ISH) respectively.  Tenti et al. 16 
found an overall rate of HPV DNA of 32.9% and the prevalence of HPV 16 and 
/or HPV 18   infection was significantly higher in low-grade than in high-
grade tumours. P53 positive cases were more common in papillary, deeply 
infiltrating tumours, and HPV-positive cases in papillary, non-infiltrating 
lesions. In this study there was an inverse correlation between p53 
overexpression  and HPV 16/18 infection with tumour aggressiveness. 
Positivity for both HPV and p53 was mainly seen in high-grade, papillary and 
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infiltrating neoplasm which could suggest a cumulative effect of both genetic 
alterations on progression in transitional cell carcinoma. On the contrary, 
Kamel et al. found HPV DNA in 57% of the tumours, but no inverse 
relationship between HPV positivity and abnormal p53 protein accumulation 
in bladder carcinomas was seen 11. They concluded that an HPV infection may 
play a role in the pathogenesis of bladder carcinomas by a mechanism 
different from inactivation of the p53 protein. Most importantly, the impact of 
the presence of HPV DNA in determining the survival of bladder cancer 
patients was also studied. Lopez-Beltran et al. found a possible additional 
prognostic value of the viral infection in bladder cancer, although grade 
seemed the only independent parameter in the survival of bladder cancer 17. 
Herewith the results of Furihata et al. were confirmed. They found a 
significantly worse survival in patients with tumours positive for HPV DNA 
and/or p53 protein. Furihata et al. concluded that an HPV infection or over 
expression of p53 protein could be related to tumour behaviour 18. In our 
study, p53 changes were detected by mutation analysis, not by 
immunohistochemistry. An increasing frequency of high risk HPV types with 
increasing grade and stage is suggested. In order to test the statistical 
significance of this suggestion, a trend test has been performed by considering 
grade and stage as a continuous variable in logistic regression analyses. The 
trend test for high risk with increasing grade resulted in p=0.221. The trend 
test for high risk with increasing stage is p=0.045. The numbers, however, are 
very small which prohibits a really meaningful interpretation of the trend 
tests. Interestingly, infections with the high risk HPV infection type 16 are only 
seen in muscle-invasive tumours, while in Ta tumours no (high risk) HPV 
infections are seen. This may indicate a subdivision of HPV types according to 
stage. Whether this is the case should be further investigated. Furthermore,  
there is no additional risk of progression in patients in presence of a HPV 
infection without a p53 mutation. There are multiple possible reasons why 
previous data are not confirmed by our results. One of these is the fact that 
p53 mutations in our study were determined by mutation analysis, which is 
more specific than immunochemistry. Moreover, Lopez-Beltran et al. studied 
the samples of  a small group of 76 consecutive patients with TCC and 
determined HPV infection by PCR using DNA primers for HPV types 6, 11, 16 
and 18 only. Furihata et al. studied 90 patients with TCC and determined the 
presence of HPV DNA types 16, 18 and 33 by in situ hybridization. Their 
results show that the significant difference in the two patient groups, 
containing 26 and 36 patients respectively, results from the positivity of the 
p53 antibody. Our data are based on 166 samples of 107 patients, where 
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mutation analysis was used for p53 status and the SPF10-LiPA HPV detection 
/ genotyping assay for presence of  HPV DNA. This assay allows detection of 
at least 43 different HPV types. Moreover, it is difficult to determine whether 
the presence of HPV DNA has independent value. Lopez-Beltran et al. stated 
already that grade seemed the only independent parameter for survival and 
Furihata et al. could not determine whether the impact of the HPV infection 
was independent of changes in the p53 product.  In the data of this pilot study 
no additional value for the presence of HPV DNA is seen. 
 
 
 
Conclusion 
 
 
 
The data of this pilot study show the suggestion of a positive trend in the 
correlation between tumour grade / stage and high risk type HPV infection. 
However, no additional risk for progression is found for p53 wild type 
patients with a high risk HPV infection.  
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Summary 
 
Bladder cancer is a disease with high impact for the European community, 
with 120,000 new patients and 35,000 deaths in 2004.  Bladder cancer is a 
collective noun for different entities within a broad spectrum of bladder 
tumours. First, there is a difference between patients presenting with a 
muscle-invasive tumour (30%) or a non-muscle invasive tumour (70%). 
Moreover, there is a difference in patients within the group of non-muscle 
invasive tumours, a disease by definition confined to the mucosa or the 
submucosal layers of the bladder (Ta, T1, or carcinoma in situ). Within this 
latter group patients can be divided in low risk and high risk. Low risk 
patients have a high risk of recurrence, but a low risk of progression. High risk  
patients also have a high risk of recurrence, but even more important, they 
also have a high risk of progression to a muscle-invasive disease, as a result of 
loss of differentiation. As a consequence all patients within this spectrum need 
frequent surveillance with cystoscopy and cytology. Cystoscopy is an invasive 
procedure and thus bothersome for the patient. Moreover, the papillary 
lesions are easily seen, but the flat and per definition aggressive carcinoma in 
situ (CIS) lesions are readily missed. In addition, cytology is being used. High 
grade lesions are easily diagnosed, but the more differentiated lesions remain 
frequently undetected. Furthermore, cytology is operator dependent, with a 
low intra- and interpersonal reproducibility, the result is unreliable in case of 
infection, stones or after intravesical instillations. The requirements for a new 
urinary marker are therefore multiple: the test must adequately detect both 
high grade and low grade lesions,  it must be non-invasive, objective, easy to 
perform and cheap.  
Furthermore, patients with a non-muscle invasive bladder tumour can have 
totally different courses of their disease. The low risk tumours remain 
superficial in the majority of cases, but for patients with a pT1 G3 or CIS 
tumour, the chance of progression to muscle-invasive disease is up to 50%. 
The clinical outcome in patients after progression to muscle-invasive disease is 
worse with a 3-year specific survival of only 37%. Therefore the two main 
goals in diagnosis and prognosis of non-muscle invasive bladder carcinoma 
are 1) add to the value of, or replace the gold standard, herewith decreasing 
the number of unnecessary cystoscopies and 2) to identify patients at risk for 
progression, so they can be treated more aggressively. Together,  the 
morbidity and mortality of the disease can be minimised.  
In this thesis potential new markers in diagnosis and prognosis of  non-muscle 
invasive bladder cancer, until recently called superficial bladder cancer,  are  
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being studied.  Furthermore, the value of some older markers is again 
evaluated, since the follow-up of the patients can now be taken into 
consideration.  To be able to interpret the value of the various markers, the 
definitions of sensitivity, specificity, negative predictive value and positive 
predictive value must be known. Sensitivity is the number of cases that a test 
is positive in the case that there is a tumour, specificity is the number of cases 
that the test is negative in the absence of tumour, negative predictive value is 
the chance that there is no tumour in the case of a negative test result and 
positive predictive value is the chance that there is a tumour in the case of a 
positive test result. Chapter 2 gives an overview of the current gold standard 
in diagnosis, namely cystoscopy and cytology, and of fluorescence cystoscopy 
and urinary markers.  In general these markers have an equal or higher 
sensitivity compared to cytology, but at the cost of specificity. 
Chapters 3 to 7 cover urinary markers in the diagnosis of non-invasive bladder 
cancer. Chapter 3 describes a prospective study to the value of the NMP22® 
BladderChek test performed in 106 patients with symptoms suggesting a 
bladder tumour. The NMP22® BladderChek Point Of Care (POC) test with 
instant result, is the outcome of adjustments in the precursor of this test, the 
NMP22 Bladder Cancer Test, performed in the laboratory. These tests detect a 
nuclear matrix protein in the urine, associated with the presence of urothelial 
cell carcinoma. In the patient group under surveillance, a sensitivity of 57% 
and a specificity of  90% was found for the NMP22® BladderChek test. This is a 
small increase in sensitivity compared to cytology, without relevant loss of 
specificity. However, no extra tumours were detected by the use of the test. 
Furthermore, the test gave an instant result, was objective and easy to 
perform. In all, the NMP22® BladderChek test is convenient for use in patients 
under surveillance, but does not seem to have additional value compared to 
earlier tests. Whether the test has value in the evaluation of patients with 
haematuria (screening),  remains to be investigated.   
Chapter 4 is an overview of the value of fluorescence in situ hybridisation 
(FISH) in bladder cancer. Currently, FISH appears to be one of the most 
sensitive and promising markers in bladder cancer. UroVysion® is a FISH 
analysis detecting abnormalities in chromosomes 3, 7, 17 and locus 9p21. The 
combination of these chromosomal abnormalities was determined as an 
optimal set for the detection of urothelial cell carcinoma. Unfortunately, the 
recommendations for execution of the test and the selection of patients who 
benefit most of the test remain indefinite. As a result, the implementation in 
daily practise stays behind. The next years, consensus about the definition of a 
positive test and patient selection (probably patients with an equivocal 
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cytology result, after intravesical instillations, or patients in follow-up after 
cystecomy) must be attained. Large prospective randomized studies will have 
to be performed, and automated techniques will increase the ease of the test 
and decrease the costs.  
Chapter 5 shows the result of the value of such a FISH test, namely 
UroVysion® in a prospective study with 113 voided urine samples from 
patients with symptoms suggesting a bladder tumour and a positive history 
for bladder cancer. The value of UroVysion® is compared to cytology and 
quantitative cytology (Quanticyt®). Sensitivity and specificity of UroVysion® 
were 39% en 90%, respectively, of cytology 41% and 90%, respectively, and of 
quantitative cytology, 42% en 68% respectively.  Detection by UroVysion® of 
grade 1, grade 2 and grade 3 tumours was 21%, 37% and 67% respectively.   
Based on these data, no evidence for an additional value was found for 
UroVysion® in the diagnosis of non-muscle invasive bladder cancer, compared 
to cytology or quantitative cytology.  
In chapter 6 the value of UroVysion®  is again being studied, this time in a 
large retrospective study performed in a community centre, where the test is 
being used in daily practise since 4 years. The results of this test were 
compared to the results of the earlier study in a selected group of patients in 
an academic hospital (see chapter 5).  The results of 1,000 analyses were 
matched with the clinicopathological results.  In this study the test had a 
sensitivity of 78% and a specificity of 76%. Cytology had an unexpected high 
sensitivity of 86% and a unexpectedly low specificity of 71%. Based on these 
results it may be concluded that 1)  UroVysion®  performs better in an 
unselected group of patients in a community centre, than in a patient group 
under surveillance in an academic hospital, 2) the complexity of the test 
requires experience and expertise and 3)  UroVysion® increases the value of 
cytology. Earlier studies suggest that UroVysion® may have a prognostic 
value, in other words, a tumour may be detected before it is visible on 
cystoscopy. For the determination of the prognostic value, patients with a 
true-negative result were compared to those with a false-positive result with 
respect to clinical outcome. Furthermore patients were divided in a low risk 
group and a high- risk group, based on their chromosomal abnormalities. The 
clinical information of 258 patients with a mean follow-up of 12 months (0 to 
38 months) was studied. Although the chance of recurrence is higher in the 
patients with a false-positive and a high risk FISH result, this difference 
between the groups was not significant.  Further investigation will need to be 
done to the development of risk-stratification schemes based on chromosomal 
abnormalities in patients.  
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Chapter 7 describes a marker which was discovered a few years ago in the 
Radboud University Nijmegen Medical Centre, the Netherlands. Quantitative 
cytology (Quanticyt®) is an automated karyometric analysis. Based on two 
parameters, DNA content and nuclear shape, the patients are being divided 
into risk groups. Earlier studies have suggested that 1) the marker has value in 
the identification of patients with a high risk tumour and 2) that the treatment 
policy can be individualized based on the test result. Disadvantage of the test 
is the necessity to perform an invasive procedure (catheterisation), to obtain 
the required bladder wash sample. After adjustments in the method of the 
analysis, 144 combined samples (meaning voided urine and a bladder wash 
sample) were obtained. Results were compared to each other and to the 
clinicopathological results. Provided that a urinary sample is correctly 
processed, quantitative cytology can be used. This new application of the test 
can be implemented in daily practise.  
     
Chapters 8 to 12 cover markers with potentially prognostic value in non-
muscle invasive bladder cancer. Chapter 8 gives an overview of prognostic 
markers and risk stratification schemes at this moment. In the majority of the 
schemes, tumour stage, tumour grade and multiplicity are being mentioned as 
factors with prognostic value. Extensive research has been done to the use of 
the stratification schemes, and there are some limitations in the use of it.  Even 
if a marker has the ability to differentiate between risk groups, that is no 
guarantee that the disease prediction in an individual patient will be accurate 
(the ultimate goal for a prognostic model). Moreover, these schemes are hardly 
ever used in daily practise. Apparently it is very difficult to make a risk 
stratification for every tumour and predict their possible evolution. So, further 
validation of risk stratification classifications and development of molecular 
markers is needed.   
Chapter 9 describes the prognostic value of p53,  in a selected group of 
patients with a high-risk non-muscle invasive bladder  tumour. The p53 gene 
is a tumour suppressor gene. In case of DNA damage, p53 mediated pathways 
intervene by cell cycle arrest, DNA repair and if necessary apoptosis. In about 
half of all malignancies, abnormalities in the p53 gene are found. Also in 
urothelial cell carcinoma, the p53 gene is frequently inactivated. Mutations in 
the gene result in the production of a dysfunctional protein. Such a protein has 
a prolonged half-life and can be visualised by immunostaining. This method is 
frequently used as a surrogate for mutational analysis, because of the 
complexity of this latter method. In the current study p53 status was 
determined by mutational analysis performed on DNA isolated from bladder 
Summary and Discussion 
  
167 
wash samples.  The group of 105 high-risk patients was divided in a wild-type 
(without mutation in the p53 gene) and a mutation group. These two groups 
were then compared regarding mortality, progression, disease-worsening and 
recurrence-free survival. The median follow-up was 58 months (varying from 
3 to 161 months). A trend is seen that suggests that patients with a mutation in 
the p53 gene, have a worse clinical outcome, these differences however are not 
significant.  Based on these data, no evidence of additional value for p53 status 
is seen and adaptation of treatment policy in an individual patient based on 
this p53 status is not justified.  
In chapter 10 the value of this p53 gene is again studied, but now in an 
unselected group of patients in a community centre. The p53 status was also 
determined by mutational analysis performed on DNA isolated from bladder 
washes. Patients were divided in a group with and without a mutation in the 
p53 gene and were compared regarding clinical outcome. There was no 
significant difference regarding, progression-free survival, recurrence-free 
survival or bladder cancer specific survival. So, after studying the association 
between p53 status, determined by the most reliable technique, namely 
mutation analysis, and clinical outcome in an unselected group of patients in a 
community centre and in a selected group of high-risk patients in an academic 
hospital, it is concluded that there is no evidence for using p53 status as a 
prognostic marker in non-muscle invasive bladder cancer nor justification for 
adapting treatment policies of individual patients based on the p53 status.  
Chapter 11 describes the value of the presence of Human Papilloma Virus 
(HPV) DNA and p53 status in clinical outcome of bladder carcinoma. There is 
clear proof for an association between different types of HPV and 
development of malignancies. These types are called high risk HPVs. High 
risk types HPV stimulate degradation and deactivation of the p53 tumour 
suppressor gene. In 166 bladder wash samples obtained from 107 patients, 
HPV detection and genotyping was performed by the SPF10-LiPA assay, and 
p53 status was determined by mutation analysis. Corresponding clinical 
information was obtained from the medical files. The number of high risk 
HPV infections increases with higher tumour grade and stage. However, 
infection with high risk HPV DNA does not increase the risk of disease 
progression in patients with a wild type (no mutations) p53 status.   
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Discussion 
 
So, what have we achieved with this thesis?  Unfortunately we have not been 
able to end the search for a new gold standard in diagnosis of non-muscle 
invasive bladder cancer: a non-invasive, objective, cheap marker, with a high 
sensitivity for both low grade and especially high grade tumours. The 
NMP22® BladderChek test, UroVysion® and Quanticyt® are urinary markers 
that were described in this thesis. None of these markers is sufficient to be 
added to or replace cystoscopy and cytology.   The NMP22® BladderChek test 
is studied in follow-up of bladder cancer patients and appeared not to have 
any additional value above earlier urine tests. Further evaluation of this test as 
a screening tool will be performed in the future. The concept of this test, i.e. 
detection of proteins that are released in higher amounts in the case of tumour 
burden, is logical and gives the test potential value. Unfortunately, the results 
of this test were disappointing in our study. Although this has lowered my 
faith in de performance of this test, one must bear in mind that this is one of 
the first studies, determining the value of this test. Possibly, it will perform 
better in a next study, for example with the test as a screening tool. FISH 
(UroVysion®) has the most potential in my opinion, both as diagnostic and as 
prognostic marker. However, this test can not be implemented in daily 
practise as it performs at this moment. Adaptations shall be necessary as 
described in chapter 4 to 6. That the results of the Nijmegen study were lower 
compared to the Rotterdam study is a clear indication that patient selection 
and the complexity of the test must be taken into consideration, before this test 
is used in daily practise. FISH can become a frequently used method in the 
future, provided that it is not surpassed by new tests that can detect 
abnormalities in the genome on many more places than the four chromosomes 
as UroVysion® does. That quantitative cytology (Quanticyt®) can be used on 
urine instead of bladder wash is proven. However, the value of the 
conventional test was lower than expected in the comparative studies. Further 
evaluation of the diagnostic and prognostic performance of the test will be 
necessary, before implementation of this test as a non-invasive assay can be 
achieved. The results for this test found in this thesis are disappointing, since 
it is being used for several years in the Radboud University Nijmegen Medical 
Centre as a settled part of the cystoscopic follow-up in patients with non-
muscle invasive bladder cancer. Although we look forward to the results of 
the extensive retrospective analysis of the data collected during the past years, 
I personally fear the outcome, as a consequence of the (limited) results in this 
thesis. 
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The search for new urinary markers to replace the current gold standard will 
continue. Although, taken into consideration the small profits we see after 
several years of research in this field, my confidence in solving this issue in a 
short matter of time is declined. As has been mentioned, at this moment 
UroVysion® has the biggest chance to gain ground, maybe as diagnostic test, 
maybe as predictive test. But before this occurs, the test must be made 
applicable for use in daily practise (clear definition of test positivity and 
patient selection) and the costs must be reduced to compete with other tests.  
Indeed UroVysion® may be one of the most promosing markers at this 
moment. However this is not the result of the performance of this test, but 
mainly the consequence of the absence of a test with better results. To my 
opinion the development of new markers will go on, but the knowledge we 
have gathered in former studies, will transfer this search into the application 
of multi array tests.  Probably it is an utopia to think that with only one 
marker, how promising this may have looked, presence of tumour can be 
predicted. It is most likely that in the future a panel of markers will be needed 
rather than one specific marker for recurrence or progression of non-muscle 
invasive tumours. In the Radboud University Nijmegen Medical Centre the 
Affymetrix GeneChip® mapping assay is currently being studied, a high 
densitiy single nucleotide polymorphism (SNP) array, detecting genomic 
instability. This instability in the genome is characteristic for (bladder) cancer. 
Since this array can detect abnormalities on 10.000 to 250.000 places in the 
genome, this method can be the test of the future in the area of diagnostics. At 
this moment the test is investigated in a large number of patients with bladder 
cancer. In time, a panel with genomic aberrations is defined with which all 
patients with a bladder tumour can be indicated. Whether this test also has 
predictive value, will have to be determined subsequently. Untill the moment 
that a perfect test has been developed, patients are willing to undergo a 
cystoscopy and prefer certainty over comfort. 
 
The issues concerning p53 mutational status and bladder cancer are brought to 
an end, after analysis of the data of both the Radboud University Nijmegen 
Medical Centre and the Canisius Wilhelmina Hospital in Nijmegen. Although 
for years it was believed that p53 was the marker that could predict the clinical 
outcome in bladder cancer, we were not able to confirm this assumption in 
this thesis. Since we were very hopeful, this subject costed a lot of time and 
effort. But with the most reliable technique to detect mutations, and an 
extensive studying of the patient medical files, we did not find an additional 
value for this tumour suppressor gene. Since inactivation of the p53 tumour 
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suppressorgene function can also be caused by other causes than a mutation, 
we also studied the effect of presence of HPV DNA in patients with bladder 
cancer. Unfortunately, the association of presence of high risk HPV DNA and 
progression in p53 wild type patients is also proven unlikely, based on the 
pilot study in this thesis. The chance that investigations in this area will 
extend, is small.  Herewith the doors are being closed in the prognostic 
department for p53  alone and also the HPV DNA does not seem to be of value 
in the prediction of disease outcome. Although I was very optimistic,  
believing p53  to help us with the prognostic issues,  now I am convinced that 
this marker (alone) is not going to make it.  
In this thesis our field of research concerning prognostic markers was confined 
to the mutations in the p53 tumour suppressor gene and presence of HPV 
DNA.  Herewith, a large number of possible prognostic markers remain 
undiscussed. Genetic imbalances, oncogenes, cell cycle regulators, 
angiogenesis-related factors and markers in the extracellular matrix or 
adhesion molecules are examples of markers with possible prognostic value. 
Unfortunately, at this moment the level of research into prognostic markers is 
not comparable to the level of research into diagnostics. And that is a 
shortcoming in my opinion. I think that the prediction of the course of the 
disease is more important at this moment than improving the gold standard in 
diagnosis. The harm we do with cystoscopy, bladderwash and cytology lies 
most importantly in the discomfort for the patient. And moreover, in the high 
costs with frequent surveillance for a large number of patients. The harm we 
do in not having identified a reliable prognostic marker at this moment, lies in 
the number of patients that are still dying from non-muscle invasive bladder 
cancer, a disease that we can treat so good if we do it in time. Fortunately, we 
had the opportunity to perform research to the most promising marker we 
know at this moment, namely, the p53  tumour suppressor gene. And 
although our expectations were high, we only found disappointing results in 
the analysis of our data collected during the last years. In all, to my opinion, 
the micro array techniques will be the future for diagnosis in non-muscle 
invasive bladder cancer. And there is a big chance that it will be also the 
answer for the prediction of the course of the disease in time. Efforts must 
increase to indicate a sufficient prognostic marker as soon as possible, since 
lowering  the  mortality  of  superficial  bladder cancer is equal, or maybe even        
more important  than decreasing morbidity.
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Samenvatting  
 
Blaaskanker is een ziekte met grote maatschappelijke impact voor Europa,  
met 120.000 nieuwe patiënten per jaar en 35.000 sterfgevallen in 2004. De term 
blaaskanker is een overkoepelende naam voor een heterogene groep 
patiënten. Ten eerste is er een verschil tussen de patiënten die zich presenteren 
met een spierinvasieve tumor (30%), of met een niet-spierinvasieve tumor 
(70%). Daarnaast is er nog een verschil binnen de groep van patiënten met een 
niet-spierinvasieve tumor, een ziekte die per definitie beperkt is tot de mucosa 
of de submocusa van de blaas (Ta, T1, of carcinoma in situ). Hierin worden 
laag-risico en hoog-risico patiënten onderscheiden. Laag-risico patiënten 
hebben een grote kans op recidieven maar de kans dat men aan de ziekte zal 
overlijden is klein. Hoog-risico patiënten hebben ook een grote kans op 
recidieven, maar belangrijker nog, ook een grote kans op progressie naar 
spierinvasieve ziekte als gevolg van differentiatieverlies van het weefsel. Als 
gevolg van bovenstaande moet elke patiënt regelmatig gecontroleerd worden 
op de aanwezigheid van nieuwe tumoren, middels cystoscopie 
(blaasspiegeling) en cytologie. Cystoscopie is een invasieve handeling en dus 
belastend voor de patiënt. Daarnaast worden papillaire lesies goed gezien, 
echter worden de vlakke, maar agressieve carcinoma in situ lesies gemakkelijk 
gemist. Cytologie is daarom een goede aanvulling, deze test detecteert juist 
goed de hooggradige lesies (zoals CIS), maar de goed gedifferentieerde 
tumoren worden veelvuldig gemist. Daarnaast blijkt cytologie subjectief te 
zijn, met een hoge intra- en interpersoonlijke variabiliteit in de beoordeling en 
de test is onbetrouwbaar in het geval van infecties, stenen of na intravesicale 
spoelingen. Een nieuwe urinemarker moet dus aan verschillende eisen 
voldoen: hij moet zowel de hooggradige als de laaggradige tumoren adequaat 
detecteren, hij moet niet-invasief zijn, gemakkelijk uitvoerbaarbaar, objectief 
en goedkoop.   
Daarnaast kan het klinisch beloop tussen patiënten met een oppervlakkige 
blaastumor erg verschillen. Van de patiënten met en laag risico tumor blijft het 
grote merendeel oppervlakkig. Voor patiënten met een pT1 G3 tumor of CIS 
kan de kans op progressie echter oplopen tot 50%. Verder is het klinische 
beloop van patiënten die progressie hebben vertoond van een niet-
spierinvasieve tumor naar een spierinvasieve tumor, duidelijk minder positief, 
met een 3-jaars ziektespecifieke overleving van maar 37%.  Twee belangrijkste 
doelen in het onderzoek naar diagnostiek en prognostiek van het niet-
spierinvasieve blaascarcinoom, zijn dan ook 1) verbeteren c.q. vervangen van 
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de gouden standaard middels een urinemarker, zodat het aantal onnodige 
cystoscopieën verminderd wordt  en 2) het  identificeren van patiënten met 
een hoog risico om een spierinvasieve tumor te ontwikkelen, zodat deze op 
voorhand agressiever kunnen worden behandeld. Hiermee zal  de morbiditeit 
en de mortaliteit van de ziekte geminimaliseerd worden.    
In dit proefschrift worden potentiële nieuwe markers besproken in de 
diagnostiek en prognostiek van het niet–spierinvasieve blaascarcinoom, tot 
voor kort oppervlakkig blaascarcinoom genoemd. Daarnaast wordt de waarde 
van reeds bekende markers opnieuw bestudeerd nu de follow-up van de 
patiënten kan worden meegenomen in deze analyse. Om de waarde van de 
verschillende markers goed te kunnen interpreteren moet de definitie van 
sensitiviteit, specificiteit, negatief voorspellende waarde en positief 
voorspellende waarde bekend zijn. Sensitiviteit in het aantal maal dat een test 
positief is in het geval van een tumor, specificiteit is het aantal maal dat een 
test negatief is bij afwezigheid van een tumor, negatief voorspellende waarde 
is de kans dat er geen tumor is in het geval van een negatieve test en positief 
voorspellende waarde is de kans dat er  tumor is in het geval van een positieve 
test. Hoofdstuk 2  geeft een overzicht van de gouden standaard in diagnostiek 
op dit moment, te weten  cystoscopie in combinatie met cytologie. Daarnaast 
wordt fluorescentie cystoscopie en een aantal reeds bekende urinemarkers 
beschreven. Over het algemeen hebben deze markers een sensitiviteit die 
vergelijkbaar is of iets hoger dan cytologie, maar deze verbetering gaat ten 
koste van de specificiteit, die zeer hoog is bij cytologie.   
De hoofdstukken 3 tot en met 7 behandelen urinemarkers in de diagnostiek 
van het niet-spierinvasieve blaascarcinoom. Hoofdstuk 3 beschrijft een 
prospectieve studie naar de waarde van de NMP22® BladderChek test 
uitgevoerd bij 106 patiënten met een verdenking van een blaastumor.  De 
NMP22® BladderChek Point Of Care (POC) test met direct resultaat is het 
gevolg van aanpassingen op de voorloper van deze test, de NMP22 Bladder 
Cancer Test, die werd uitgevoerd in het laboratorium.  Deze testen detecteren 
een nucleair matrix eiwit in de urine, welke correleert met de aanwezigheid 
van urotheelcelcarcinoom. In de patiënten groep met een positieve 
voorgeschiedenis voor blaaskanker werd een sensitiviteit gevonden van 57% 
en een specificiteit 90% voor de NMP22® BladderChek test. Dit is een kleine 
toename in sensitiviteit vergeleken met cytologie, zonder relevant verlies van 
specificiteit. Er werden echter geen extra tumoren gevonden door het gebruik 
van deze test. Verder bleek de test objectief, eenvoudig uit te voeren en direct 
resultaat te geven. Samenvattend is het gebruik van de test geschikt voor 
patiënten in follow-up, maar heeft geen additionele  waarde boven eerdere 
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urine tests. De waarde van de NMP22® BladderChek test in screening van 
patiënten met haematurie, moet nader onderzocht worden.  
Hoofdstuk 4 is een overzicht van de waarde van fluorescentie in situ 
hybridisatie (FISH) bij blaaskanker. FISH blijkt één van de meest sensitieve en 
veelbelovende methoden voor detectie van het niet-spierinvasieve 
blaascarcinoom op dit moment. UroVysion® is een FISH analyse die 
afwijkingen detecteert in chromosomen 3, 7, 17 en locus 9p21. De combinatie 
van deze afwijkingen is gedefinieerd als de optimale set voor de detectie van 
urotheelcelcarcinoom. Helaas blijven de precieze toepassing van de test en de 
groep van patiënten die het meest gebaat zijn bij het gebruik ervan onbepaald. 
Dientengevolge blijft de toepassing in de dagelijkse praktijk laag. In de 
komende jaren moet er consensus komen over de definitie van een positieve 
test en over de patiënten selectie (waarschijnlijk patiënten met een onduidelijk 
cytologie resultaat, patiënten die intravesicale spoelingen hebben gehad, of 
patiënten die gecontroleerd worden na cystectomie). Er zullen grote 
prospectieve studies moeten worden uitgevoerd en daarnaast zullen nieuwe 
geautomatiseerde methodes de uitvoerbaarheid van de test verbeteren en de 
kosten verlagen.   Hoofdstuk 5 beschrijft de waarde van een dergelijke FISH 
test, namelijk UroVysion® in een prospectieve studie met 113 urine monsters 
van patiënten met (verdenking) blaascarcinoom en een positieve 
voorgeschiedenis.  De waarde van UroVysion®  werd vergeleken met die van 
cytologie en quantitative cytologie (Quanticyt®).  De sensitiviteit en de 
specificiteit van UroVysion®, cytologie en quantitative cytologie waren 
respectievelijk 39% en 90%,  41% and 90% en 42% en 68%. Detectie van graad 
1, graad 2 en graad 3 tumoren door UroVysion®   was respectievelijk  21%, 37% 
en 67%. Op basis van deze data kan er geen toegevoegde waarde worden 
gezien voor UroVysion® in de diagnostiek van een recidief blaascarcinoom in 
deze patiëntenselectie, vergeleken met cytologie en quantitatieve cytologie.  
In hoofdstuk 6 is de waarde van UroVysion®  nogmaals bestudeerd, ditmaal in 
een grote retrospectieve studie in een perifeer centrum waar de test sinds bijna 
4 jaar geïmplementeerd is in de dagelijkse praktijk. De resultaten werden 
vergeleken met die uit de eerdere studie in een geselecteerde groep patiënten 
uit een academisch centrum (zie hoofdstuk 5). De resultaten van 1000 analyses 
werden gekoppeld aan de klinische gegevens. Hierbij had de test een 
sensitiviteit van 78% en een specificiteit van 76%. Cytologie had een boven 
verwachting hoge sensitiviteit van 86% en een beneden verwachting lage 
specificiteit van 71%.  Gebaseerd op deze resultaten kon geconcludeerd 
worden dat 1) UroVysion®  beter presteert in een ongeselecteerde groep 
patiënten in een perifeer centrum, dan in een groep patiënten in follow-up uit 
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een academisch centrum, 2) de complexiteit van de test, ervaring en expertise 
noodzakelijk maakt en 3) UroVysion® de waarde van cytologie verhoogd.     
Uit de literatuur is gebleken dat UroVysion®  een predictieve waarde zou 
kunnen hebben, met andere woorden dat een tumor eerder gedetecteerd 
wordt dan dat hij zichtbaar is voor het blote oog. Om dit te onderzoeken zijn 
de patiënten verdeeld in een groep met een vals-positieve FISH uitslag en een 
terecht-negatieve FISH uitslag. Ook zijn de patiënten onderverdeeld in laag 
risico en hoog risico op basis van hun chromosomale afwijkingen. De klinische 
gegevens van 258 patiënten met een gemiddelde follow-up van 12 maanden (0 
– 38 maanden) zijn bestudeerd. De recidief-vrije periode is lager in de 
patiëntengroep met een vals-positief FISH resultaat en in de patiëntengroep 
met een hoog-risico profiel op basis van hun chromosomale afwijkingen. Het 
verschil tussen de twee groepen is echter in beide vergelijkingen niet 
significant. Er zal nader onderzoek gedaan moeten worden naar de 
ontwikkeling van een risico stratificatie voor patiënten op basis van 
chromosomale afwijkingen. Hoofdstuk 7 behandelt een marker die een aantal 
jaar geleden is ontwikkeld in het UMC St Radboud, te Nijmegen. 
Quantitatieve cytologie (Quanticyt®) is een geautomatiseerde karyometrische 
analyse. Op basis van de DNA inhoud en de kernvorm als parameters, 
worden de patiënten ingedeeld in risicogroepen. Uit eerder onderzoek is 
gebleken dat 1) de marker waarde heeft in de identificatie van patiënten met 
een hoog-risico tumor en 2) dat het beleid van patiënten geïndividualiseerd 
kan worden op basis van de uitslag. Een nadeel van de marker is dat hij wordt 
uitgevoerd op een blaaswas, wat een invasieve handeling (katheterisatie) 
noodzakelijk maakt.  Na aanpassingen in de methodiek van de analyse, zijn er 
144 monsterkoppels afgenomen, dat wil zeggen een spontaan urinemonster en 
een blaaswas. De resultaten zijn met elkaar vergeleken en met de klinische 
gegevens. Mits een urinemonster met de juiste methodiek wordt verwerkt, 
kan quantitatieve cytologie worden gebruikt voor deze analyse. Deze nieuwe 
toepassing van een reeds bestaande test kan geïmplementeerd worden in de 
dagelijkse praktijk.  
 
Hoofdstuk 8 tot en met 12 behandelen de waarde van markers met potentieel 
prognostische waarde voor het niet-spierinvasieve blaascarcinoom.  
Hoofdstuk 8 geeft een overzicht van verschillende risico-stratificatie schema’s 
en van prognostische markers op dit moment.  In de meerderheid van de  
schema’s worden stadium, graad en multipliciteit genoemd als factoren met 
een prognostische waarde. Hoewel er uitgebreid onderzoek is gedaan naar de 
ontwikkeling van risico-stratificatie schema’s, zijn er beperkingen in het 
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gebruik ervan. Zelfs als een prognostische marker de  bekwaamheid heeft om 
te differentiëren tussen subgroepen, dan geeft dat geen garantie dat ook het 
ziekteverloop in een individuele patiënt kan worden voorspeld (het ultieme 
doel van een prognostisch model). Verder worden dit soort schema’s in het 
dagelijks leven niet of nauwelijks gebruikt. Klaarblijkelijk is het erg lastig om 
een risico-stratificatie  te maken voor elke tumor en zijn biologische gedrag te 
voorspellen.  Het laatste onderzoek naar dit onderwerp is dus nog niet 
voltooid. In hoofdstuk 9 wordt de prognostische waarde van p53 bestudeerd, 
in een geselecteerde groep patiënten met een hoog-risico niet-spierinvasieve 
blaastumor.  Het p53 gen behoort tot de groep van tumorsuppressorgenen. In 
het geval van DNA schade grijpt het p53 systeem in door het stoppen van de 
celcyclus, het repareren van de DNA schade en indien nodig apoptose. In 
ongeveer de helft van alle maligniteiten worden afwijkingen in het p53 gen 
gevonden. Ook in het urotheelcelcarcinoom is dit gen vaak geïnactiveerd. 
Inactivatie van dit gen zorgt voor de productie van een dysfunctioneel 
proteïne. Dit proteïne kan worden aangetoond middels 
immunohistochemische kleuring, een methode die vaak als surrogaat wordt 
gebruikt voor de mutatieanalyse, vanwege de complexiteit van deze 
laatsgenoemde methode. In deze studie is de p53 status bepaald door mutatie 
analyse op het DNA verkregen uit blaaswas monsters. De groep van 105 hoog-
risico patiënten is verdeeld in een wild-type (zonder afwijkingen in het p53 
gen) groep en een mutatiegroep. Deze twee groepen zijn daarna vergeleken 
voor wat betreft, mortaliteit, progressie, disease-worsening en recidief- vrije 
periode. De mediane follow-up duur was 58 maanden (uiteenlopend van 3 tot 
161 maanden).  Er wordt een trend gezien dat patiënten met een mutatie in het 
p53 gen een slechter klinisch beloop hebben, deze verschillen zijn echter niet 
significant. Op basis van de resultaten in dit hoofdstuk moet geconcludeerd 
worden dat p53 geen additionele waarde heeft boven de reeds bekende 
prognostische factoren en dat het aanpassen van individueel beleid op basis 
van deze marker niet is gerechtvaardigd. Hoofdstuk 10 bestudeert de waarde 
van het p53 gen in een ongeselecteerde groep patiënten in een perifeer 
centrum. P53 status werd wederom bepaald door mutatieanalyse en 
uitgevoerd op DNA verkregen uit blaaswas monsters. Patiënten werden 
verdeeld in een groep patiënten met en zonder een mutatie en het klinische 
beloop van beide groepen werd met elkaar vergeleken. Er is geen significant 
verschil tussen blaaskankersterfte, tijd tot progressie en tijd tot recidief tussen 
de twee groepen. Na bestuderen van de associatie tussen p53 – bepaald met de 
meest betrouwbare techniek, namelijk mutatieanalyse – en klinische beloop in 
een ongeselecteerde groep patiënten in een perifeer centrum én in een 
Developments in diagnosis and prognosis of superficial bladder cancer 
176  
geselecteerde groep hoog-risico patiënten in een academisch centrum, moet 
geconcludeerd worden dat er geen bewijs is dat p53 gebruikt kan worden als 
prognostische marker in niet-spierinvasieve blaastumoren of dat het beleid in 
individuele patiënten op basis hiervan kan worden aangepast. Hoofdstuk 11 
beschrijft de invloed van de aanwezigheid van Humaan Papilloma Virus 
(HPV) DNA en p53 status op het klinische beloop in het blaascarcinoom. Er is 
duidelijk bewijs dat verschillende HPV typen geassocieerd zijn met de 
ontwikkeling van maligniteiten. Deze worden hoog-risico HPV’s genoemd. 
Hoog-risico typen HPV stimuleren degradatie en deactivatie van het p53 
tumorsuppressorgen.  In 166 blaaswasmonsters van 107 patiënten werd HPV 
detectie en genotypering gedaan middels de SPF10-LiPA onderzoek en werd 
de p53 status bepaald middels mutatieanalyse. Medische gegevens werden uit 
de dossiers gehaald. Het aantal infecties met hoog-risico HPV typen neemt toe 
met hogere graad en hoger stadium. Infecties met een hoog-risico HPV type 
heeft echter geen invloed op het risico op progressie in patiënten met een wild 
type p53 status.  
 
 
Discussie 
 
Dus, wat hebben we bereikt met dit proefschrift? Helaas hebben we de 
zoektocht naar een nieuwe gouden standaard in diagnostiek van het niet-
spierinvasieve blaascarcinoom niet kunnen beëindigen.  Een non-invasieve, 
objectieve, goedkope marker, met een hoge sensitiviteit voor zowel de 
laaggradige tumoren, maar vooral voor de hooggradige tumoren. De NMP22® 
BladderChek test, UroVysion® en Quanticyt®  zijn de urinemarkers die zijn 
bestudeerd in dit proefschrift. Geen van deze markers is toereikend om aan de  
cystoscopie en cytologie toe te voegen of deze te vervangen.  De waarde van 
de NMP22® BladderChek test is onderzocht in een groep patiënten onder 
controle voor een niet-spierinvasieve blaastumor. Hier lijkt de test geen 
additionele waarde te hebben boven eerdere urine testen. Of de test meer 
waarde heeft in de screening van patiënten, zal verder onderzocht worden. 
Het concept achter de test, de detectie van eitwitten die in geval van tumor in 
verhoogde hoeveelheden aanwezig zijn,  is logisch en maakt de test potentieel 
waardevol. Helaas zijn de resultaten in onze studie toch teleurstellend. 
Hoewel hierdoor mijn vertrouwen in de prestatie van deze test is afgenomen, 
moet in het achterhoofd worden gehouden dat dit nog maar een van de eerste 
studies is die deze test heeft bestudeerd. Wellicht dat in een volgende studie, 
bijvoorbeeld in een screenings setting, de test beter zal presteren. FISH 
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(UroVysion®) heeft het meeste potentieel, zowel als diagnostische- als 
prognostische test. Voordat deze test echt geïmplementeerd zou kunnen 
worden moet er echter nog veel werk verricht worden zoals beschreven in 
hoofdstukken 4 tot en met 6. Dat het resultaat in de Nijmegen studie veel lager 
is vergeleken met die van de Rotterdam studie, geeft in ieder geval aan dat 
men rekening moet houden met patiënten selectie en de complexiteit van de 
test alvorens deze toe te passen in de dagelijkse praktijk. FISH kan een 
veelgebruikte methode worden in de toekomst, mits hij niet voorbij gestreefd 
wordt door nieuwe testen, die afwijkingen in het genoom kunnen detecteren 
op veel meer plaatsen dan de 4 chromosomen zoals UroVysion® dat doet. Dat 
quantitatieve cytologie (Quanticyt®) gebruikt kan worden in urine, in plaats 
van blaaswas is bewezen. Helaas presteerde de conventionele test lager dan 
verwacht in de vergelijkende studies. Er zal dus nader onderzoek gedaan 
worden om de diagnostische – en prognostische waarde van de test te 
bepalen, alvorens quantitatieve cytologie als urinetest gebruikt kan gaan 
worden. Dat de resultaten van deze test in de studies van dit proefschrift zo 
tegenvielen, is een teleurstelling te noemen. De test is namelijk in het UMC St 
Radboud sinds enkele jaren een vast onderdeel van de cystoscopische controle 
van patiënten met een niet-spierinvasief blaascarcinoom. Hoewel er erg wordt 
uitgekeken naar de uitgebreide retrospectieve analyse van de data verzameld 
gedurende de afgelopen jaren, vrees ik persoonlijk voor de resultaten ervan als 
gevolg van de (beperkte) resultaten in dit proefschrift. Het onderzoek naar 
nieuwe urinemarkers ter vervanging van de gouden standaard zal dan ook 
voortduren. Het feit dat er de afgelopen jaren maar weinig vooruitgang is 
geboekt, vermindert echter mijn vertrouwen om dit probleem op korte termijn 
op te lossen. Zoals gezegd heeft UroVysion® op dit moment de grootste kans 
om terrein te winnen, misschien als diagnostische test en wellicht als 
predictieve test. Voor het zover is zal de test toepasbaar moeten worden 
gemaakt voor gebruik in de dagelijkse praktijk (duidelijke definitie van 
positieve test en patiënten selectie) en zullen de kosten lager moeten worden 
om te kunnen concurreren met andere testen. Inderdaad zou  UroVysion®   één 
van de meest veelbelovende markers kunnen zijn van dit moment. Dit is 
echter niet het gevolg van de goede testresultaten van deze marker, maar meer 
de consequentie van de afwezigheid van een test met betere resultaten. De 
ontwikkeling van nieuwe markers zal voortduren, maar met de kennis die we 
uit vorige studies hebben vergaard, zal dit onderzoek zich verplaatsen naar 
het gebied van de micro array techniek.  Het lijkt een utopie te denken dat met 
één marker – hoe veelbelovend ook – aanwezigheid van tumor kan worden 
voorspeld. In de toekomst zal het waarschijnlijk niet één specifieke marker 
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zijn, maar een panel van markers die recidief en progressie voorspellen. Meer 
onderzoek op dit gebied wordt uitgevoerd en de technische ontwikkelingen 
zoals micro array - technieken zullen deze voortgang versnellen. In het UMC 
St Radboud wordt momenteel de Affymetrix GeneChip® mapping assay 
bestudeerd, een high density single nucleotide polymorphism (SNP) array, 
welke genomische instabiliteit detecteert. Deze instabiliteit in het genoom is 
kenmerkend voor (blaas) kanker. Daar deze test afwijkingen op 10.000 tot 
250.000 plaatsen in het genoom kan detecteren, zou deze methode de test van 
de toekomst kunnen zijn op het gebied van diagnostiek. Op dit moment wordt 
de test toegepast bij een groot aantal patiënten met een blaastumor. 
Uiteindelijk zal er een panel van genetische afwijkingen worden gedefinieerd, 
waarmee alle patiënten met een blaastumor kunnen worden geïdentificeerd. 
Of deze methode ook predictieve waarde heeft, zal daarna bestudeerd moeten 
worden. Tot het moment dat er een perfecte test is ontwikkeld, zijn patiënten 
bereid om een cystoscopie te ondergaan en prefereren zekerheid boven 
comfort.  
 
Het hoofdstuk over p53 is na analyse van alle data uit zowel het UMC St 
Radboud als het CWZ gesloten. Hoewel men jaren heeft geloofd dat p53 de 
marker was die het beloop van de ziekte kon voorspellen, hebben we deze 
vooronderstellingen in dit proefschrift niet kunnen bevestigen. Juist omdat wij 
zelf ook hoopvol waren, heeft dit onderwerp veel tijd en inspanning gekost. 
Maar met gebruik van de meest betrouwbare analyse om mutaties aan te 
tonen en uitgebreide bestudering van het klinische beloop van patiënten, 
hebben we geen toegevoegde waarde gevonden voor dit tumorsuppressor 
gen. Omdat inactivatie van de p53  tumorsuppressorgen functie ook 
veroorzaakt kan worden door iets anders dan mutatie, hebben we ook 
gekeken naar de invloed van HPV DNA aanwezigheid bij patiënten met 
blaaskanker. Helaas is ook de associatie tussen aanwezigheid van hoog risico 
HPV DNA en progressie in patiënten met een wild type p53 status,  
onwaarschijnlijk gebleken uit de pilot studie in dit proefschrift. De kans dat 
onderzoek naar dit onderwerp zal worden uitgebreid is klein. Hiermee lijken 
de deuren op prognostiek gebied gesloten te zijn voor p53 alléén en ook het 
HPV DNA lijkt niet van waarde te zijn in de voorspelling van het ziekte 
beloop. Hoewel ik persoonlijk goede hoop had dat p53 ons vooruit zou helpen 
op dit gebied, ben ik ervan overtuigd geraakt dan deze marker (alléén) het niet 
gaat redden. 
In dit proefschrift was het aandachtsgebied voor prognostische markers 
beperkt tot mutaties in het p53 tumor suppressor gen en aanwezigheid van 
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HPV DNA. Hierdoor is een groot aantal mogelijke prognostische markers 
onderbelicht gebleven. Genetic imbalances, oncogenen, cell cyclus regulatoren, 
angiogenese gerelateerde factoren en markers in de extracellulaire matrix of 
adhesiemoleculen zijn voorbeelden van markers met mogelijke prognostische 
waarde. Helaas is op dit moment het niveau van onderzoek naar 
prognostische markers niet te vergelijken met het niveau binnen de 
diagnostiek. En dat is een tekortkoming naar mijn mening. Ik denk dat het 
voorspellen van het beloop van de ziekte belangrijker is dan het verbeteren 
van de gouden standaard in diagnostiek. De schade die wij berokkenen met 
cystoscopie, blaaswas en cytologie ligt voor het grootste deel in het discomfort 
voor de patiënt en daarnaast in de hoge kosten dat frequente controle van een 
groot aantal patiënten met zich meebrengt. Echter de schade die we 
berokkenen door nog geen betrouwbare prognostische marker te hebben 
ontwikkeld, ligt in het aantal patiënten dat nog steeds sterft ten gevolge van 
het niet-spierinvasieve blaascarcinoom, een ziekte die we zo goed kunnen 
behandelen als we progressie voor zijn.  
Gelukkig bestond de mogelijkheid om onderzoek te doen naar de meest 
veelbelovende prognostische marker die we op dit moment kennen, namelijk 
het p53 tumor suppressor gen. En hoewel onze verwachtingen 
hooggespannen waren, hebben we alleen maar teleurstellende resultaten 
gevonden in de analyses van de data die verzameld waren gedurende de 
afgelopen jaren. Het onderzoek naar prognostische markers gaat gelukkig 
door. Samenvattend, naar mijn mening, zal de micro array techniek  de 
toekomst zijn voor de diagnostiek van het niet-spierinvasieve  blaascarcinoom.  
Daarnaast bestaat een grote kans dat het uiteindelijk ook het antwoord zal zijn 
voor de predictie van het beloop van de ziekte.  De inspanning om zo snel 
mogelijk een betrouwbare prognostische marker  te vinden zal moeten 
toenemen, daar het verlagen van de sterfte ten gevolge van het niet-
spierinvasieve  blaascarcinoom  minstens  zo  belangrijk is als het verminderen  
van de morbiditeit. 
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Bis vincit qui se vincit. Wie zichzelf overwint, heeft een dubbele overwinning 
behaald. Na een periode van 3 jaar fulltime onderzoeker te zijn geweest is het 
einde van mijn promotie-project een feit. Ik ben dankbaar dat ik de kans heb 
gekregen  om deze ervaring op te doen, het was een geweldige tijd! Zonder de 
illusie te hebben dat ik niemand zal vergeten, wil ik toch een aantal mensen 
persoonlijk bedanken voor hun bijdrage aan mijn proefschrift, de interesse die 
ze hebben getoond, of gewoon omdat dat ze er voor me waren.  
Prof. dr. JA Witjes, beste Fred. Mijn dank naar jou toe is groot. Allereerst voor 
het vertrouwen dat je in me hebt gesteld. Dankzij jou kan ik nu uitkijken naar 
mijn promotie en ben ik in opleiding tot uroloog. Het snel en kritisch 
corrigeren van de manuscripten heeft ertoe bijgedragen dat ik dit proefschrift 
in deze periode heb kunnen afronden. Dat je daarnaast altijd tijd voor me had 
of het gewoon maakte, zal ik ook niet vergeten. Voor dit alles, bedankt!  
Prof. dr. LALM Kiemeney, beste Bart. Jij hebt me de kneepjes van SPSS 
geleerd, ook heb je me de zin en onzin van statistiek in onderzoek proberen bij 
te brengen. Jouw strenge commentaar, maar meer nog je scherpe inzichten 
tijdens onze besprekingen hebben dit proefschrift naar een hoger niveau 
mogen tillen. Dank daarvoor.  
Prof. dr. JA Schalken, beste Jack. Jouw laboratorium voor experimentele 
urologie is 3 jaar lang mijn thuishaven geweest. Dank dat je me de 
mogelijkheid hebt gegeven om vanuit hier, mijn voornamelijk klinische 
onderzoek uit te voeren. Ons gezamenlijk begin van de dag zorgde altijd weer 
voor uitdaging en inspiratie op de vroege ochtend.  
Beste Dr. HFM Karthaus,  samen met u heb ik een aantal studies uit dit 
proefschrift in het CWZ kunnen uitvoeren. Hierdoor heb ik uw afdeling 
aardig leren kennen en kan ik uitzien naar de twee jaar die ik hier in het kader 
van mijn opleiding zal gaan doorbrengen. Bedankt daarvoor.  
Prof. dr. DFCM Smeets, dank dat u mij de kans hebt gegeven samen te werken 
met uw afdeling. Gerard Merkx, dank je voor de zorgvuldige uitvoering van 
de FISH analyses. Ik had dit zelf nooit zo snel en adequaat gekund als jij.  
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Drs. R. Beekman , dr. SC Henzen-Logmans, dr. AS Bierkens en Maarten 
Vermeulen, bedankt voor julllie samenwerking in de grote retrospectieve 
studie naar de waarde van FISH in blaaskanker. 
Drs. K. Hendricksen, beste Kees. Samen hebben we twee jaar lang praktisch 
elke blaaskankerpatiënt in het Radboud gezien. Dat dit veel werk is hoef ik je 
niet meer uit te leggen! Bedankt voor de samenwerking en heel veel succes 
met je eigen proefschrift en verdere loopbaan.  
Alle medewerkers op het laboratorium voor experimentele urologie wil ik 
bedanken voor de samenwerking, de gezelligheid en de getoonde interesse. In 
het bijzonder wil ik Pim, Daphne en natuurlijk Gerald vernoemen.  
Collega arts-onderzoekers, we hebben een leuke groep gevormd, waarbij we 
zowel in huis als buitenshuis veel gezellige uren hebben doorgebracht. Zonder 
afbreuk te doen aan de rest, wil ik graag Kim de Weijer,  Farida van Rey en 
Luc Roelofs bij naam noemen. Allen bedankt voor de leuke tijd en succes met 
jullie carrières.    
Alle secretaresses van de afdeling urologie in zowel Radboud ziekenhuis, als 
het CWZ, wil ik van harte bedanken voor hun hulp bij de planmatige kant van 
mijn studies en minstens zo belangrijk, voor de gezelligheid tussendoor.    
Verpleging, balie- en archiefmedewerkers van zowel het Radboud ziekenhuis 
als het CWZ wil ik bedanken voor hun inzet en hulp de afgelopen jaren.  
Operatieassistenten, dank voor jullie adequate hulp bij de Hexvix- OK’s. Ik 
ben blij dat jullie er waren om te zorgen dat de juiste apparatuur klaarstond  
en ook functioneerde!  
Een speciaal woord van dank aan alle patiënten die op eniger wijze hebben 
bijgedragen aan de totstandkoming van dit proefschrift. Jullie vertrouwen in 
en medewerking aan de diverse studies wordt ontzettend gewaardeerd, 
zonder jullie was dit proefschrift er niet geweest.    
Marketingbureau De Combinatie van Factoren en met name Kees-Jan 
Rozestraten, bedankt voor de buitengewoon gulle bijdrage in de vorm van de 
omslag van mijn proefschrift.  
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Tot slot wil ik mijn dierbaren bedanken. Vrienden,  zowel diegene die ik met 
grote regelmaat heb gezien en op de hoogte kon houden van de vorderingen 
van dit proefschrift, maar ook diegenen die ik minder frequent zag zonder dat 
dit afbreuk deed aan onze vriendschap. Dank voor jullie interesse en het 
aanhoren van mijn verhalen:  arts zijn blijft het mooiste vak wat er is! Speciaal 
woord voor één van mijn beste maatjes, Erik. Jouw kritische blik op zaken 
heeft mijn visie veranderd. Dat carrière maken ook zijn mindere kanten heeft, 
hebben we aan den lijven ondervonden. Dank voor alles.   
Speciaal woord tot mijn paranimfen. Loes, 10 jaar lang hebben we lief en af en 
toe ook leed gedeeld. Onze vriendschap is er alleen maar sterker door 
geworden. Je bent een ongelooflijk goede arts en een nog veel betere vriendin. 
Dank je dat je ook vandaag weer naast me staat. Toine, dat jij mijn paranimf 
zou zijn, wisten we eigenlijk 3 jaar geleden al. Jouw laatste en mijn eerste 
onderzoeksjaar, was er één uit duizenden. Ik ben blij dat we naast collega’s 
ook vrienden zijn geworden. Dank dat jullie vandaag aan mijn zijde willen 
staan.  
Mijn ouders, zus en Bart, vervelend genoeg hebben jullie allen op je eigen 
manier de urologie leren kennen. Dit heeft er wel voor gezorgd dat ik dit vak 
ook van de andere kant van de tafel heb mogen ervaren, iets wat niet verkeerd 
is geweest voor mijn ontwikkeling. Onbeschrijflijk veel dank voor jullie 
onaflatende vertrouwen in mijn kunnen en jullie interesse in wat ik doe. Nooit 
zal er iemand trotser op mij zijn dan jullie.  
Lieve Bert, de beruchte laatste loodjes van dit proefschrift heb ik met jou 
mogen delen. Dank je voor je motiverend vermogen, als het daar eens aan 
ontbrak en voor je begrip als ik weer eens een mooie zondag achter mijn 
laptop zat. Dat je trots op me bent dat weet ik, maar vergeet niet dat ik 
minstens zo trots ben op jou en elke dag weer blij ben bij je thuis te komen. Ik 
hou van je.  
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Paula MJ Moonen werd geboren op 18 maart 1978 te Geleen in het zuiden des 
lands. In 1996 behaalde zij haar Gymnasium diploma aan het Stella Maris 
College te Meerssen, waarna zij verhuisde naar het gezellige Diepenbeek in 
België om daar Geneeskunde te studeren aan het Limburgs Universitair 
Centrum (LUC). Tot haar grote vreugde werd ze echter het jaar daarna 
ingeloot, waarna ze terugkeerde naar Nederland om in Nijmegen aan de 
Katholieke Universiteit Nijmegen de studie te volbrengen. Haar 
doctoraalexamen werd behaald in 2001. Haar keuze-co-schap liep ze op de 
afdeling urologie van het Canisius Wilhelmina Ziekenhuis te Nijmegen onder 
leiding van Dr. H.F.M. Karthaus en zowel het afsluitend co-schap als haar 
wetenschappelijke stage op de afdeling urologie van het UMC St. Radboud 
onder leiding van Prof. dr. J.A. Witjes. Haar artsexamen behaalde ze in 2003. 
Aansluitend werd gestart met een promotieproject naar nieuwe diagnostische 
– en prognostische markers bij het oppervlakkig blaascarcinoom. In deze 
periode is zij ook aangenomen voor de opleiding Urologie (cluster Nijmegen, 
opleider: Prof. dr. J.A. Witjes). Op 01 januari 2007 is ze gestart met de 
vooropleiding op de afdeling heelkunde van het Canisius Wilhelmina 
Ziekenhuis te Nijmegen (opleider:  Dr. W. B. Barendregt). 
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